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ABSTRACT
The reduced engraftment potential of haemopoietic stem/progenitor cells 
after exposure to cytokines may be related to the impaired homing ability of 
actively cycling cells. I tested this hypothesis by quantifying the short-term 
homing of human adult CD34+ cells in NOD/SCID animals. I have 
demonstrated in adult CD34+ cells that cytokine exposure ex-vivo leads to a 
loss of engraftment ability in vivo which occurs rapidly and which is 
associated with a striking alteration in the tissue distribution of homed cells. 
Loss of homing to the BM and to a lesser extent, the spleen, coincides with 
increased accumulation of cells in the lungs. The loss of BM homing and 
engraftment is not related to cell cycle phase, and was not restored by 
blocking Fas ligation in vivo. The co-transplantation of adult MPB CD34+ cells 
with non-haemopoietic stem cells (e.g. MSCs and MAPCs) and heterologous 
T cells (e.g. CD4+ and CD8+) was also unable to improve the homing to the 
BM in the NOD/SCID mice. The work from this thesis suggest that these 
changes in homing, and as a consequence engraftment, induced by cytokine 
exposure are due to increased migratory capacity of infused activated cells, 
leading to loss of selectivity of the homing process.
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Chapter 1: Introduction
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1.1 Haemopoiesis: an overview
Haemopoiesis is the process of blood cell formation. Haemopoiesis is a 
highly orchestrated process and each day the human body produces billions 
of new white blood cells, red blood cells, and platelets to replace blood cells 
lost to normal cell turnover processes as well as illness and trauma. The total 
cellular content is estimated at around 2x1012 cells with a daily turnover of 
2x1011 red blood cells, 1x1010 white cells and 4x1011 platelets (Tavassoli, 
1980). The vast majority of haemopoietic cells are morphologically 
recognisable and mature end-cells but within the marrow there are much 
smaller sub-populations of more primitive multipotent and lineage restricted 
cells (around 1-10x106, (Moore, 1996)) which are morphologically similar in 
appearance to that of small or intermediate lymphocytes.
Haemopoietic stem cells (HSCs) generate the multiple haemopoietic lineages 
through a successive series of intermediate progenitors. These include 
common lymphoid progenitors (CLPs), which can generate only B, T and NK 
cells, and common myeloid progenitors (CMPs), which can generate only red 
cells, platelets, granulocytes, and monocytes (Akashi et al, 2000;Kondo et al, 
1997). Downstream of the CLPs and CMPs are more mature progenitors that 
are further restricted in number and type of lineages that they can generate 
(Akashi et al, 2000). Ultimately terminally differentiated cells are produced 
that cannot divide and undergo apoptosis after a period of time ranging from 
hours (e.g. neutrophils 1 hr) to days (e.g. erythrocytes 120 days) in humans. 
A schematic representation of haemopoietic lineage development in the bone 
marrow is shown in Figure 1.1.
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Figure 1.1 - Schematic representation of haemopoietic cell development and haemopoietic assays (highlighted in blue)
1.1.1 Sites
The sites of haemopoiesis in foetal life are the yolk sac (0-2 months), and 
later the liver and spleen (2-7 months). The bone marrow is the most 
important site from 6-7 months of foetal life (Tavassoli & Minguell, 
1991;Tavassoli, 1991) and, after birth normal haemopoiesis is restricted to 
the bone marrow. Infants have haemopoietic marrow in all bones but in 
adults it is confined to axial skeleton and proximal ends of the femurs and 
humeri.
1.1.2 Haemopoietic stem and progenitor cells (HSPCs)
The best characterised stem cells are those responsible for haemopoiesis. 
HSCs have certain hallmark properties and they include the following: HSCs 
have the capacity for self-renewal, proliferation and differentiation to 
increasingly specialised progenitor cells which, after many cell divisions 
within the marrow, form mature cells (red cells, granulocytes, monocytes, 
platelets, and lymphocytes) of the peripheral blood (Figure 1.1). HSCs are 
rare, with a frequency of 1 in 10,000 to 100, 000 total blood cells and the 
majority of HSCs and many progenitors are quiescent in the Go phase of the 
cell cycle in a steady-state adult haemopoietic system (Uchida et al, 1997). 
The appearance of stem and progenitor cells is similar to that of small or 
intermediate sized lymphocytes, (Figure 3.1), however, progenitors can be 
detected by in vitro assays (see section 1.3) in which they form colonies for 
e.g. GM-CFC and BFU-E in semi-solid media.
1.1.3 Bone marrow stroma
After birth normal haemopoiesis is restricted to the bone marrow. The bone 
marrow is composed of stromal cells (e.g. fibroblasts, endothelial cells, 
macrophages, fat cells) and extracellular matrix (e.g. fibronectin, laminin, 
collagen, proteoglycans) and forms a suitable environment for stem cell 
growth and development, providing supportive signals for survival, 
proliferation, differentiation of HSPC, as well as anchorage points to ensure 
appropriate anatomical localisation.
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1.1.4 Haemopoietic growth factors
Haemopoietic growth factors and cytokines are glycoproteins that regulate 
the proliferation and differentiation of haemopoietic progenitor cells and 
function of mature blood cells (Table 1.1). The major cell sources for these 
growth factors are T cells, monocytes and macrophages and the stromal 
cells (fibroblasts and endothelial cells) found in the BM except for EPO, 90% 
of which is synthesised in the kidney. Key cytokines for the expansion of 
progenitor cells are SCF and Flt3L (Williams et al, 1992;Rosnet et al, 
1993;Verfaillie et al, 2000) as outlined below (see section 1.2) and discussed 
in detail in Chapter 5.
Table 1.1 - Haemopoietic growth factors (adapted from (Hoffbrand & Pettit, 
1993))
Act on cells Growth factors
Stromal cells IL1, TNF
Pluripotent cells SCF (stem cell factor, c-kit ligand,
Steel factor), Flt3L
Early multipotential cells IL-3, IL-6, GM-CSF
Late cells committed to one (or two) G-CSF, M-CSF, IL-5, Epo, TPO
lineages
1.2 Cytokines and ex vivo expansion
Many investigators are now attempting ex vivo manipulation of HSCs for 
potential therapeutic purposes for example expansion of small umbilical cord 
blood grafts to expand HSCs responsible for long term haemopoietic 
reconstitution for HSC transplantation. Gene transduction also requires 
cytokine stimulation. Below is a list of the major cytokines used for expansion 
of human HSCs (reviewed in (Heike & Nakahata, 2002)). However, the 
optimal choice of cytokine combinations for the ex vivo expansion of human 
HSPCs has not yet been determined and is discussed in detail in Chapter 5.
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1.2.1 Stem cell factor (SCF)
SCF also known as c-Kit ligand is the ligand for the tyrosine kinase receptor 
c-Kit, which is expressed on both primitive and mature haemopoietic 
progenitor cells (Galli et al, 1994;McNiece & Briddell, 1995). SCF plays a 
central role in the regulation of early haemopoiesis (Andrews et al, 1994). 
SCF has been studied extensively in ex vivo expansion experiments and was 
frequently represented in the most effective combinations. The addition of 
SCF to combination of IL-3 and GM-CSF resulted in a 12 fold increase in the 
numbers of HPP-CFC derived colonies. SCF resulted in the increase of BFU- 
E, CFU-GM and BFU-MK colonies (Brandt et al, 1992;Hoffman et al, 1993).
1.2.2 Fms-like tyrosine kinase receptor ligand (Flt3L)
Flt3L is the ligand for the tyrosine kinase receptor Flt3 and as with KL, Flt3L 
affects proliferation and differentiation of primitive progenitors in vitro. Flt3L is 
efficacious in prompting stem cell cycling with retention of self renewal, 
particularly when combined with TPO, and SCF (Petzer et al, 1996). In a 
primate study the addition of Flt3L and stromal support to a 4 day cytokine 
priming with IL-3, IL-6 and KL alone, increased the degree of subsequent 
long term engraftment of retrovirally transduced cells from 0.01% to a 
clinically relevant 10-20% (Dunbar et al, 2001).
1.2.3 lnterleukin-3 (IL-3)
IL-3 has a broad target specificity and is used in a number of cytokine 
combinations used for ex vivo expansion. The contribution of IL-3 for ex vivo 
expansion of HSCs remains controversial and is discussed in detail in 
Chapter 5. The study by Peters et al., (1996) showed that stimulation with IL- 
3 may result in decreased ability of stem cell repopulation to self renew as 
assessed by long term repopulating capacity (Peters etal, 1996;Yonemura et 
al, 1996).
1.2.4 lnterleukin-6 (IL-6)
IL-6 is member of the IL-6 cytokine family and these cytokines mediate their 
biologic action through the common subunit gp130. IL-6 alone does not have 
distinct biological activity on HSC expansion, however, it has been shown to
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act as a potent co-factor in the expansion of human CD34+ progenitor cells in 
vitro (Moore et al, 1997;Bernad et al, 1994;Shah et al, 1996). Therefore IL-6 
acts in synergy with the SCF, Flt3L to expand immature human HSCs.
1.2.5 Thrombopoietin (TPO)
TPO is the ligand for Mpl and is responsible for the regulation of 
megakaryocyte proliferation and differentiation (Kaushansky et al, 1994). 
TPO has been shown to induce proliferation of primitive progenitors in vitro 
and has therefore become an important factor in ex vivo HSC expansion 
schemes (Kaushansky, 1997;Borge et al, 1997). The role of TPO in 
optimising HSC engraftment is reviewed recently by Verfaillie (Verfaillie, 
2002b) and is discussed further in Chapter 5.
1.3 Isolation and characterisation of HSCs
1.3.1 Isolation and purification of HSCs
A variety of techniques have been used to enrich HSCs, including density 
centrifugation, activation and/or cell cycle status e.g. sensitivity to cell cycle- 
active cytotoxic agents (Orschell-Traycoff et al, 2000;Szilvassy & Cory, 
1993), and surface antigen expression (Spangrude et al, 1988;Szilvassy et 
al, 1989;Baum et al, 1992), dye efflux properties (Goodell et al, 1996), but no 
unique characteristics have been found to identify these elusive cells 
specifically. An important point in the isolation of HSCs is the one-to-one 
correspondence between physically purified cells and their potential ability to 
function as stem cells.
1.3.1.1 Cell surface markers
Currently, there is no single phenotypic characteristic that can be used to 
define uniquely human or murine haemopoietic stem cells. However, using a 
variety of separation techniques and functional assays, numerous 
laboratories have established a pattern of surface antigen expression that 
can be used largely to isolate HSCs. The identification of rare populations 
highly enriched for stem cell (SRC and /or LTCIC) activity (see section 1.3.2) 
has come about due to the systematic functional analysis of HSCs
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expressing a particular cell surface antigen or other markers. HSCs are 
characterised by the absence of lineage antigens expressed predominantly 
on terminally differentiated lymphocytes (CD45R/B220, CD3, CD4, CD8), 
myeloid (CD11b/Mac-1, Ly-6G/Gr-1), and erythroid cells (TER-119/molecule 
associated with cell surface Glycophorin A). Thus, many HSC isolation 
techniques use the removal of such lineage-positive cells to leave a 
suspension of predominantly immature cells.
1.3.1.2 CD34 as the universal marker of HSCs
Surface expression of the sialomucin CD34, a transmembrane cell surface 
glycoprotein, has rapidly become the distinguishing feature used as the basis 
for the enumeration, isolation, and manipulation of human stem cells, 
because CD34 is down regulated as cells differentiate into more abundant 
mature cells (Andrews et al, 1989;Krause et al, 1996). It was initially 
identified by the My10 mAb, which was raised against the immature myeloid 
cell line KG-1a (Civin et al, 1984). Other CD34 mAb include the clones 
HPCA2 (8G12) which is routinely used for detecting CD34+ cells in cytokine 
MPB (Watts et al, 2002) and the antibody QBEndIO used in CD34+ cell 
selection in the commercial CD34 selection device from Miltenyi Biotec 
(Watts et al, 2002). The normal function of the CD34 molecule in 
haemopoiesis has remained enigmatic but a potential role in cell adhesion 
and in the homing process has been described (Healy et al, 1995;Lanza et 
al, 2001). CD34 is expressed selectively on stem cells and early progenitors 
during human (Civin et al, 1984;Berenson etal, 1991;Siena et al, 1991) and 
murine (Brown et al, 1991;Simmons et al, 1992) haemopoiesis, but both 
mouse and human CD34 are expressed outside the haemopoietic system on 
vascular endothelial cells (Fina et al, 1990) and some fibroblasts (Brown et 
al, 1991). Transplant studies in several species, including baboons 
(Berenson et al, 1988) and mice, have shown that long term marrow 
repopulation can be provided by CD34+ cells (Horn et al, 2003). However, 
several recent studies have suggested that there may be human and murine 
stem cells that do not express CD34 (Zanjani et al, 1998;Bhatia et al, 
1998;Goodell etal, 1997).
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1.3.1.3 Other stem cell markers
In addition to the ‘classical’ phenotype, several novel markers of primitive 
HSCs have been identified over the past several years. These markers are 
summarised in Table 1.2, adapted from (Szilvassy, 2003). AC133 (CD133) is 
a transmembrane glycoprotein antigen of unknown function that is selectively 
expressed on the majority of CD34+ cells from human BM, Foetal Liver and 
normal and mobilised peripheral blood (Yin et al, 1997). Details on CD133 
expression in human stem cells are reviewed by (Bhatia, 2001). Several 
other markers have proven useful in further dividing the population into more 
functionally homogeneous populations e.g. current evidence indicates that all 
human HSCs are CD38', whereas more mature progenitor cells are CD38+ 
(Peled et al, 1999b). Another novel marker allowing the identification of 
human HSCs is the vascular growth factor receptor 2 (VEGFR2), also known 
as KDR or Flk1 in mice (Ziegler et al, 1999). It had been reported that CD34+ 
KDR+ cells are highly enriched in putative HSCs (SRC and E-LTC-IC or 
CAFC) (Ziegler etal, 1999).
1.3.1.4 ‘Side population’ of Dye efflux properties
A alternative method which exploits the ability of HSCs to efflux the 
fluorescent dye Hoechst has been used for obtaining enriched populations of 
HSCs from adult mouse bone marrow (Goodell et al, 1996). This strategy is 
based more on function than phenotype. The Hoechst 33342-low cells 
isolated were called side population (SP) cells and in 1997, SP cells were 
identified in adult bone marrow from several species, including humans 
(Goodell etal, 1997).
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Table 1.2 - Phenotype of human and murine haemopoietic stem and 
progenitor cells, adapted from (Szilvassy, 2003).
Stem cells Progenitor cells
Human
CD34+ and ' CD34+
CD38' CD38+
Thy-1 10 Thy-1'
c-k it10 c-kit+
HLA-DR-'10 HLA-DR+
CD45RA'/k>
CD71',I°
AC 133*
Rh-12310 Rh-123 hi
H O 10 HO hi
KDR* (Flk1*) KDR'/l0
Adult Mouse BM
Sca-1 + Sca-1'/+
CD34' CD34*
CD38+ CD38-/IO
c-k it10 c-kit*
Lin' Lin'
Thy-1 10 Thy-1'
HO'° HO hl
Flk-2' Flk-2*
1.3.2 Characterisation of HSCs
Stem cells have an extensive ability to self-renew, and are able to persist in 
recipients for long periods of time after transplantation, continuously 
replenishing the blood with mature differentiated cells (Till & McCulloch, 
1980). As repopulation assays cannot be carried out in humans, surrogate in 
vitro and in vivo assays are used to evaluate HSCs.
1.3.2.1 Surrogate in vitro assays
Quantitative analyses of human HSPC have historically been limited to in 
vitro assays where the proliferative potential of stem cells is evaluated in the 
presence of various combinations of cytokines. In vitro assays used to 
assess primitive human progenitors include several stromal based assays 
including the long term culture initiating cell (LTC-IC) assays, cobblestone 
area-forming cell (CAFC) assays and extended LTC-IC (E-LTC-IC) assays
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(reviewed in (Gordon, 1993)). The LTC-IC assay detects primitive cells 
capable of giving rise to colony forming cells (CFCs) after 5-8 weeks of 
culture on a stromal cell (feeder) layer (Sutherland eta/, 1990;Sutherland et 
al, 1989). The E-LTC-IC assay is a modification of the LTC-IC assay where 
there is an extended period preculture, up to 10 weeks (Hao et al, 1996). 
This E-LTC-IC assay detects even more primitive cells than week 5 or week 
8 LTC-IC (Hao et al, 1996). Both the LTC-IC and the E-LTC-IC assays are 
time consuming and cumbersome to perform. The CAFC assay is used to 
assess the frequency of primitive HSCs subsets (Ploemacher et al, 
1989;Breems et al, 1994). This assay scores a particular morphologic growth 
pattern, which forms a cobblestone appearance in the stromal monolayer. 
The time required for generation of these colonies defines the CAFC assay. 
Appearance of cobblestones within 7 days indicates progenitor cells, while 
appearance after several weeks to 1 month indicates a more primitive stem 
cell (Neben etal, 1993).
The most common approaches to quantify multi-lineage or single lineage 
committed haemopoietic progenitors, called colony-forming cells (CFCs) or 
colony forming units (CFUs), utilise viscous or semi-solid matrices and 
culture supplements that promote their proliferation and differentiation and 
allow the clonal progeny of a single progenitor cell to stay together and thus 
form a colony of mature cells (Gordon, 1993). In such assays, committed 
cells, which can give rise to cells of single lineages are named after the cell 
type of the colonies obtained (for instance colony forming cells-granulocyte). 
In addition, bipotent cells giving rise to colonies with cells of different lineages 
can be detected e.g. GM-CFC. The disadvantage of the assay is that it is 
critically dependent on the culture conditions used, including the type of 
serum and the cytokines used for stimulation. However, the availability of 
commercially available standardised reagents has led to increased 
reproducibility of CFC assays. CFC assays are used to quantify and 
characterise haemopoietic progenitors from different sources (e.g. BM, UCB, 
MPB) and for quality control of clinical stem cell collection, processing and 
cryopreservation. They are also used to investigate progenitor responses to 
growth factors, to quantitate progenitor cell numbers after ex vivo expansion.
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1.3.2.2 In vivo assays
A conclusive way to assay stem cells is based on their capacity to repopulate 
the entire haemopoietic system in conditioned recipients after transplantation. 
In an attempt to develop in vivo animal models for human haemopoiesis 
several groups have transplanted human cells in xenogeneic transplant 
recipients e.g. immunodeficient mice (McCune, 1996;Dick, 1996) and foetal 
sheep (Zanjani etal, 1997).
1.3.2.3 NOD/SCID mouse model
For the purpose of studying HSPC transplantation, several animal models 
have been developed, including the severe combined immuno-deficient 
(SCID) mice (Bosma et al, 1983), severe combined immuno-deficient-human 
(SCID-hu, foetal bone fragments are implanted under the skin; (McCune et 
al, 1988)), non-obese diabetic/severe combined immuno-deficient (Shultz et 
al, 1995) (NOD/SCID, transplanted cells need to migrate actively to the 
marrow) and non-obese diabetic/severe combined immuno-deficient P2 
microglobulin (NOD/SCID P2m, reduced innate immunity in comparison to 
NOD/SCID mice) models (reviewed in (Voermans et al, 2001 ;Dao & Nolta, 
1999;Greiner etal, 1998)).
The SCID mice, homozygous for the SCID mutation lack both humoral and 
cell-mediated immunity due to the absence of mature T or B lymphocytes 
(Bosma & Carroll, 1991). The lack of an adaptive immune system in SCID 
mice results from their inability to express rearranged antigen receptors 
(Lieber et al, 1988;Malynn et al, 1988). This defect is due to a defective 
recombinase activity (a failure to activate a DNA recombinase enzyme) that 
results in abnormal and non-functional antigen receptor gene 
rearrangements (Bosma & Carroll, 1991). The arrest in lymphocyte 
development is not absolute as some young adult SCID mice are ‘leaky’ and 
generate a few clones of functional B and T cells (Nonoyama et al, 
1993;Shultz et al, 1995;Bosma et al, 1988). SCID mice that have serum Ig 
levels greater than 1pg/ml are considered ‘leaky’ and by 10-14 months of 
age, virtually all SCID mice are ‘leaky’. Most of the earlier studies used the
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SCID mice, which required high cell doses to overcome significant antigen 
non-specific immunity.
The creation of the NOD/SCID mice by crossing the SCID gene onto NOD 
background, proved to be a better recipient because this mice strain 
appeared to have lower NK and complement activities, and a defect in 
macrophages (Shultz et al, 1995). Ten to twenty fold lower number of cells 
were necessary to engraft n o d /s c id  32m j , when compared with n o d /s c id  mice 
(Glimm et al, 2001). The NOD/SCID (32m mice has become available 
recently and is thought to be a even better recipient than the NOD/SCID mice 
because of reduced innate immunity (lack NK cells) in comparison to 
NOD/SCID mice (Kollet et al, 2000).
1.3.2.4 The foetal sheep HSC assay
This is a large animal model of human haemopoiesis based on the 
permissive environment of the early gestational age foetus of a sheep 
(Zanjani et al, 1996). This assay allows the long term engraftment and multi­
lineage expression of human HSCs in the absence of irradiation or other 
myeloablative therapies (Zanjani et al, 1992;Srour et al, 1992). Due to the 
high costs of this model it is not utilised widely.
1.4 Sources of HSCs
HSCs have been collected from adult bone marrow, mobilised peripheral 
blood and umbilical cord blood (Korbling & Anderlini, 2001). Primitive HSCs 
are normally present in very low numbers in peripheral blood (Barr et al, 
1975;Hong & Deeg, 1994). However the numbers of progenitor cells in 
peripheral blood can be greatly increased (mobilised) after treatment with 
chemotherapy and/or cytokines e.g. G-CSF, the most widely used cytokine 
for mobilisation of stem cells (Watts et al, 2000). Mobilised peripheral blood is 
an attractive stem cell source for clinical use. HSCs obtained from umbilical 
cord blood are numerically fewer (rarely able to extract more than a few 
million from one donor) but on a per cell basis, UCB cells engraft 10 to 15 
fold better in xenogeneic hosts than BM progenitors (van der Loo et al, 
1998a;Holyoake et al, 1999). HSCs from G-CSF mobilised PB grafts (MPB)
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have become the preferred cell source for transplantation because of earlier 
neutrophil and platelet recovery, which is though to be due to the increased 
number of STRCs (Korbling & Anderlini, 2001). HSCs found in MPB may be 
qualitatively different from those found in the BM and evidence for this comes 
from a study which compared BM CD34+ Lin* cells with PB CD34+ Lin* cells. 
These workers found that the proliferation and differentiation capacity inferior 
in PB CD34+ Lin* cells (Prosper et al, 1996). One study in a xenogeneic 
transplant model found that more MPB than BM cells are required to 
reconstitute haemopoiesis (Verfaillie et al, 2000;van der Loo et al, 1998a), 
and the long-term repopulation ability of peripheral blood HSPCs, as 
assessed by secondary and tertiary repopulation assays, may be inferior to 
that of BM progenitors (Verfaillie et al, 2000;van der Loo et al, 1998a). 
Another important source of HSCs in research, but not in clinical use, is from 
foetal blood and liver (Yong et al, 2002a).
1.5 Clinical applications of HSC transplantation
Haemopoietic stem cell transplantation is performed to rescue a patient’s 
haemopoietic system after myeloblative chemo- or radiotherapy. In these 
applications, the patient’s own cancerous haemopoietic cells are destroyed 
via radiation or chemotherapy, then replaced with a bone marrow transplant, 
or, as is done now, with a transplant of HSCs collected from the peripheral 
circulation of a matched donor. In the case of autologous stem cell 
transplantation, HSCs are collected from mobilised peripheral blood and then 
cells are frozen and stored while the patient undergoes intensive 
chemotherapy or radiotherapy to destroy the cancer cells at the same time 
ablating the haemopoietic system. The HSCs are then re-infused into the 
patient to reconstitute haemopoiesis. HSC transplantation is in widespread 
use for the treatment of haematological malignancies (Korbling & Anderlini, 
2001). Haematological malignancies include ALL, AML, CML, Hodgkin’s 
disease, multiple myeloma, and non-Hodgkin’s lymphoma. Non malignant 
disorders are also treated with BMT/HSCT e.g. aplastic anaemia and SCID.
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1.6 Biological basis of HSC transplantation
HSPCs migrate between different tissues in foetal life and continue to 
recirculate in adult life. During development, HSCs initially migrate from the 
AGM (aortogonadomesonephros) (Godin et al, 1995;Medvinsky & Dzierzak, 
1996) to the foetal liver, and later, to the spleen and bone marrow. In adults, 
small numbers of stem cells circulate in the bloodstream (Barr et al, 
1975;Hong & Deeg, 1994), and this number can be augmented by 
chemotherapy (To etal, 1984;Tavassoli, 1992) and growth factors and is 
referred as ‘mobilisation’ (Watts et al, 2000). Thus, these cells must be able 
to selectively localise in haemopoietic tissue.
A special feature of intravenously transplanted haemopoietic stem and 
progenitor cells is their ability to migrate from the peripheral blood to the bone 
marrow, a process referred to as ‘homing’ (Papayannopoulou, 2003). The 
ability of circulating HPCs to home to the extravascular compartment of the 
bone marrow is of central importance to the clinical practice of HPC 
transplantation. The reverse process, by which HPCs are ‘mobilised’ from the 
marrow into the general circulation, is now exploited clinically to obtain 
circulating HPCs for autologous and allogeneic transplantation. Despite this 
clinical and biological significance, the mechanisms by which the process of 
homing of HPC to the bone marrow microenvironment are mediated are still 
not fully understood.
1.7 Functional properties of HSC
1.7.1 Homing of HSC to the Bone Marrow
1.7.1.1 Definition of homing
Confusion regarding the definition of homing still exists in the field because, 
in most instances, homing is equated with engraftment (see section 1.7.4). 
Recently, however more attention has been focussed on the initial homing 
phases of transplantation. “Homing” refers to the selective ability of 
circulating HSPC to localise within the bone marrow (BM), and involves a 
complex series of adhesive and migratory processes which are still not fully 
understood (reviewed in (Papayannopoulou, 2003;Quesenberry & Becker,
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1998;Hardy, 1995;Tavassoli & Hardy, 1990;Hardy & Megason, 1996)). It is 
generally considered to be a multi step process analogous to the mechanism 
of leukocyte extravasation (von Andrian et al, 1991;lmhof & Dunon, 1995). In 
this model, cells initially roll on vascular endothelium tethered by selectins 
and their respective ligands. Cell activation by signalling molecules, such as 
the chemokines, which are released by vascular and non vascular cells, 
leads to upregulation of integrin function, and the high affinity binding of 
activated integrins to endothelial ligands produces tight adhesion, shape 
change, and diapedesis to localise in extravascular foci (Imhof & Dunon, 
1995), Figure 1.2 (Adapted from (Peled etal, 2000)).
Studies on homing of HSC to the BM have also pointed to a multi step 
process mediated by a variety of adhesion molecules and receptors 
(reviewed in (Voerm ans et al, 2001 ;Quesenberry & Becker, 
1998;Papayannopoulou & Craddock, 1997)), including E, and P selectin 
(CD62E and CD62P), VLA-4 (CD49d/CD29), VLA-5 (CD49e/CD29), LFA-1 
(CD11a/CD18), and the stromal derived factor 1 (SDF-1) receptor CXCR4 
(Williams e ta l, 1991;Papayannopoulou et al, 1995;van der Loo et al, 
1998b;Aiuti et al, 1997;Frenette et al, 1998;Mazo et al, 1998;Peled et al, 
1999b;Peled et al, 1999a). The selectins (E and P selectins) mediate initial 
engagement of rolling cells and tethering of CD34+ cells with BM sinusoidal 
endothelium (Frenette et al, 1998). The integrins (VLA-4 and VLA-5) are 
considered to be important for anchorage and migration into the BM tissue 
(Papayannopoulou etal, 2001). For example, a blocking antibody to VLA-4 or 
its ligand (VCAM-1), has been shown to reduce the accumulation of 
progenitors cells in the BM 3hr after transplantation (Papayannopoulou et al,
1995). The chemoattractant SDF-1 (ligand to the receptor CXCR4) which is 
released by BM stromal cells leads to upregulation of integrin function, and 
the high affinity binding of activated integrins to endothelial ligands and tight 
adhesion (Hidalgo et al, 2001 ;Wright et al, 2002;Peled et al, 2000;Peled et al, 
1999a), Figure 1.2 adapted from (Peled et al, 2000).
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Figure 1.2 - HSPC rolling, firm adhesion and transendothelial migration. (A) HSC rolling interactions on constitutively expressed E and P selectins. 
Following rolling, CXCR4+ stem cells are activated by SDF-1, which is secreted from BM endothelial cells and triggers LFA-1/ICAM-1 and VLA-4A/CAM-1 
interactions promoting firm adhesion to endothelial cells (B). Cells that do not express sufficient levels of CXCR4 will detach from the endothelial layer and return 
to the blood stream (Bi). (C) The arrested human CXCR4+ HSC, in response to SDF-1, will extravasate and migrate through the underlying basal lamina ECM 
using VLA-4 and VLA-5 integrin receptors to fibronectin. (D) Migrating stem cells will eventually reach the ‘stem cell niches’, which consist of stromal cells that 
present the proper set of adhesion molecules (e.g. VCAM-1 and Fibronectin), SDF-1, and growth stimulatory factors (Modified from Peled et al., 2000).
1.7.1.2 Model o f HSC homing
1.7.1.3 Tethering/Rolling
The first step in the migration consists of tethering and rolling of HPC along 
the endothelium (Zannettino et al, 1995;Dercksen et al, 1995;Schweitzer et 
al, 1997). Tethering refers to the establishment of loose and somewhat 
transient adhesion between HPCs and endothelium (Figure 1.2; A). Because 
of the shear forces by the blood stream, this results in the rolling of HPCs 
along the endothelium. It is the selectins (E-selectin, P-selectin and L- 
selectins) and their ligands that mediate this tethering/rolling step (Hardy, 
1995;Hardy & Megason, 1996;Tavassoli & Hardy, 1990;Quesenberry & 
Becker, 1998;Frenette et al, 1998;Papayannopoulou et al, 2001), a short­
term cell-cell contact that allows HPCs to sample the local endothelium for 
the presence of specific trigger factors that can activate HPC integrins and 
allow the cascade to continue. In the absence of such factors, the transient 
nature of selectin binding allows HPCs to disengage and move on (Figure 
1.2; Bi).
1.7.1.4 Triggering/lntegrin activation
Rolling HPCs express substantial amounts of different integrins on the cell 
surface, however they are functionally not active. On the rolling HPC, (31 and 
(32-integrins e.g. VLA-4 and LFA-1 are activated by chemokines (chemotactic 
cytokines) for example SDF-1 the major chemoattractant for HPC (Prosper & 
Verfaillie, 2001), which are located on the endothelial surface or bound to 
proteoglycans in the endothelial extracellular matrix. The activation of HPCs 
triggers an increase in avidity caused by a conformational change in the 
integrin heterodimer, resulting in greater affinity for ligands and/or to post­
receptor events (Ginsberg etal, 1992).
1.7.1.5 Strong adhesion
The binding of chemokines to their specific receptors, which are seven- 
transmembrane spanning G-protein coupled receptors (Rollins, 1997), leads 
to firm adhesion to endothelial cells mediated by the binding of integrins to 
it’s ligands (Levesque etal, 1995;Levesque et al, 1996;Sato et al, 2000). The
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predominant pathways are mediated by the integrin adhesion molecule pairs 
V L A - 4 / V C A M - 1  and L F A - 1 / I C A M - 1  (Papayannopoulou, 
2003;Papayannopoulou & Craddock, 1997;Papayannopoulou et al, 
1995;Papayannopoulou et al, 2001).
1.7.1.6 Transmigration
The firm adhesion is followed by transendothelial migration of HPC (Mohle et 
al, 1999;Mohle et al, 2001). The process of transmigration starts with 
locomotion of adherent HPCs toward the endothelial cell-cell junction. This is 
a rapid event and is a one-way trafficking event resulting the cell reaching the 
subendothelial basal membrane. Prior to migration in response to a 
chemotactic stimulus, leukocytes (and probably HPC) display a complex 
repertoire of motility associated changes, including shape change, 
polarisation of signalling complexes, actin polymerisation, and polarised 
adhesion. Co-ordinated formation of lamellipodia and acto-myosin-based 
contractility moves the cell forward, in the direction of the chemotactic 
gradient (Figure 1.2; B). Recently the transmigration of CD34+ cells across 
BMECs and HUVECs has been demonstrated to be mediated by PECAM-1 
(CD31) (Yong et al, 1998). PECAM-1 is an Immunoglobulin superfamily cell 
adhesion molecule that is concentrated at the junctions between endothelial 
cells and is also expressed on platelets, monocytes, neutrophils and a subset 
of T cells. Muller et al., (1993) demonstrated that PECAM-1 was also directly 
involved in the process of monocyte diapedesis between endothelial cells 
(Muller etal, 1993).
Finally interaction between adhesion molecules on HPC and ligands in the 
stroma leads to anchoring of the HPC in the bone marrow microenvironment 
(Aiuti et al, 1997;Yong et al, 1998;Mohle et al, 1997). The anchoring of HPC 
depends mainly on adhesion via integrins to stromal cells and to the 
extracellular matrix proteins, Figure 1.2; C and D (Turner et al, 1998;Kerst et 
al, 1993;van der Schoot & Dercksen, 1994).
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1.7.2 Adhesion molecules and receptors involved in HPCs homing
1.7.2.1 Selectins and their ligands
The selectins (reviewed in (Gonzalez-Amaro & Sanchez-Madrid, 1999;Chan 
& Watt, 2001;lmhof & Dunon, 1995)) are a family of three proteins, E 
(endothelial, CD62E), P (platelet, CD62P) and L (Leukocyte, CD62L)- 
selectins. All the selectins structurally are composed of a 120 amino terminal 
C-type calcium-dependent domain, followed by an epidermal growth factor­
like domain and two to nine short consensus repeat units homologous to 
domains found in complement binding proteins. E-selectin and P-selectin are 
expressed by endothelial cells following stimulation by inflammatory 
mediators (e.g. IL-1(3, TNF-a and INF-y), P-selectin is also present on 
activated platelets and L-selectin is constitutively on leukocytes, including 
CD34+ cells. The role of selectins in the homing process has been studied in 
genetically deficient mice and with antifunctional antibodies. These knockout 
mice show defects in HPC homing to the bone marrow, but not the spleen, 
after bone marrow transplantation into irradiated recipients (Frenette et al, 
1998). Although homing was not influenced when neutralising antibodies 
against a single selectin were used, homing studies in mice deficient in both 
E and P selectins showed that E/P selectins and a4 integrins contributed 
equally to this process (Mazo etal, 1998;Frenette etal, 1998). Also irradiated 
E/P selectin-deficient mice in transplantation experiments had early deaths 
(Frenette et al, 1998). All 3 selectins can bind to sialylated, fucosylated 
lactosamines, sialyl Lewis x, and sialyl Lewis a, when presented on the 
appropriate backbone and L-selectin bind to CD34.
1.7.2.2 Integrins and their ligands
Integrins are adhesion molecules that are heterodimeric proteins consisting 
of noncovalently linked a and p subunits. At present at least 17 a subunits 
(a i, a2, a3, 04, as, 06, 0.7, as, ag, av, ai_, aM, ax, ajib, aiE, och and ao) and 8 p 
subunits (P1, P2 , P3, P4, P5, P6 , P7 and P8 ) exist and as many as 24 different 
integrin combinations have been reported, while many a  subunits associate 
with a single p subunit, several a subunits can associate with more than one 
type of p subunit (reviewed in (Gonzalez-Amaro & Sanchez-Madrid,
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1999;lmhof & Dunon, 1995;Reddy & Mangale, 2003)). The integrin subunit 
association and classification is outlined in Table 1.3. Both VLA-4 and VLA-5 
(31 integrin receptors play roles in haemopoietic development and migration 
(Papayannopoulou & Nakamoto, 1993;Papayannopoulou et al, 1995). For 
example, a blocking antibody to VLA-4 or its ligand (VCAM-1), has been 
shown to reduce the accumulation of progenitors cells in the BM 3hr after 
transplantation (Papayannopoulou etal, 1995).
Table 1.3 - Integrin classification (adapted from(Reddy & Mangale, 2003))
Family p
subunit
a
subunit
aP
complex
Receptor Ligand
VLA proteins P1 a 1 a ip i VLA-1
a2 a2 p1 VLA-2 L,C
a3 a3p1 VLA-3 C,Fn,entactin
a4 a4p1 VLA-4 Fn,VCAM-1
a5 a5p1 VLA-5 Fn
a6 a6 p1 VLA-6 L
a 7 a7p1 Fn, Vn, Tna 8 a 8pi Tn, Fn, Vn
a9 a9p1
av avpi
Leukocytes P2 aL aLp2 LFA-1 ICAM-1,2,3
proteins aM aMp2 MAC-1 C3b,Fb, ICAM-1
aX aXp2 P150, 95 C3b, LPS
aD aDP2 ICAM-3
P7 a4 a4p7
aH aHP7 LPAM-1 Fn, VCAM-1
aE aEP7 E-cadherin
Cytoadhesin P3 aV aVP3 Vitronectin Vn,Fb, Fn.OPN,
VWF, Tn, Thr
aiib aiibp3 Gpllb/llla Fb, Fn, VWF,
Vn
Other P5 aV aVP5 Vn, Fn
combinations P6 aV aVp6 Fn, Tn
P8 aV aVP8 Vn
P4 a6 a6p4 L
C=collagen, Fn=fibronectin, L=laminin, M=macrophage, Tn=tenasin, Fb=fibronogen, 
Vn=vitronectin, VWF=von willebrand factor, Thr=thrombospondin, OPN=osteopontin, 
LFA=leukocyte function associated antigen, VLA=very late antigen
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1.7.2.3 Chemokines
Chemokines (chemotactic cytokines) are a group of small (8-14kDa) 
molecules that regulate cell trafficking of various types of leukocytes through 
interactions with a subset of seven-transmembrane, G-protein-coupled 
receptors (Zlotnik & Yoshie, 2000;Baggiolini et al, 1997). Chemokines induce 
the upregulation and activation of integrins, which enable the HPCs to adhere 
to the endothelial cells to the vessel wall before migrating into the tissue 
(Springer, 1994).
Chemokines have been divided into two major subfamilies (a and (3 
chemokines) on the basis of the arrangement of the two amino terminal 
cysteine residues, depending on whether the first two cysteine residues have 
an amino acid between them (CXC) or adjacent (CC) (Rollins, 1997;Zlotnik & 
Yoshie, 2000). The receptors for these chemokines are also divided into 
subfamilies, i.e. the CXCR, CCR, CR and CX3CR family (Zlotnik & Yoshie, 
2000).
In 1997, SDF-1 was described as the first powerful chemoattractant for 
CD34+ cells. SDF-1 is produced by stromal cells, including those from the BM 
(Aiuti et al, 1997;Mohle et al, 1998). SDF-1 is classified as a CXC-chemokine 
and is also a chemoattractant for monocytes and lymphocytes (Bleul et al,
1996). The receptor for SDF-1 is a G-protein coupled receptor called CXCR4 
(also known as Fusin and LESTER). The chemokine SDF-1 and its receptor 
CXCR4 have been implicated in selectively directing the homing of HSCs to 
the BM (reviewed in (Lapidot & Kollet, 2002;Lapidot & Petit, 2002)). The 
engraftment of human cells in NOD/SCID mice was prevented by treatment 
with antibodies against CXCR4 (Peled et al, 1999b). The expression of 
CXCR4 on CD34+ human HSCs has suggested a role for SDF-1 in the 
homing process (Peled et al, 1999b). Peled et al., (1999b) reported that 
surface CXCR4 levels on freshly isolated human BM or CB CD34+ enriched 
cells are fairly constant (about 40-50%), as is their migratory ability toward 
SDF-1 in transwells (about 25%). However, MPB CD34+ enriched cells 
obtained from G-CSF-treated healthy donors display highly variable 
expression of CXCR4, and migration toward a gradient of SDF-1 (Peled et al, 
1999b). Aiuti et al., (1997) found very low levels of surface CXCR4
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expression on mobilised human CD34+ enriched cells and reduced migration 
in vitro toward a gradient of SDF-1 in transwells (Aiuti et al, 1997). However, 
Rosu-Myles et al., (2000) recently demonstrated that CXCR4 expression on 
human HSCs was not required for effective stem cell repopulation function 
(Rosu-Myles et al, 2000). They reported that human CB and foetal blood 
CD34+ CD38' CXCR4' and CD34+ CD38' CXCR4+ sorted cells both have 
similar repopulating capacity in NOD/SCID mice (Rosu-Myles et al, 2000). 
These observations by Rosu-Myles et al., (2000) may be because despite 
the absence of CXCR4 on the surface, CD34+ CXCR4' sorted cells express 
intracellular CXCR4 that can be induced to cell surface expression by 
stimulation with cytokines (Kollet et al, 2002). This suggests that perhaps 
CXCR4 levels may be modulated in vivo (Kollet et al, 2002).
1.7.3 Cell cycle status of HSCs from different sources
The majority of haemopoietic stem cells are non-cycling quiescent cells, but 
with the potential of multiple divisions with self-renewal capacity as well as 
giving rise to different committed maturing cells. Adult human MPB show a 
highly quiescent phenotype (Uchida et al, 1997) with greater than 95% of 
peripheral blood CD34+ cells in G0/G1 of the cell cycle (Yong et al, 
1998;Williams et al, 1997). Similarly more than 97% of UCB CD34+ cells are 
in G0/G1 (Traycoff et al, 1994;Yong et al, 1999). In contrast only 85% of adult 
BM CD34+ cells are in the G0/G1 phase of the cell cycle (Gothot et al, 1998). 
HSC found in extravascular haemopoietic tissue appear to contain a higher 
proportion of cells in the proliferative phase (S+G2/M) of the cell cycle. Thus, 
while foetal CD34+ cells are in general less quiescent than adult CD34+ cells, 
those from foetal liver contain a greater proportion of cells in S+G2/M (28%) 
than those found in foetal blood (11%) (Yong et al, 2002a).
1.7.4 Engraftment of HSCs
Following transplantation into the recipient, HSCs, in order to engraft and 
reconstitute the BM, must home to and lodge in the specialised niches of the 
BM microenvironment (see section 1.7.1) and this is followed by the onset of 
their proliferation (engraftment). One of the factors that may be involved in 
engraftment ability of HSCs is the homing process itself, as discussed above
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(see section 1.7.1) and also in more detail in Chapter 3. The other factors 
including cell cycle status (Chapter 4), cytokine exposure (Chapter 3 and 5), 
CXCR4 expression (Chapter 3), Fas expression (Chapter 5) and accessory 
cells (Chapter 6 ) and are discussed in detail in the chapters indicated and 
highlighted below.
1.7.4.1 Factors influencing engraftment ability o f haemopoietic stem cell 
grafts
1.7.4.2 Cytokine exposure
One of the major efforts in stem cell research has been on ex vivo expansion 
of HSPCs. Cytokine expansion may, however have detrimental effects on 
subsequent engraftment (Liu et al, 2003;Young et al, 2001). The effect of 
cytokine exposure on HSPCs has been demonstrated in both murine and 
xenogeneic systems and studies highlighting that cytokine exposure alters 
engraftment potential of HSCs is discussed in detail in Chapters 3 and 5. The 
reasons for this remains unclear, but are commonly thought to relate to cell 
cycling.
1.7.4.3 Cell cycle status
One of the major factors is thought to be the role of the cell cycle status in 
homing of HPCs. This has been shown in both syngeneic murine models 
(Habibian et al, 1998;Fleming et al, 1993) and also in xenogeneic transplant 
models (Gothot et al, 1998;Glimm et al, 2000). Studies in the xenogeneic 
transplant model observed that human haemopoietic stem cells lose 
engraftment potential during their S/G2/M transit. This is discussed in detail in 
Chapter 4 and also studies modulating the cell cycle progression and it’s 
effects on engraftment.
1.7.4.4 CXCR4 expression
Studies by Peled et al., (1999b) showed the influence of the CXCR4 receptor 
in affecting the ability of HSC to engraft (Peled et al, 1999b). This group 
demonstrated in the murine NOD/SCID model that the engraftment of human 
HSCs can be impaired by antibodies against CXCR4 (Peled et al, 1999b). In 
the clinical setting, Spencer et al., (2001), enumerated CXCR4-positive HSC
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(MPB) used for allogeneic transplantation and investigated the relationship 
with rate of subsequent haemopoietic reconstitution (Spencer et al, 2001). 
This group reported that transplantation of a minimum of 2.5x106 CXCR4 
CD34 positive cells/kg ensured rapid post-transplant platelet recovery. They 
concluded that co-expression of CXCR4 on CD34-positive cells may be an 
important determinant of post-transplant engraftment (Spencer et al, 2001). 
The influence of CXCR4 in engraftment ability of HSC grafts is discussed in 
detail in Chapters 1, 3 and 5.
1.7.4.5 Fas (CD95) expression
Ex vivo expansion is associated with increased expression of Fas (CD95) on 
cultured HSCs (Young et al, 2001 ;Liu et al, 2003). This increased Fas 
expression could make these HSCs more susceptible to apoptosis upon 
transplantation into recipients and in turn influence the engraftment ability of 
the expanded HSC graft. This is discussed in detail in Chapter 5.
1.7.4.6 Accessory cells
Recent results have pointed to the enhancing effect on engraftment ability of 
HSC grafts by co-transplantation in the presence of accessory cells. 
Examples of these accessory cells include ex vivo expanded MSCs and 
CD8+ T cells, discussed in detail in Chapter 6 .
1.8 Other adult stem cells found in the BM (non-haemopoietic)
Aside from HSCs, BM also contains mesenchymal stem cells (MSCs) 
(Pittenger et al, 1999) and the recently identified mesodermal progenitor cells 
(MPCs) (Reyes et al, 2001). These two types of marrow derived stem cells 
are outlined below and discussed in detail in Chapter 6 .
1.8.1 Types of marrow-derived stem cells
The bone marrow was originally thought to function mainly as a structural 
framework for the haemopoietic stem and progenitor cells (HSPC; discussed 
in detail in Chapters 3, 4, and 5) in the bone marrow. Since then, it has been 
established that the stroma consists of a heterogenous population of cells 
including endothelial, fibroblasts, adipocytes, and osteogenic cells, a subset
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of which exerts both positive and negative regulatory effects on the 
proliferation and differentiation of haemopoietic cells (Dexter et al, 
1977;Verfaillie, 1993). The adherent stromal cell population is also believed 
to contain other non-haemopoietic cells that are capable of self-renewal and 
differentiation into bone, cartilage, muscle, tendon and fat (Bruder et al, 
1997;Mackay et al, 1998;Pittenger et al, 1999). These characteristics have 
led to many workers to refer to these cultured cells as Mesenchymal Stem 
Cells (MSCs) reviewed by (Short et al, 2003). Recently a second rare cell 
type which is termed Multipotent Adult Progenitor Cells (MAPCs) was 
identified by (Reyes et al, 2001).
1.8.2 Mesenchymal stem cells (MSCs)
The MSCs were first identified by Fridenshtein (Fridenshtein, 1982), who 
demonstrated that when BM is plated in FCS containing medium, colonies of 
adherent fibroblast-like cells develop that can differentiate to form osteocytes, 
chondrocytes, adipocytes, tenocytes and BM stromal fibroblasts under 
defined in vitro conditions (Pittenger et al, 1999;Deans & Moseley, 2000). 
MSCs can be purified on the basis of their ability to adhere to plastic or using 
mAbs SH2 and SH4 or Stro-1 (Gronthos et al, 1994;Pittenger et al, 1999). 
While there is not a clearly defined cell surface antigenic phenotype for 
MSCs, there is agreement that they do not express typical haemopoietic cell 
surface antigens such as CD45 and CD34 and therefore have been 
characterised phenotypically in humans as non-haemopoietic cells. Human 
MSCs can be identified flow cytometrically by the mAbs SH2 (CD105), SH3, 
and SH4 (CD73) (Pittenger et al, 1999). Some of the other surface antigens 
reported to be on these cells are CD13, CD49e and CD49b, (31 integrins, 
CD44, CD71, CD90, CD106 (VCAM-1), CD124 (IL-4 receptor) (Pittenger et 
al, 1999). Variation in the isolation techniques and culture media used to 
grow MSCs in different laboratories has led to variable findings regarding the 
differentiation potential of these cells. For example, (Reyes et al, 2001) report 
that there was no evidence that MSCs cultured under conditions initially 
developed by (Pittenger et al, 1999) differentiate into cells with endothelial 
characteristics (Reyes et al, 2001). However, very recently Oswald et al., 
(2004) have shown that culture of confluent MSCs in low-serum (2% FCS)
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supplemented with VEGF (50ng/ml), results in the acquisition of several 
features of mature endothelium, including the expression of VEGF receptors 
(KDR and FLT1), VE-cadherin, VCAM-1, and vWF. They show also an 
enhanced ability to form capillary-like structures in semi-solid medium 
(Oswald et al, 2004). As another example of the controversy regarding the 
d iffe ren tia te  capacity of MSCs, some workers report that MSCs can be 
differentiated into neuronal-type cells, whereas others have not succeeded in 
differentiating MSCs into neuronal cells (Azizi et al, 1998).
1.8.3 Multlpotent adult progenitor cells (MAPCs)
A population of highly plastic, adult-derived BM cells, referred to as 
multipotent adult progenitor cells (MAPCs), can be grown in vitro from 
postnatal marrow (and other organs; (Jiang et al, 2002b)) of mice, rats and 
humans (Jiang et al, 2002a). The isolation and ex vivo expansion of MAPCs 
from adult derived-BM cells was first described by (Reyes et al, 2001), who 
demonstrated that these cells can differentiate at the single cell level not only 
into MSCs, but also into cells of visceral mesodermal origin, such as 
endothelium (Reyes et al, 2001;Reyes et al, 2002). They co-purify initially 
with MSCs and grow as adherent cells in vitro. MAPCs were selected by 
depleting BMMNCs of CD45+ and GlyA+ cells and culture on fibronectin with 
EGF and PDGF-BB and 2% or less FBS (Reyes et al, 2001). MPCs 
phenotypically are negative for CD34, CD45, c-Kit, HLA Classl and HLA-DR. 
Cells expressed low levels of p2microglobulin, CD44 and high levels of CD13 
and CD49b (Reyes e ta l, 2001). However unlike MSCs, MAPCs can be 
cultured indefinitely and expanded in culture for more than 80 population 
doublings (Reyes et al, 2002).
1.9 PhD Aims
To fully explore the clinical potential of HSCs it is important to understand the 
molecular basis for the observed loss of repopulating stem cells resulting 
from ex vivo manipulation and to investigate ways of improving the efficacy of 
HSPC transplantation by modulating the ability of stem cells to home to the 
BM.
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The initial aims of the thesis were to characterise the changes in engraftment 
behaviour in conjunction with alteration in adhesion molecule expression and 
homing, of MPB CD34+ cells after culture with SCF, Flt3L, IL-3 and IL-6 . We 
quantified short term homing of human CFC to different organs and of 
PKH26 labelled CD34+ cells homing to the BM in NOD/SCID animals in 
parallel with engraftment studies carried out on the same cells. I have 
investigated whether the reduced engraftment of cytokine stimulated CD34+ 
cells is directly related to an alteration in short term organ specific homing 
(Chapter 3).
The second aim of the thesis was to determine if alterations in the homing 
and engraftment of cytokine stimulated MPB CD34+ cells are cell cycle 
dependent. I investigated the cell cycle dependence of the homing and 
engraftment process by using sorted cells in G0G1 and S/G2/M phases of the 
cell cycle, and also by inducing cell cycle arrest at the G1/S border, followed 
by synchronised S phase progression (Chapter 4).
The third aim of the thesis was to test several ex vivo manoeuvres (culture 
condition and blockade of Fas L) which have been reported to restore the 
engraftment of preactivated cells, and to investigate if such strategies were 
able to modulate the homing behaviour of adult CD34+ cells (Chapter 5).
The final aim of the thesis was firstly, to isolate, expand and characterise 
MAPCs from postnatal BM and secondly to determine if co-transplantation of 
non-haemopoietic stem cells and heterologous T cells enhanced CD34+ cell 
homing to the BM in the NOD/SCID mice. I investigated the influence of 
MSCs and MAPCs on short term BM homing of freshly isolated CD34+ cells 
by co-infusion of cells at 1:1 ratio. I also determined if CD4+ and CD8+ cells 
co-infused at a 1:1 ratio enhanced the homing potential of CD34+ cells to the 
BM in the NOD/SCID mouse model (Chapter 6 ).
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Chapter 2: General Methods
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2.1 GENERAL REAGENTS
All materials, plastics, antibodies, reagents (including composition) and 
equipment are listed in Appendix I (page 193).
2.2 HSPC cell isolation, culture and characterisation
2.2.1 Primary haemopoietic stem cell source
In accordance with local ethical guidelines, and with local ethics committee 
approval, peripheral blood stem cells (PBSCs) were collected either from 
normal subjects donating cells for allografting or from patients being treated 
for either lymphoma or myeloma on the University College London Hospitals 
NHS Trust stem cell programme. In the case of normal donors, PBSCs were 
mobilised with G-CSF. In the case of patients with malignant diseases 
PBSCs were mobilised with G-CSF and either cyclophosphamide or ESHAP 
(a chemotherapy regimen containing cisplatin, etoposide, cytarabine and 
methylprednisolone protocols described in (Velasquez et al, 1994;Watts et al,
2000)).
2.2.2 CD34+ cell isolation.
CD34+ cells were isolated (Abs recognising the CD34 epitope QBEND/10) 
using a large scale CliniMACs system described in (Watts et al, 2002) 
(Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) in accordance with 
manufacturers instructions, by Dr MJ Watts and Mr SJ Ings. A small aliquot 
of processed cells, surplus to clinical requirements, was then made available 
for experimental purposes. CD34+ cells were also immunomagnetically 
selected using the VarioMACS LS column (Miltenyi Biotec). Cells from 1ml of 
PBSC harvest product were washed once in 10ml of PBS/EDTA solution 
(Miltenyi Biotec), pelleted by centrifugation (1800rpm for 10 minutes) and 
then, following aspiration of the supernatant, resuspended in 10Optl of anti- 
CD34 iron/dextran conjugated antibodies (Miltenyi Biotec) and incubated for 
20 minutes at 4°C. The VarioMACS LS column, placed in its magnetic 
retainer, was washed once in 3ml of PBS/EDTA to remove residual azide. 
The immunolabelled cells were then washed once in 10ml PBS/EDTA and 
the cell pellet resuspeded in 1ml of PBS/EDTA and loaded onto the column.
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Retained CD34+ cells were washed once with 4ml of PBS/EDTA before the 
column was removed from the magnet. Cells were eluted from the column 
with a further 1ml of PBS/EDTA which was gently pushed through the column 
using the plunger provided. Cells were then passed down a fresh column in a 
similar manner to maximise CD34+ purity. CD34+ cell preparations by both 
methods, as evaluated by immunofluorescence using anti-CD34-PE (HPCA- 
2), had an average purity of 93±3%. Cells were cultured either directly or 
following a period of storage in liquid nitrogen in equal volume of freeze mix 
(9ml PBS w/o Ca++ Mg++ and 3ml DMSO chilled for 30 minutes at 4°C 
followed by the addition of 8 ml 20% HSA). Freshly isolated versus 
cryopreserved cells were compared for CFC output, and in vivo homing and 
engraftment, and no significant difference was found between these 2 
sources of cells.
2.2.3 Cell culture.
CD34+ cells were cultured in tissue culture flasks (Nalge Nunc) in X-VIVO 10 
(Biowhittaker) and 1% HSA (Immuno Ltd) at a density of 0.5x106/ml 
supplemented with SCF, Flt3L (100ng/ml) IL-3, IL-6 (20ng/ml) at 37°C and 
5% C 02. In some experiments cells were cultured with SCF, Flt3L (100ng/ml) 
and TPO (20ng/ml) or SCF, TPO (50ng/ml) and SDF-1a (100ng/ml). In 
appropriate experiments cells were also cultured on RetroNectin (Takara 
Shuzo Co., Shiga, Japan) coated 6 well tissue culture plates (Costar). 
Percentage of CD34+ cells up to 96 hr in culture was 87±4%. The viability of 
cultured cells was >95% as judged by TB exclusion.
2.2.4 Viability counts
The cell viability of purified CD34+ cell fractions and cultured cells was 
assessed using a haemocytometer following an appropriate dilution in 0 .4 % 
Trypan Blue solution (Sigma).
2.2.5 Cytocentrifuge preparations
Cytocentrifuge preparations were made by adding 0.5 to 1x105 of the cell 
suspension to 2 drops of 2 0 % human serum albumin in a disposable 
cytocentrifuge cup (Shandon). The cells were spun onto the slides at 500rpm
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for 7 minutes and air dried. Cytospins were stained by standard May- 
Grunwald-Giemsa for blast cell morphology (Figure 3.1) and visualised with 
an Olympus inverted microscope.
2.2.6 Cell thaw methods
For some studies cryopreserved CD34+ cells were used. The cryovials were 
thawed quickly in a 37°C waterbath and thawed cell suspension transferred 
to a sterile 20ml conical universal. This was resuspended to 10ml dropwise 
with X-VIVO 10/4% HSA and pelleted at 1800 for 10 minutes. The cell pellet 
was resuspended in 1ml X-VIVO 10/4% HSA and cell count, viabilities and 
CFC performed. CD34+ cells were ‘rested’ overnight at 4°C in X-VIVO 10/4% 
HSA at a density of 0.5x106/ml in tissue culture flasks (Nalge Nunc) before 
use in experiments. HUVECs were thawed in a similar manner except the 
thawed cell suspension was resuspended to 10ml with lscoves/20% FCS and 
pelleted at 1000rpm for 10 minutes.
2.2.7 Clonogenic assays
CFC activity was assessed in semi-solid methylcellulose based media 
(Methocult H4230 Stem Cell Technologies, Canada) with 20% IMDM and 
supplemented with GM-CSF 25ng/ml, SCF 10ng/ml and IL-3 30ng/ml. 
Aliqouts of cells were suspended in 2.5ml of media as indicated and were 
cultured in 0.5ml aliquots in wells in a 24 well tissue culture plate at 37°C and 
5% CO2. Colonies were counted 14 days later for GM-CFC by morphologic 
criteria (if cell numbers exceeded 64) by means of an inverted stereo 
microscope (Olympus Optical, London). The appearance of colonies formed 
are shown in Figure 3.7.
2.2.8 Cell cycle analysis
CD34+ cells were pelleted (0.5-1 x106/tube) and fixed in 1ml ice-cold 70% 
methanol in PBS w/o Ca++ Mg++ overnight at -20°C.The cells were pelleted 
once more, washed once in PBS w/o Ca++ Mg++ and then incubated in 0.5ml 
staining solution for 30 min at 37°C. Samples were then analysed using an 
Epics-Elite flow cytometer (Beckman-Coulter, UK).
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2.2.9 Immunophenotyping
To determine surface expression of CD34, CD38, CXCR4, CD95, VLA4, 
VLA5, CD31, CD11a, CD3, CD4, CD8 , CD45, CD13, SH2, SH4, HLA-DR, 
HLA-ABC, CD49d and CD44, aliquots of 5x104 cells (except MAPCs due to 
limited cell numbers 3x104 were stained) were incubated with saturating 
concentrations (5-20pl) of either specific FITC, PE, RD-1 and PC5 
conjugated antibody or the appropriate matching isotype control antibodies in 
50pl of PBS w/o Ca++ Mg++ for 20 minutes at room temperature. Cells were 
then washed once in 2ml PBS w/o Ca++ Mg++ and fixed in 2 0 0 j l i I  of 2% 
paraformaldehyde. Samples were stored at 4°C in the dark until ready to run 
on the EPICS Elite flow cytometer (Beckman-Coulter).
2.2.10 Labelling human MPB CD34+ cells with PKH26.
Fresh or cultured MPB CD34+ cells were labelled with PKH26 dye according 
to manufacturer’s (Sigma) instructions with some modifications. Briefly, cells 
were washed once using 10ml of HBSS without serum and resuspended in 
1ml of Diluent C at a concentration of 20-40x106/ml in a 50ml polypropylene 
tube. Cells were combined with an equal volume (1ml) of PKH26 dye freshly 
prepared at 10pM in Diluent C (1 Opil of PKH26 dye stock at 1mM was added 
to 1ml of Diluent C in a 15 ml polypropylene tube), and incubated at room 
temperature for 4 minutes with periodic gentle mixing. Staining was 
terminated by the addition of an equal volume of FCS for 1 minute, and the 
labelled cells then washed three times in HBSS/2% FCS. A cell count was 
performed using trypan blue exclusion on a haemocytometer and the cell 
recovery after this procedure was between 71-88%. An aliquot of cells before 
and after PKH26 staining was assayed for CFCs and generated comparable 
numbers of total colonies (Table 3.6). A small number of cells were also kept 
from each group to determine the staining efficiency (Figure 3.13). The 
remaining cells were then injected intravenously into sub-lethally irradiated or 
non-irradiated NOD/SCID mice (10 million cells per mouse in a maximum of 
500pl HBSS).
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2.3 Mice and transplantation of human MPB CD34+ cells.
2.3.1 Mice
NOD/LtSz-PrKdcscld (NOD/SCID) mice were housed under positive pressure 
in a ‘ventirack’ obtained from Biozone, Kent, UK. 8-10 week old mice were 
sub-lethally irradiated (325cGy from 137Cs source) and immediately 
transplanted with the cells resuspended in a maximum volume of 500pl of 
HBSS by lateral tail vein injection. Mice were sacrificed by CO2 inhalation at 
selected intervals post transplantation.
2.3.2 Removal o f bones (femurs and tibias) the spleen, lungs and livers from 
NOD/SCID mice
Once the mouse had been sacrificed by CO2 inhalation it was positioned on 
its back and 70% IMS used to wet fur thoroughly. This step decreased the 
possibility of contaminating cell preparations with fur. A slit was cut in the fur 
just below the rib cage without cutting the peritoneal membrane. Skin was 
firmly grasped and peeled back to expose hind limbs. Using sterile sharp 
dissecting scissors, the knee joint was cut in the center. The ligaments and 
excess tissue were cut. The femur was grasped with forceps and femur cut 
near hip joint. The ends of the long bones were trimmed to expose the 
interior marrow shaft. We obtained a clean bone and one tibia was placed 
into 1ml fomalsaline. The other long bones (2 femora and 1 tibia), were 
placed in 1ml of 10% fcs/rpmi supplemented with 20U/ml heparin. For the 
removal of the spleen, the skin was peeled back to expose the peritoneum as 
above. Using a sterile dissecting scissors a incision was made in the 
peritoneal membrane. The spleen was gently pulled out and detached by 
cutting the splenic blood vessel. The lungs and livers were also removed and 
placed in formalsaline and 10% fcs/rpmi supplemented with 20U/ml 
heparin, as above.
2.3.3 Analysis of murine tissues for human progenitor cell homing.
BM cell suspensions were prepared from two femurs and one tibia and from 
spleens, lungs and livers. BM was flushed out using HBSS and a 5ml syringe 
(Terumo) attached to a 26 gauge needle (BD) and put through a 40pM cell
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strainer (BD) and collected into a 50ml polypropylene tube containing 0.5ml 
of FCS. The spleen, lungs and livers were cut up finely and eased through a 
40pM cell strainer using a plunger of a sterile 1ml syringe (Terumo) and 
collected into a 50ml polypropylene tube containing 0.5ml FCS. The cell 
suspensions were pelleted at 1600rpm for 10 minutes. The supernatant was 
removed and the cell pellet was resuspended and incubated on ice for 5 
minutes. RBC were lysed in 2ml of red cell lysis buffer (155mM NH4CI, 20mM 
NaHC03, 1mM EDTA ;BDH, Poole, UK) for 4 minutes on ice and rescued 
with 10ml of HBSS supplemented with 1% Glucose and 1% BSA (RBC lysis 
rescue buffer). The cells were pelleted at 1600rpm for 10 minutes and 
washed once in 10ml of HBSS /5% FCS. Cell counts and viability were 
performed (see section 2.2.4) and set up in clonogenic assays in 
methylcellulose (Methocult (H4230; Stem Cell Technologies Inc., Vancouver, 
Canada), with 20% IMDM)) supplemented with GM-CSF 25ng/ml, SCF 
10ng/ml and IL-3 30ng/ml. These conditions are selective for human colonies 
as no colony growth was seen using BM from control saline-injected animals. 
Purified CD34+ cells (5.0x102/ml) or harvested BMMNCs (2-4x105/ml) were 
plated in quadruplicates. Total human GM-CFC colonies per animal were 
calculated based on the assumption that 1 tibia and 2 femurs represent 12% 
of total BM (Chervenick et al, 1968) and were expressed as a percentage of 
the number of GM-CFC infused (see calculation below). To quantify the level 
of homing in other tissues, GM-CFC were counted and expressed per 106 
cells. This is because parts of the spleens, lungs and liver were removed for 
immuno-histochemistry.
Calculation for % homing of GM-CFC to BM
% of infused in BM = KA/BY»C1*D X 100
E
A= Number of GM-CFCs 
B= Number of BMMNCs seeded 
C= Total murine BMMNC count
D= 8.333 (2 femurs & 1 tibia represent 12% of total BM, therefore 100/12=8.33) 
E= Total number of GM-CFCs infused
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2.3.4 Analysis of human cell engraftment.
Six weeks post infusion, mice were sacrificed and single cell suspensions 
prepared from the BM of two femurs and one tibia (see section 2.3.3). One 
million BMMNCs were aliquoted into capped plastic test tubes for flow 
cytometry and were incubated with 100pl of mouse serum in PBS w/o Ca++ 
Mg++/1%BSA for 15 min on ice. The cells were washed once with PBS w/o 
Ca++ Mg++/1% BSA and stained at 4°C in the dark with anti-human CD45- 
PerCP, CD34-FITC, CD38-FITC, CD19-PE, CD13-FITC, CD3-FITC, CD2-PE 
in appropriate combinations (Table 2.1) in 10Opil staining buffer (PBS w/o 
Ca++ Mg++ /1%  BSA / 0.1% sodium azide). A sample from each mouse was 
also stained with isotype-matched control antibodies (Table 2.1). Cells were 
washed twice with PBS w/o Ca++ Mg++/1% BSA and fixed in 200-400pl of 1% 
paraformaldehyde. Samples were stored at 4°C in the dark until flow 
cytometry. Samples were analysed on the Epics-Elite flow cytometer 
(Beckman-Coulter, High Wycombe, UK), and at least 50,000 events were 
acquired and analysed using Elite Workstation Analysis Software Version 
4.5. An animal was considered to have successfully engrafted if the BM 
contained >1% CD45+ cells.
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Table 2.1. Antibody panel combinations for engraftment analysis
Tube 1 Isotvpe controls volume per test tube
IgGi FITC 5pl
IgGi PE 5pl
IgGi PerCP 5pl
Staining buffer 85pl
Tube 2 CD19/13/45
CD19PE 20pl
CD13FITC 10pl
CD45 PerCP 5pl
Staining buffer 65pl
Tube 3 CD34/38/45
CD34FITC 1 OjliI
CD38 PE 5pl
CD45 PerCP 5pl
Staining buffer 80pl
Tube 4 CD3/2/45
CD3 FITC 5pl
CD2 PE 5pl
CD45 PerCP 5pl
Staining buffer 85pl
2.3.5 Immunohistochemistry
Tissues (BM, Spleen and Lungs) from transplanted animals and controls 
(saline) were fixed in 1ml of 10% formalsaline. For histopathological 
examination, mouse tibias were decalcified in 10% formic acid while stirring 
overnight and then all tissues were embedded in paraffin and sectioned. 
Slides were stained with human anti-CD45 RB (Dako). For CD45-RB 
immunohistochemistry, formalin-fixed paraffin sections were dewaxed
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(xylene and 100% alcohol for 2 minutes x2 ) and treated with peroxidase 
block for 10 minutes at room temperature (12ml methanol + 2 00pil H2C>2 at 
30%). Slides were washed thoroughly in tap water and heat retrieval of 
antigen was done using a domestic pressure cooker in 3L citrate buffer at 
pH6 for 2 minutes. MOM Immunodetection Kit (PK-2200 Vector Laboratories, 
Burlingame, CA, USA) was used to block background as per manufacturers 
instructions. Briefly, sections were incubated with MOM mouse Ig blocking 
reagent for 1 hour and washed three times with Tris Buffered Saline (TBS). 
Sections were then incubated with MOM Diluent for 5 minutes and excess 
MOM Diluent was tipped off. Sections were incubated with mouse anti­
human CD45-RB (Dako M0833) for 30 minutes at 1/100 and washed twice 
with TBS, then incubated with a MOM biotinylated anti-mouse IgG for 10 
minutes (Vector Labs), washed with TBS and finally incubated with 
Vectastain Avidin Biotin Complex for 5 minutes (ABC; Vector Labs). Sections 
were washed twice with TBS and developed with 3’,3’-diaminobenzidine 
(DAB; Ken-En-Tec A/S, Denmark) substrate (1 DAB tablet was dissolved in 
10ml distilled water in the fridge for 5 minutes and 10jnl of H2O2 added just 
before use). Colour reaction was stopped by washing slides in tap water. 
Sections were lightly counterstained with haematoxylin for 4 minutes and 
differentiated in 1% acid alcohol for 1-2 seconds. The sections were then put 
through series of alcohol steps (70, 95, 100% and xylene) for 1 minute. 
Slides were mounted with Styrolite mounting medium (BDH) and analysed 
under 400x magnification.
2.4 Statistical analysis.
Data are expressed as median and range of multiple measurements or mean 
± SEM. The statistical significance between groups was carried out using the 
nonparametric Mann-Whitney U Test (on GB STAT for Apple Macintosh, 
version 6.5.4, Dynamic Microsystems, Inc) and unpaired 2-tailed Student’s t- 
test (on Excel for PC) and a P value of <0.05 was considered significant.
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2.4.1 Statistical test selection
The t-test (e.g. students t-test), like many statistical tests, assumes that you 
have sampled data from populations that follow a Gaussian bell shaped 
distribution. An alternative approach does not assume that data follow a 
Gaussian distribution. In this approach, values are ranked from low to high 
and the analyses are based on the distribution of ranks. These tests, called 
non-parametric tests, are appealing because they make fewer assumptions 
about the distribution of the data. The Mann-Whitney U test, also called the 
rank sum test, is a non-parametric test that compares two unpaired groups. If 
the data are paired or matched, then you should choose a Wilcoxon matched 
paired test instead (Table 2.2). The Mann Whitney U test compares the 
medians of two groups
Table 2.2 - Statistical test selection
Test Paired Non-parametric Unequal Variance
Unpaired t-test No No No
Paired t-test Yes No N/A
Mann-Whitney U test No Yes N/A
Wilcoxon test Yes Yes N/A
53
Chapter 3: Effect of cytokine 
exposure on the engraftment and 
homing of CD34+ cells in the 
NOD/SCID mouse model
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3.1 INTRODUCTION
Cytokine exposure alters engraftment potential of HSC 
In recent years, much effort in stem cell research has focussed on ex vivo 
manipulation of haemopoietic stem/progenitor cells (HSPCs). The 
potential advantages for ex vivo HSPC expansion are many and include the following: 
(i) decreased time to haemopoietic recovery after chemotherapy or 
transplantation; (ii) an increased long term repopulating cell (LTRC) 
component of small grafts, such as umbilical cord blood (UCB) grafts, or 
grafts from patients heavily pretreated with chemotherapy; (iii) the removal of 
cancer cells from a graft; and (iv) the genetic modification of LTRCs either to 
replace defective genes, or to express therapeutic genes of interest 
(reviewed in (Verfaillie, 2002a)). CD34+ cells from granulocyte-colony 
stimulating factor (G-CSF) mobilised peripheral blood (MPB) grafts have 
become the preferred source of stem cells for transplantation because of 
earlier neutrophil and platelet recovery, thought to be due to the increased 
number of short term repopulating cells (STRCs) (Korbling & Anderlini,
2001), and hence represent an attractive model for ex vivo expansion.
Cell expansion requires exposure to cytokines as this is required for 
maintenance of primitive haemopoietic progenitors viability ex vivo. In 
addition, cell expansion and gene transduction strategies require cells to 
pass through mitosis (Lewis & Emerman, 1994), which also involves cytokine 
stimulation. Cytokine activation may, however have detrimental effects on 
subsequent engraftment (Liu et al, 2003;Young et al, 2001). Exposure of 
stem cells to growth factors in vitro reduces the in vivo repopulating ability of 
these cells, as demonstrated in murine and xenogeneic systems (van der 
Loo & Ploemacher, 1995;Peters et al, 1996;Szilvassy et al, 1999;Szilvassy et 
al, 2000;Guenechea et al, 1999), and as evidenced in studies on retrovirally 
transduced cells (Dorrell etal, 2000;Demaison etal, 2000). In the xenogeneic 
model (Guenechea et al, 1999), fresh UCB CD34+ cells were compared with 
cells stimulated for 6 days with IL-3, IL-6 and SCF or IL-11, SCF and Flt3L. A 
significant impairment in the short term repopulation (20 days post 
transplantation) of NOD/SCID animals was associated with the
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transplantation of ex vivo expanded cells when compared with the fresh cells. 
Such observations have raised serious concerns regarding the use of 
cultured HSPC products for clinical transplantation.
In vivo homing of HSC
Much work, therefore has focussed on discovering the basis for the reduced 
engraftment of cytokine exposed cells. A frequently made assumption is that 
the reduced engraftment of cytokine exposed HSPC results from changes in 
their homing ability. It has been hypothesised that the failure of cultured 
transplanted haemopoietic cells to efficiently engraft in vivo may be related to 
a change in the ability of such cells to negotiate the BM endothelial cell 
barrier (i.e. HSCs acquire a homing defect). Some support for this comes 
from murine studies where seeding of HPC/CFC to the BM/spleen was found 
to decrease following ex vivo cytokine exposure (Szilvassy et al, 1999;van 
der Loo & Ploemacher, 1995). In one study (van der Loo & Ploemacher, 
1995), the effect of cytokine exposure on the short term seeding efficiency of 
murine haemopoietic stem cells to BM and spleen was assessed using the 
CAFC assay. Preincubation with cytokines for 2-3 hr at 37°C led to a 
substantial decrease in seeding efficiency compared with control cells kept 
on ice. Such changes in seeding efficiency may be related to the finding that 
ex vivo culture induces a down regulation of (31 integrin on mouse 
haemopoietic cells (Szilvassy et al, 2001b).
Other workers have reported that ex vivo culture of progenitors leads to 
changes in expression of members of the (31 integrin family as well as the 
chemokine receptor CXCR4, which play key roles in homing and engraftment 
of HSPC (Giet et al, 2001;Glimm et al, 2000;Orschell-Traycoff et al, 
2000;P e led  e t al, 2000 ;P apayannopou lou  & N akam oto, 
1993;Papayannopoulou et al, 1998;Levesque et al, 1995). Changes in the 
expression of such critical surface receptors in response to cytokine 
stimulation could alter stem/progenitor cell homing properties and reduce 
engraftment by several mechanisms including; (i) random egress of 
transplanted cells into non haemopoietic organs or (ii) inability of transplanted
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cells to localise or secure anchorage in bone marrow (Szilvassy et al, 
1999;Papayannopoulou & Craddock, 1997). There has not yet been a 
systematic study of the effect of cytokine stimulation on the homing abilities 
of adult human HSPC. Most studies have been carried out using UCB (Liu et 
al, 2003;Kerre et al, 2001) or murine stem cells (Hendrikx et al, 1996;Cui et 
al, 1999;Szilvassy et al, 2001a;Lanzkron et al, 1999;Cerny et al, 
2002;Dooner et al, 2004). However, there is evidence that the primitive 
progenitors in mobilised PB are qualitatively different from those found in 
bone marrow (BM) (van der Loo et al, 1998a;Verfaillie et al, 2000) and UCB 
(Yong et al, 1999;Holyoake et al, 1999;Zheng et al, 2003).
In vitro transmigration of HSCs
Previous studies in this area using an in vitro assay have focussed on the 
early critical step of transendothelial migration, whereby HSPC egress from 
the circulation into haemopoietic tissue (Yong et al, 1998). They have shown 
that while CD34+ cells adhere readily to the endothelial surface, they do not 
undergo transmigration unless activated by cytokines that induce cell division 
(Yong et al, 1998). The difficulty of assessing homing using an in vitro assay 
arises because it cannot totally mimic the complex process of homing which 
involves circulation through blood, recognition and extravasation through BM 
vascular endothelium, and migration into a supportive microevironment. 
Hence many investigators have directed their efforts to the development of 
small animal models of human HSPC transplantation (see section 1.3.2.3).
Homing studies
In general two types of homing studies have been carried out. The first is one 
in which whole unseparated marrow is infused and a surrogate assay (see 
section 1.3.2.1) is used as marker for stem cells (Frenette et al, 
1998;Szilvassy etal, 1999;Oostendorp etal, 1999). In the second, purified 
stem cells are labelled (for e.g. with fluorescent aliphatic dye PKH26) to 
enable them to be tracked after infusion (Hendrikx et al, 1996;Lanzkron et al, 
1999;Cui etal ,  1999;Szilvassy etal ,  2001b). The first approach raises 
concerns for the validity of the surrogate assay and the possibility that the 
biological phenotype of the cell may change after engraftment. The second
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approach is difficult because of the relatively large number of purified stem 
cells needed.
Chapter Aims
To effectively use haemopoietic stem cells and progenitor cells for clinical 
gene transfer (Williams & Smith, 2000), and for graft expansion (Lewis et al, 
2001), it is important to understand whether and how homing and 
engraftment of haemopoietic cells is affected by ex vivo manipulation. The 
initial aims of the project were to characterise the changes in engraftment 
behaviour in conjunction with alteration in adhesion molecule expression and 
homing, of MPB CD34+ cells after culture with SCF, Flt3L, IL-3 and IL-6. This 
cytokine combination was selected because it has been optimised for support 
and maintenance of primitive HSCs and used for retroviral transductions 
(Conneally et al, 1997;Dao et a/, 1997;Demaison et al, 2000). We quantified 
short term homing of human CFC to different organs and of PKH26 labelled 
CD34+ cells homing to the BM in NOD/SCID animals in parallel with 
engraftment studies carried out on the same cells. We have investigated 
whether the reduced engraftment of cytokine stimulated CD34+ cells is 
directly related to an alteration in short term organ specific homing.
3.2 RESULTS
3.2.1 Effect o f cytokine activation on CD34+ cell expansion and morphology 
CD34+ cells were cultured in X-VIVO 10 (a serum free medium suitable for 
cultivation of stem cells) 1% HSA and supplemented with the following 
growth factors, SCF (100ng/ml), Flt3L (100ng/ml), IL-3 (20ng/ml) and IL-6 
(20ng/ml), referred as the 4 cytokine mixture here after. CD34+ cells cultured 
in this medium proliferated rapidly, as shown in Table 3.1. At 48 hr of culture 
cells had not expanded significantly (1.1 ± 0.3 fold expansion, mean ± sem) 
but by day 3, cells had expanded 4-fold. During this culture period, the 
morphological features of CD34+ cells were observed by staining cytospin 
preparations with MGG, as shown in Figure 3.1. Freshly isolated CD34+ cells 
were primitive in appearance with a scanty cytoplasm and high nuclear to 
cytoplasmic ratio. By 24hr, cells had begun to go into cycle as demonstrated 
by the presence of the odd mitotic cell. At 48hr of culture cells were larger
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with cytoplasmic basophilia and the presence of primary azurophilic granules 
and vacuoles.
Table 3.1 - Culture and fold expansion of human MPB CD34+ cells.
Time of culture (hr) Fold expansion
(mean ± SEM)
48 1.1 ±0.3
72 4 ±0.8
CD34+ selected PBSC progenitors were cultured in X-VIVO 10/1% HSA 
supplemented with SCF and Flt3L 100ng/ml, IL-3 and IL-6 20ng/ml at a cell 
density of 0.5x106/ml. Fold expansion of input numbers is shown for 5 
separate experiments.
3.2.2 Effect of cytokine expansion on CFC numbers.
I assessed the functional activity of freshly isolated haemopoietic progenitors 
and cells cultured for 1, 4, 24 and 48hr in the 4 cytokine mix by 
methylcellulose colony assay in vitro. As shown in Table 3.2, up to 48hr of 
culture, cells generated comparable numbers of total colonies as fresh cells, 
n=2, however, culture for longer period (72 and 96 hours) also resulted in a 
comparable frequency of CFC (Table 3.3).
Table 3.2 - Effect of culture duration on colony forming cells (CFCs)
No. of GM-CFC per 1000 cells
Time in culture (hr) Expt 1 Expt 2
0 69 183
1 54 N/D
4 75 182
24 81 183
48 97 142
Freshly isolated CD34+ cells (0) were cultured for 1, 4, 24 or 48 hr in X-VIVO 
10/1% HSA supplemented with the 4 cytokine mix as described in Chapter 2 
General Methods. Colony forming activity of cells was assessed in 
methylcellulose culture. Data are expressed per 1000 cells plated and given 
for 2 independent experiments.
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Table 3.3 - Effect of culture time (3 or 4 days) on colony forming cells 
(CFCs)
No. of GM-CFC per 1000 cells
________________________ Expt 1 Expt 2
Fresh 27 127
7 2hr cultured 109 123
No. of GM-CFC per 1000 cells
___________________Expt 1___________ Expt 2__________ Expt 3
Fresh 117 60 53
96hr cultured 131 70 75
Freshly isolated CD34+ cells were stimulated with the 4 cytokine mix for 72 
and 96 hrs. Colony forming activity of cells was assessed in methylcellulose 
culture. Data are expressed per 1000 cells plated and given for independent 
experiments.
3.2.3 Human MPB CD34+ cells placed in liquid culture undergo changes in 
expression of surface receptors
Concomitant with the morphological changes observed in liquid culture 
(Figure 3.1), changes in expression of cell surface proteins occurred during 
cytokine stimulation. Freshly isolated CD34+ cells were compared to cells 
stimulated for 48hr with the 4 cytokine mixture. There was little change in 
surface expression of the early haemopoietic progenitor marker CD34 and 
the differentiation marker CD38 (Figure 3.2). In contrast, surface expression 
of the p1 integrins VLA-4 and VLA-5 were upregulated upon cytokine 
exposure. VLA-4 expression on CD34+ cells increased from 23 ± 9 to 93 ± 
2% (P<0.01) after culture, while VLA-5 increased from 20 to 88% (n=2) for 
fresh and cytokine cultured cells, respectively. In contrast there was no 
significant change in the expression of CD11a (6 to 20%) or of PECAM-1, 
also known as CD31 (59 ± 20 to 87± 4%) after 2 days of culture (Figure 3.2). 
Other surface receptors which were altered by cytokine exposure of CD34+ 
cells are Fas (also known as CD95) and CXCR4 (7 span transmembrane 
receptor). Fas expression on CD34+ cells increased from 6±1 to 65±9% after 
2 days of culture, (P<0.01, n=3) and CXCR4 expression on CD34+ cells also 
increased from 3 ± 1 to 51 ± 15% after 2 days of culture, P<0.05.
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Figure 3.1 - Morphology of selected MPB CD34+ cells and after short term suspension culture.
CD34+ selected PBSCs were cultured in X-VIVO 10/1% HSA supplemented with SCF (100ng/ml), Flt3L 
(100ng/ml), IL-3 (20ng/ml), IL-6 (20ng/ml) at 0.5x106/ml for 24 and 48 hr. Cells were spun onto glass 
slides and stained with MGG.Representative cytospins of fresh and cultured cells are shown, made on 
the indicated hours. Cells were viewed with the magnification as indicated in each plate.
Figure 3.2 - Effect of cytokine exposure on the expression of surface 
receptors in MPB CD34+ cells. Freshly isolated CD34+ cells (open bars) or 
cultured cells (48hr stimulation with SCF, Flt3L 100ng/ml and IL-3, IL-6 
20ng/ml, solid bars) were stained with FITC or PE-conjugated anti-human 
CD34, CD38, CXCR4, Fas/CD95, VLA-4, VLA-5, CD11a and PECAM-1 mAb 
and analysed by flow cytometry. Each bar represents mean ± SEM of 3 
experiments, except VLA-5 and CD11a mean of 2 experiments shown 
(*P<0.05 and **P<0.01 compared to fresh cells, Student t-test)
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3.2.4 Cytokine activation reduces engraftment o f MPB CD34+ cells in 
NOD/SCID animals
In order to confirm that cytokine stimulation of human MPB CD34+ cells 
compromises engraftment potential, I studied the engraftment of freshly 
isolated and cytokine activated MPB CD34+ cells in NOD/SCID animals by 
FACS analysis of murine BM (Figure 3.3) performed at 6 weeks post 
transplantation. Freshly isolated CD34+ cells were stimulated with the 4 
cytokine mixture (Table 3.4b) for 2-5 days (Table 3.4a) and tested for their 
engraftment potential, in comparison with fresh cells. As shown in Table 3.4a 
and Table 3.1, cytokine exposure (for >48 hrs) led to an increase in cell 
number (130% to 520% of initial) hence in order to avoid any dilutional effect 
on stem cells initially present in the graft, the numbers of cytokine exposed 
CD34+ cells infused represented the expanded equivalent of fresh cells. 
Table 3.4a summarises the results of the first set of experiments performed 
in this way. Animals which received cytokine activated cells showed lower 
engraftment (median 0.7%, range 0.0-22.7% CD45+ cells in murine BM) with 
only 3 out of 7 animals engrafting, while all animals (7 of 7) receiving fresh 
cells engrafted (median 4.6%, range 2.0-78.4% CD45+ cells in murine BM), 
n=2, P<0.05. I also performed a second series of experiments in which equal 
numbers of fresh or cultured cells were infused (Table 3.4b). Although the 
engraftment levels were generally lower (median of 1.7% [range 1.2-16%] 
and 0.1% [range 0-0.5%] for fresh and cultured cells, respectively), cultured 
cells again demonstrated a marked engraftment defect, such that no animal 
(0 of 5 animals) receiving cultured cells engrafted n=2, P<0.01. Assessment 
of engraftment by FACS analysis was confirmed by colony assays on cells 
recovered from murine BM (Figure 3.3) using human-specific cytokines (GM- 
CSF, SCF and IL-3). As shown in Figure 3.4, BM from mice transplanted with 
fresh CD34+ cells formed a median of 31 GM-CFC colonies per 105 murine 
BM cells plated, in comparison to colony yield from BM of animals 
transplanted with cultured cells which formed only a median of 2 colonies per 
105 cells, (n=2, P<0.01).
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1. Neutrophil
2. Megakaryocyte
Figure 3.3 - NOD/SCID mouse bone marrow single cell suspension. Bones removed from 
NOD/SCID mice transplanted with cells were flushed with HBSS and the cells recovered were lysed 
with RBC lysis buffer. Cells were spun onto glass slides and stained with MGG. Representative 
cytospin of murine BM cells is shown. Cells were viewed under the magnification indicated in the plate.
Table 3.4 - Effect of cytokine stimulation on the engraftment of CD34+ 
cells in NOD/SCID mice.
Cells/mouse (106) % CD45+ cells in mouse BM
Fresh Post culture Fresh Post culture
1 0.5 0.7 2.0, 2.3 0.0, 1.3
2 0.5 2.6 4.6 2.7
1 1.0 1.3 2.1, 10.5 0.1, 0.1
2 1.0 5.2 72.3, 78.4 22.7, 0.7
Median (range) 4.6 (2.0-78.4) 0.7 (0.0-22.7)
Animals 7 of 7 3 of 7
engrafted
(b)
Expt. No. Cells/mouse (106)
% CD45+ cells in mouse BM 
Fresh Post culture
1 0.5 1.4, 1.2 0.1
1 1.0 5.8, 16.2 0.1, 0.0
2 1.0 1.9, 1.3 0.5, 0.1
Median (range) 1.7(1.2-16.0) 0.1 (0.0-0.5)**
Animals 6 of 6 Oof 5
engrafted
Freshly isolated CD34+ cells (0.5 or 1.0 x 106/animal) or the expanded 
equivalent number (a) or equal number (b) of cultured cells were infused into 
sub-lethally irradiated NOD/SCID mice. Cultured cells were stimulated with 
SCF (100ng/ml), Flt3L (100 ng/ml), IL-3 (20ng/ml) and IL-6 20 ng/ml) in X- 
VIVO 10 with 1% FCS for 2-5 days (a) or 48 hours (b). For all experiments 
engraftment was assessed at 6 weeks post transplantation by 
immunophenotype analysis of BM cells as detailed in Chapter 2 General 
Methods. An animal was considered to have successfully engrafted if CD45+ 
cells comprised > 1% of BM cells. Data are given for each animal, and also 
as median and ranges of each group as indicated. *P<0.05 and **P<0.01 
compared to fresh cells, Mann-Whitney U Test.
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Figure 3.4 - Effect of cytokine stimulation on the engraftment of CD34* 
cells in NOD/SCID mice. Engraftment was assessed at 6 weeks post 
transplantation in mice that received freshly isolated CD34+ cells or cultured 
cells (48hr stimulation with SCF, Flt3L (100ng/ml) and IL-3, IL-6 (20ng/ml)) 
0.5 or 1.0 x 106/animal. Bone marrow cells were assayed for human colony 
formation (as detailed in Chapter 2 General Methods). Data are given for 
each animal in 2 independent experiments and the median for each group is 
indicated. **P<0.01 compared to fresh cells, Mann-Whitney U Test.
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3.2.5 Multi-lineage engraftment potential o f MPB CD34+ cells in the 
NOD/SCID mice
To compare the in vivo differentiation potential of engrafting fresh and post 
cultured CD34+ cells (Table 3.4a&b), the phenotypic profile of CD45+ cells in 
BM of recipient mice was determined by 3 colour immunostaining. As shown 
in Figure 3.5 and 3.6, multi-lineage engraftment was demonstrated in animals 
which engrafted with either fresh or cytokine activated cells, although the 
skewing to B-lineage engraftment seen using fresh CD34+ cells was not 
evident in animals transplanted with cytokine activated cells (Figure 3.5). 
Multilineage engraftment is shown for both expanded equivalent number 
(Figure 3.5) and equal number (Figure 3.6) of cultured cells. Expression of 
CD19 and CD13 (11% and 30%, respectively, for fresh CD34+ and 6% and 
12.4% for cultured CD34+ cells recipients) demonstrated the presence of 
engrafted cells in lymphoid and myeloid lineages, respectively. Expression of 
CD2 and CD3 (15% and 2%, respectively, for fresh CD34+ and 10% and 9% 
for cultured CD34+ cells recipients) demonstrated the presence of engrafted 
cells with T cell potential (Figure 3.6).
3.2.6 Cytokine activation impairs short term homing of CD34+ cells to BM in 
NOD/SCID animals
Initial experiments were done to assess the localisation of freshly isolated 
CD34+ cells in the BM, spleen and lungs at 1 and 24 hours post­
transplantation. Mononuclear cells recovered from murine BM, spleen and 
lungs 24hr post transplantation were plated into semisolid culture for 
enumeration of human CFC, as described in materials and methods. Aliquots 
of pre-infusion CD34+ cells were set up in parallel methylcellulose culture and 
used as reference in order to quantify homing efficiency of CFC. The 
morphology and number of colonies was determined 14 days later. Examples 
of the typical appearance of GM-CFCs are shown in Figure 3.7. GM colonies 
formed by purified CD34+ cells and by CD34+ cells recovered from the BM 
and spleen were similar in appearance, while CD34+ cells recovered from the 
lungs formed colonies which were less compact and smaller in size.
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Figure 3.5 - Effect of cytokine stimulation on the 
multi-lineage engraftment of expanded equivalent 
number of cultured CD34+ cells in NOD/SCID mice.
Lineage specific engraftment of fresh (open symbols) and 
cultured cells (stimulated with SCF, Flt3L (100ng/ml) and 
IL-3, IL-6 (20ng/ml) for 2-5 days, closed symbols) was 
assessed by flow cytometry. The percent of huCD45+ cells 
(Table 3.2a) that also expressed human lymphoid, 
myeloid and progenitor surface markers is shown. Data 
are given for each animal from two independent 
experiments.
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Figure 3.6 - Effect of cytokine stimulation on the multi-lineage 
engraftment of equal number of cultured CD34+ cells in NOD/SCID mice.
Lineage specific engraftment of fresh (open symbols) and cultured cells (48hr 
stimulation with SCF, Flt3L (100ng/ml) and IL-3, IL-6 (20ng/ml), closed 
symbols) was assessed by flow cytometry. The percent of huCD45+ cells 
(Table 3.2b) that also expressed human lymphoid, myeloid and progenitor 
surface markers is shown. Data are given for each animal from two 
independent experiments.
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Figure 3.7 - Appearance of human CFC in methylcelluose colony 
assay. Methylcellulose cultures were viewed at 14 days using an 
inverted stereo microscope (Zeiss). Colonies from a representative 
experiment. White cell colonies were scored as GM-CFC if cell numbers 
exceeded 64. High power view of GM-CFC colonies from purified CD34+ 
cells and from NOD/SCID mice BM, spleen and lungs 24 hr post 
transplantation. Magnification x100
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As seen in Figure 3.8, homing of CFC to BM (Figure 3.8a) and spleen (Figure 
3.8b) was evident at 1 hr post infusion but the numbers of CFC increased 
substantially at 24 hrs. In contrast, while CFC accumulated in the lungs at 1 
hr, numbers were reduced at 24 hrs (Figure 3.8c), suggesting that this 
represented transient accumulation rather than active homing. To investigate 
the effect of cytokine exposure, CD34+ cells were incubated with the 4 
cytokine mixture for 2-5 days and the expanded equivalent (2, or 5 x 106) of 
CD34+ cells was infused per animal. Cytokine stimulation resulted in a 
marked reduction in the homing of CFC to the BM when assessed at both 1 
and 24 hrs (fresh GM-CFC median 2.0% (range 0.5-2.4) and 2.8% (1.9-6.1) 
at 1 and 24hr respectively vs 0.1% (0.0-0.2) and 0.3% (0.0-0.7) for cultured 
cells, n=3, P<0.01 for both time points, Figure 3.8)). In contrast, cytokine 
stimulated CFC showed significantly increased localisation to lung tissue, at 
both 1 (P<0.05) and 24hr post infusion (P<0.01). Homing of fresh and post 
cultured cells to the spleen was also analysed, as the spleen is a 
haemopoietic site in the mice. Cytokine activated CD34+ cells also showed 
significant reduction in homing to the spleen (Figure 3.8B). As shown in 
Figure 3.8B, fresh CD34+ transplanted mice formed a median of 111 (range 
15-160) and 205 (range 75-415) GM-CFC colonies per 106 murine spleen 
cells at 1 and 24 hr post transplantation, whereas cultured CD34+ 
transplanted mice formed significantly less colonies with a median of 15 
(range 10-48) and 33.5 (range 8-135), for 1 and 24 hr post transplantation, 
respectively. The BM homing defect was evident after 2 days and remained 
unaltered up to 5 days of cytokine stimulation (Figure 3.9). A look at a 
detailed time course of cytokine exposure (1, 4, 24 and 48hr) showed that 
homing of CFC to the BM was significantly impaired by 24 hours following 
cytokine stimulation (mean of 0.6% of infused GM-CFC in BM), and had 
already begun to fall at 4 hours (Figure 3.10). The reduction of CFC homing 
to the spleen followed a similar time course of cytokine exposure. As shown 
in Figure 3.11, fresh CD34+ transplanted mice formed a mean of 65 GM-CFC 
colonies per 106 murine spleen cells, whereas 24 and 48hr cultured CD34+ 
transplanted mice formed significantly lower number of colonies with a mean 
of 8 and 6, respectively.
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Figure 3.8 - Homing of freshly isolated and cytokine stimulated 
CD34+ cells. Cell suspensions from the BM, spleen and lungs of 
transplanted NOD/SCID mice recovered 1 hr and 24hr after 
transplantation were assayed for colony formation using human 
specific cytokines. Number of CFC in lungs and spleen were 
corrected for the cell expansion after cytokine culture. Median and 
interquartile range of 4-7 animals pooled from 3 experiments are 
shown. (*P<0.05, **P<0.01, ***P<0.001 compared to fresh cells, 
Mann-Whitney U Test)
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Figure 3.9 - Homing of freshly isolated and cytokine stimulated CD34+ 
cells. Time course of changes in BM homing following cytokine activation. 
CD34+ cells exposed to cytokines (SCF, Flt3L 100ng/ml and IL-3, IL-6 
20ng/ml) for 2, 4 or 5 days were infused into sub-lethally irradiated animals 
and homing to BM assessed at 24hr post infusion. The homing of fresh cells 
is shown for comparison. The data are from 4 independent experiments, 
each data point represents 1 animal, and the mean values are indicated 
(*P<0.05, **P<0.01, ***P<0.001 compared to fresh cells, Mann-Whitney U 
Test)
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Figure 3.10 - Homing of freshly isolated and cytokine stimulated CD34+ 
cells. CD34+ cells were cultured (stimulated with SCF, Flt3L at 100ng/ml and 
IL-3, IL-6 at 20ng/ml) for 1, 4, 24 or 48hr and homing of infused cells to BM 
assessed at 24h post-transplantation, n=2 experiments, data given for each 
animal and the mean values are indicated (*P<0.05, **P<0.01, ***P<0.001 
compared to fresh cells, Mann-Whitney U Test)
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Figure 3.11 - Homing of freshly isolated and cytokine stimulated CD34+ 
cells to the spleen. Homing of freshly isolated CD34+ cells or cultured cells 
(stimulated with SCF, Flt3L 100ng/ml and IL-3, IL-6 20ng/ml) after 24 and 
48hr of culture to the spleen at 24hr post transplantation. The homing of fresh 
cells is shown for comparison. The data are from 10, 3 and 8 independent 
experiments for Fresh, 24 and 48 hr, respectively. Each data point represents 
1 animal, and the mean values are indicated (*P<0.05, **P<0.01, ***P<0.001 
compared to fresh cells, Mann-Whitney U Test)
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In further experiments, we used 48 hr-stimulated cells because these cells 
had not expanded significantly (a mean 1.1 ±0 .3  fold expansion over input 
numbers), n=5 (Table 3.1), so avoiding any confounding effect of infusing 
large numbers of cells.
3.2.7 Assessment of short term homing of transplanted CD34+ cells by flow 
cytometric assay.
It is possible that CFC recovery of expanded human CD34+cells may be 
adversely affected by conditions in the irradiated murine BM. Hence I sought 
to confirm our results on clonogenic cells by determining the actual numbers 
of cells which had homed to the BM at 24 hours. To track intravenously 
transplanted human MPB CD34+ cells, we used a well established cell 
labelling procedure using the fluorescent dye PKH26.
An initial experiment was carried out to determine the optimal concentration 
of PKH26 required to brightly stain fresh CD34+ cells while maintaining cell 
viability. Fresh CD34+ cells were stained with 2, 5, 10 and 20pM PKH26 and 
analysed on a flow cytometer for fluorescence intensity. Fresh unlabelled 
CD34+ cells (viability 79%) stained with 2^iM PKH26 resulted in a MFI of 7 
and no loss of cell viability (82%). At a higher PKH26 concentration of 5pM 
cells had a 3 fold higher MFI (25) but with a fall in viability to 58%. PKH26 
concentrations at 10 and 20^iM showed no further increase of staining 
intensity (MFI of 26 and 24, respectively) but significantly affected cell 
viability (52% and 54%, respectively), shown in Figure 3.12. The above data 
show that optimal cell labelling of CD34+ cells while maintaining cell viability 
was achieved with PKH26 at a concentration of 5jliM. Therefore in all further 
experiments cells were labelled with PKH26 at 5pM.
Using the staining method described in Materials and Methods, 99% of MPB 
CD34+ cells (fresh and post cultured) could be brightly stained, (Table 3.5) 
yielding a fluorescence intensity that is at least 1 log higher than that of 
unlabelled control cells. Profiles from a representative experiment of fresh 
and cultured cells stained with PKH26 at 5pM are shown in Figure 3.13.
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Figure 3.12 - PKH26 staining intensity and viability of MPB CD34* cells.
CD34+ selected PBSC progenitors were stained with PKH26 as described in 
Chapter 2 General Methods and were analysed for staining intensity 
(diamonds) and viability (triangles). Data from a representative experiment.
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Table 3.5 - PKH26 labelling of CD34+ selected cells, fresh and post culture
CD34+ cells Staining
Experiment 1* 
PKH26+ cells (%) MFI
Experiment 2A 
PKH26+ cells (%) MFI
Fresh Control 0.4 0.1 0.1 0.1
PKH26-labelled 99.2 56.2 100 178.8
Post Culture Control 0.2 0.17 0.3 0.21
PKH26-labelled 99.7 22.5 99.8 29.4
Freshly isolated CD34+ or cultured cells were PKH26-labelled as described in materials and methods. Cultured cells had been 
stimulated with the 4 cytokine mix for 48 hours. Fluorescence intensity was assessed by flow cytometry. As control unstained cells 
were analysed. Data are given from two independent experiments. * Frozen thawed cells. A Freshly selected.
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Figure 3.13 - PKH26-labelling intensity and purity of CD34+ selected PBSC progenitors. Fluorescence 
histograms showing freshly isolated MPB CD34+ cells (A) and CD34+ cells stimulated with SCF (100ng/ml), 
Flt3L (100ng/ml), IL-3 (20ng/ml), IL-6 (20ng/ml) in X-VIVO 10/1% HSA for 48 hr (B), unstained (left) and PKH26 
stained (right) as described in Chapter 2 General Methods. Fluorescence of stained PKH26 cells was at least 1 
log above that of unstained cells. A representative experiment is shown.
In order to assess PKH26 effects on CFC formation of CD34+ cells, 
unlabeled and labelled CD34+ cells were set up in the methylcellulose colony 
assay. As shown in Table 3.6, PKH26 labelled cells generated comparable 
numbers of total colonies as unstained cells, n=2. Therefore PKH26 staining 
did not have any deleterious effect on CFC growth assessed by 
methylcellulose colony assay in vitro. This indicates that PKH26 does not 
alter the functional activity of haemopoietic progenitors and is suitable to 
track their homing in vivo.
In order to evaluate the effect of cytokine exposure on homing in vivo, BM 
from mice transplanted with unlabelled and PKH26-labelled cells (fresh and 
post culture) was collected at 24hr post transplantation, and analysed for the 
presence of PKH26-labelled cells by flow cytometry. Table 3.7 shows the 
number of labelled cells that were detected in irradiated (Experiment 2) and 
non-irradiated (Experiment 1) mice per million BM cells analysed at 24hr by 
flow cytometry. It is clear that the short term (24hr) homing of CD34+ cells 
was consistently reduced after cytokine exposure (PKH26+ events per 106 
BM cells were 695, 1136 and 391, 292 for each of 2 non-irradiated and 2 
irradiated mice, respectively which received fresh cells vs 201, 204 and 68, 
48 respectively for mice which received for 48hr cultured cells, n=2, p<0.01). 
There was a mean 5 fold reduction in homing of the cytokine-treated (48hr) 
cells when compared to non-cultured fresh CD34+ cells. These results are 
presented in Table 3.7 and depicted in graphical form in Figure 3.14. As 
reported previously (Hendrikx et al, 1996), homing to non-irradiated BM was 
2 to 4 times higher than to irradiated BM and this difference was observed for 
both fresh and cultured cells (Table 3.7). Dot plot profiles from a 
representative experiment are shown in Figure 3.15.
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Table 3.6 - Effect of PKH26-labelling on colony forming cells (CFCs)
No. of GM-CFCs/1000 cells
CD34+ cells Staining Experiment 1 Experiment 2
Fresh Control 63 54
PKH26-labelled 60 40
Post Culture Control 64 58
PKH26-labelled 63 42
Freshly isolated CD34+ or cultured cells were PKH26-labelled as described in 
Chapter 2 General Methods. Cultured cells were stimulated with the 4 
cytokine mix for 48 hours. Colony forming activity of cells was assessed in 
methylcellulose culture. As control, unstained cells were analysed. Data are 
given from two independent experiments.
Table 3.7 - Number of PKH26-labelled cells detected in NOD/SCID BM, 
24hr post-transplantation.
CD34+ cells Staining
No. of PKH26+ 
Experiment 1*
events/million BM cells 
Experiment 2
Fresh Control 4 2
PKH26-labelled 695, 1136 391,292
Post culture Control 1 2
PKH26-labelled 201, 204 68, 48
Freshly isolated CD34+ or cultured cells (unstained and PKH26-labelled) 
were infused into sub-lethally irradiated NOD/SCID mice. Cultured cells were 
stimulated with SCF (100ng/ml), Flt3L (100 ng/ml), IL-3 (20ng/ml) and IL-6 
(20 ng/ml) in X-VIVO 10 with 1% HSA for 48 hours. For both experiments 
homing was assessed at 24hr post transplantation by flow cytometric 
analysis of BM cells as detailed in Chapter 2 General Methods. Data for the 
homing of cells has been presented here as number of positive events per 
million BM cells analysed. Data are given for each animal from 2 independent 
experiments. * Experiment 1 mice non-irradiated.
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Figure 3.14 - Homing defect after 48hr cytokine exposure. To examine the effects of cytokine culture on the homing 
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analysed. *Mice received 325rads sub-lethal irradiation immediately before injection of cells.
PKH26-labelled
<1)oc0o
C/)0
O
LL
CD
CM
X*
CL
Unlabelled
(A) Fresh (C)
© = © = © - H -
0
CUI
I
Q.
Illlll i i  mull—run 
1 0 0 0
l o g 9 0 L S
(B)
.  1
(D)
©  E 
©  -  
©  -
0
CUI
I
Q.
Hi menu—run 
1 0 0 0
l o g 9 0 L S
. 1
Forward scatter
Post culture
1 0 0 0
l o g 9 0 L S
1 0 0 0
l o g 9 0 L S
Figure 3.15 - Dot plot of PKH26 
positive cells in NOD/SCID 
mice BM. A total of 10 million 
PKH26-labelled fresh (A) or 48 hr 
cultured (C) MPB CD34+ cells 
were infused by tail vein into 
NOD/SCID mice. 24hr later, 
PKH26 positive cells that were 
present in the marrow were 
identified by flow cytometry. 
PKH+ve events are indicated by 
gates. Gate F (1763 events) for 
the animal which received fresh 
cells (A) contains more cells than 
Gate A (227 events) for the 
animal which received cultured 
cells. Animals infused with 10 
million unlabelled cells (B,D) 
were analysed as a control. In 
these animals, events contained 
with Gates F and A were 
negligible (1 and 6 respectively). 
Profiles from a representative 
experiment.
3.2.8 Effect of irradiation on murine BM ceils and CFC formation 
Mice that have been sub-lethally irradiated few hours before transplantation 
may produce factors (TGF-(3 and MIP1-a) that suppress colony formation 
(the so called ‘cytokine storm’ observed after radiation). In order to exclude 
the possible suppression of colony formation by negative cytokines released 
by irradiated murine BM cells, both fresh and expanded human CD34+ cells 
were cultured in the presence of a large number of BM cells (1 million) from 
irradiated and non-irradiated animals. The number of assayable progenitors 
was determined by methylcellulose colony assay. There was no difference in 
the number of CFC produced by fresh and expanded cells in the presence of 
1 million irradiated or non-irradiated murine BM cells (Table 3.8).
Table 3.8 - Effect of murine BM (irradiated and non-irradiated) on CFC 
formation from fresh and cultured CD34+ cells.
No. of GM/CFC per CD34+cells
CD34+ cells Mouse BM cells 1000 500 250
Fresh Non-irradiated 81 49 31
Irradiated* 73 45 24
None 66 49 20
Post culture Non-irradiated 120 67 38
Irradiated* 118 42 27
None 125 51 42
Freshly isolated CD34+ cells or cultured cells were mixed with 1 million 
NOD/SCID murine BM cells and assayed for GM-CFCs in the 
methylcellulose colony assay (described in Chapter 2 General Methods). 
Cultured cells were stimulated with the 4 cytokine mix for 72 hours. Control 
colony formation was assessed in the absence (None) of murine BM cells. 
*Mice received 375rads sub-lethal irradiation. Data from one experiment is 
shown.
3.2.9 Immunohistochemical identification of human cells in mice tissues.
In order to confirm that CD34+ cells identified in murine tissues at 24hr post­
transplantation had transmigrated into extravascular tissues, we carried out 
immuno-histochemical staining for CD45RB. CD45 also known as the 
common leukocyte antigen is a human specific antigen. Thus we have used 
this antigen to identify human cells in mice tissues. As seen in Figure 
3.17A&B, CD45-positive cells (indicated by arrows) can be clearly identified
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amongst murine haemopoietic tissue outside the bone marrow sinuses. BM 
sections from animals that had received cytokine activated cells contained far 
fewer CD45+ cells at 24 hours post-transplantation, when compared with 
animals that had received fresh cells. Analysis of BM from animals at 6 
weeks post-transplantation shows the presence of numerous CD45+ cells, 
confirming haemopoietic engraftment (Figure 3.16). The human tonsil 
sections served as positive control for CD45+ cells (Figure 3.16). Immuno- 
histochemical analysis of lung sections at 24hr post-transplantation (Figure 
3.17B) confirmed the presence of CD45+ cells. BM sections from animals 
infused with 0.5ml of saline served as a negative control (Figure 3.17A). BM 
section from mice infused with saline showed no positive staining (Figure 
3.17A) as expected.
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Figure 3.16. Immunohistochemical identification of human CD45* cells in the BM of NOD/SCID 
mice at 6 weeks following transplantation. Sections of BM of mice that received 1-2x106 freshly 
isolated CD34+ cells by tail vein injection were analysed for CD45RB expression at 6 weeks post 
transplantation. Sections from BM of a representative experiment are shown. Human cells (CD45+) in 
murine tissue are indicated by arrows and a dark brown staining. Numbers indicate the percentage of 
CD45+ cells in the BM by FACS analysis. Cells were viewed with the magnifications indicated in each 
plate. Human tonsil sections served as positive control.
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Figure 3.17A. Immunohistochemical identification of human CD45+ cells in the BM of NOD/SCID 
mice at 24 hr following transplantation. Sections of BM of mice that received 1-2x106 freshly isolated 
CD34+ cells by tail vein injection were analysed for CD45RB expression at 24hr post transplantation. Saline 
control mice were infused with HBSS and served as negative control. Sections from BM of a representative 
experiment are shown. Human cells (CD45+) in murine tissue are indicated by arrows and a dark brown 
staining. Human tonsil sections served as positive control. Cells were viewed with the magnifications 
indicated in each plate.
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Figure 3.17B. immunohistochemical identification of human CD45+ cells in the spleen, lungs and 
livers of NOD/SCID mice following transplantation. Sections of spleens, lungs and liver of mice that 
received 1~2x106 freshly isolated CD34+ cells by tail vein injection were analysed for CD45RB expression 
at 24hr post transplantation. Saline control mice were infused with HBSS and served as negative control. 
Sections from spleen, lungs and liver of a representative experiment are shown. Human cells (CD45+) in 
murine tissue are indicated by arrows and a dark brown staining. Human tonsil sections served as positive 
control. Cells were viewed with the magnifications indicated in each plate.
3.3 DISCUSSION
CD34+ cells cultured with the cytokine combination of SCF, Flt3L, IL-3 and IL- 
6 demonstrate a rapid expansion in total cell number. This particular cytokine 
combination has been optimised for support and maintenance of primitive 
HSCs in culture (Conneally et al, 1997;Dao et a/, 1997) and used for 
retroviral transduction of CD34+ cells (Demaison et al, 2000). With this 
cytokine combination at 48hr of culture cells had not expanded significantly, 
but by day 3 had expanded 4 fold. Similar kinetics have been reported using 
both UCB CD34+ cells (Dorrell et al, 2000) and MPB CD34+ cells (Danet et 
al, 2001). In the former study, the cytokine combination of IL-6, G-CSF, SCF, 
Flt3L was used to culture cells for 1,2,3,4 and 6 days. During the culture 
period I performed with the cytokine combination of SCF, Flt3L, IL-3 and IL-6, 
a change in cell morphology was also observed. Freshly isolated CD34+ cells 
appeared primitive with a high nuclear to cytoplasmic ratio (scanty 
cytoplasm), but by 48hr of culture, displayed a decreased nuclear to 
cytoplasmic ratio with a basophilic cytoplasm. The presence of primary 
azurophilic granules and vacuoles were seen with the odd mitotic cell. This is 
in line with the typical morphological features of cells cultured ex vivo.
Regarding the expansion of CFCs, cytokine expanded cells in liquid culture 
generated comparable numbers of total GM-CFCs colonies as freshly 
isolated cells up to 96 hr of culture. A similar finding was reported by 
(Guenechea et al, 1999) using UCB cells. A slightly different finding was 
reported earlier by (Danet et al, 2001) using MPB CD34+ cells cultured in the 
presence of SCF, TPO and Flt3L without serum. They evaluated the 
clonogenic activity (CFC) every 24 hr for 4 days and found that the first 2 
days of culture were characterised by an increase in frequency and total 
number of CFC. From Day 2 to 4, the combination of a decreasing CFC 
frequency and increasing cell number resulted in the maintenance of the total 
number of CFC.
Immunophenotypic analysis of the ex vivo expanded CD34+ cells showed no 
significant changes in the expression of the early haemopoietic marker CD34 
and also of CD38, indicating that the cells have maintained a primitive
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phenotype within this short culture period (48 hour). The (31 integrins VLA-4 
and VLA-5, key adhesion molecules considered to be important for 
anchorage and migration into the BM tissue (Papayannopoulou et al, 
1995;Papayannopoulou et al, 2001;Orschell-Traycoff et al, 2000;Giet et al,
2002) were upregulated upon cytokine exposure. A similar finding was also 
reported by (Young et al, 2001) using human MPB CD34+ cells stimulated in 
X-VIVO 15 serum free medium containing 1% BSA with c-kit ligand 
(100ng/ml), Flt3 ligand (100ng/ml) and TPO (50ng/ml). In contrast (Szilvassy 
et al, 2001b) found that ex vivo expansion of murine haemopoietic cells led to 
a downregulation of (31 integrin expression. Such different observations may 
be due to species-related differences in the regulation of integrin expression 
in HSPC (Szilvassy et al, 2001b). The increased expression of VLA-4 and 
VLA-5 on cultured human MPB CD34+ cells may lead to a greater ability for 
cultured cells to adhere and migrate compared to non cultured fresh cells. In 
contrast there was no change in expression of PECAM-1, an adhesion 
molecule involved in the transmigration of CD34+ cells across endothelium 
(Yong et al, 1998). PECAM-1 (also known as CD31) is a member of the Ig 
superfamily and is expressed by CD34+ cells at high levels, with little 
difference in expression between freshly isolated and growth factor activated 
cells (Yong etal, 1998).
Another important receptor for homing and engraftment of transplanted 
HSPC is CXCR4, which binds the chemokine SDF-1 (see section 1.7.2.3). 
Interestingly, freshly isolated MPB CD34+ cells express very low levels (3%) 
of the chemokine receptor CXCR4, however upon cytokine stimulation the 
levels rise dramatically to 51%. Peled et al., (1999b) also reported that 
stimulation (24-48hr) of MPB CD34+ cells with SCF resulted in increased 
CXCR4 expression (Peled et al, 1999b). The key role played by the 
chemokine receptor CXCR4 in homing and engraftment of CD34+ cells was 
demonstrated by use of a blocking antibody to CXCR4 (Peled et al, 
1999b;Lapidot & Kollet, 2002). These workers found that pre-treatment of 
human cells (UCB CD34+, MPB CD34+ and BM CD34+ cells) with antibodies 
to CXCR4 prevented engraftment in NOD/SCID mice. Thus cytokine
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exposure results in cells displaying a phenotype with potentially a greater 
adhesive and migratory potential. Yet such cells display reduced homing to 
the BM in vivo and reduced engraftment. In a recent report by (Kahn et al, 
2004) they observed that both CB and MPB CD34+ cells overexpressing 
CXCR4 (lentiviral gene transfer technique) demonstrated at least 2-fold 
increase in homing to the spleen of NOD/SCID mice; however, this effect 
was not observed in the BM (Kahn et al, 2004). Finally, short term culture 
induced expression of Fas/CD95 on cultured cells. Freshly isolated CD34+ 
cells express very low levels of Fas (6%) but after 2 days of culture, Fas 
expression increased substantially to 65%. This has been reported previously 
on MPB CD34+ cells (Young et al, 2001) and UCB CD34+ cells (Liu et al,
2003). Increased Fas expression on cultured cells could result in increased 
susceptibility to apoptosis in vivo when encountering Fas ligand (FasL) e.g. 
on surface of endothelium (Josefsen et al, 1999).
The detrimental effects of cytokine stimulation on murine and human HSPC 
engraftment have been known for many years. Most of the evidence comes 
from studies carried out in animal models (Guenechea et al, 1999;Peters et 
al, 1996;van der Loo & Ploemacher, 1995;Szilvassy et al, 1999;Liu et al, 
2003;Young et al, 2001). Young and co-workers (Young et al, 2001) 
demonstrated that NOD/SCID mice receiving uncultured MPB CD34+ cells 
had a mean of 20% CD45+ (human) cells in their BM 6 weeks post 
transplantation, versus 3% for mice receiving cells cultured for 3-5 days in 
KL, FL and TPO. I confirmed that cytokine stimulation of human MPB CD34+ 
cells compromises engraftment potential. MPB CD34+ cells cultured in serum 
free medium with the cytokines SCF, Flt3L, IL-3 and IL-6 have a reduced 
engraftment in vivo, which is evident by 48 hr of culture and is unaltered up to 
5 days of culture. The cytokine induced engraftment defect was observed 
regardless of whether the expanded equivalent or equal numbers of cultured 
CD34+ cells were infused. This excluded the possible dilutional effect of 
cytokine expansion on progenitor numbers. Multi-lineage engraftment was 
demonstrated for both fresh and post cultured cells, an observation 
confirmed by (Guenechea et al, 1999), the only difference being that the 
predominant lymphoid over myeloid engraftment by fresh CD34+ cells is not
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seen with post culture cells. This confirms an earlier observation by (Blundell 
et al, 1999). As outlined above cultured CD34+ cells have increased levels of 
adhesion molecules (VLA-4 and VLA-5) and the chemokine receptor CXCR4 
shown to be important in homing and engraftment (Peled et al, 1999b;Peled 
et al, 2000), but this is in contradiction with the reduced engraftment seen in 
vivo. One explanation for the reduced engraftment of cultured HSCs may be 
that the changes in surface receptor expression outlined above lead to 
increased cell migration to non-haemopoietic organs where clearance and 
destruction of these cells occurs (Szilvassy et al, 1999;Papayannopoulou & 
Craddock, 1997). This would thus alter stem/progenitor cell homing 
properties by reducing the localisation of cells into the BM. The increased 
localisation of cultured cells to the lungs of animals would be in accord with 
this hypothesis (Figure 3.8C).
I investigated the homing ability of fresh vs cultured CD34+ cells using firstly 
the CFC surrogate assay readout. Ex vivo culture had a striking effect on the 
homing behaviour of CD34+ cells, resulting in a marked fall in homing to the 
BM, with a concomitant increase in cells localising to the lungs. Reduced 
homing to the BM was evident by 24hr and persisted for up to 5 days, with no 
sign of reversibility. Reduced homing to the spleen was also observed at 24 
and 48hr of culture. Thus, the defect in homing and engraftment occurred 
rapidly following CD34+ cells exposure to cytokines at a time when the 
majority of the cells would not have divided (Yong et al, 2002b). Yong et al., 
(2002b) used the cytoplasmic dye, CFSE to track the divisional history of 
cytokine-activated CD34+ cells and demonstrated that approximately 80% 
and 70% of cells remained undivided at days 1 and 3 post stimulation, 
respectively (Yong et al, 2002b). This rapid and sustained loss of 
engraftment potential in adult CD34+ cells after cytokine exposure is in 
accord with another published study, however in that study the authors did 
not follow in parallel the changes in homing behaviour (Young et al, 2001). 
Levels of homing in my study on freshly isolated MPB CD34+ cells are similar 
to the findings of van Hennik and co-workers, who quantified human CFC 
and CAFC at 22-24 hours after injection into irradiated NOD/SCID animals 
(van Hennik et al, 1999). The rapid time course of the homing process is also
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in accord with other reports using cord blood or adult blood CD34+ cells 
(Kerre et al, 2001 ;Kollet et al, 2001). Kollet and co-investigators (Kollet et al,
2001) found that 48 hour stimulation of cord blood CD34+ cells with SCF and 
IL-6 increased the numbers of CFC recovered from the BM of transplanted 
animals, but did not quantify these as a percentage of infused cells, hence no 
information regarding the efficiency of the homing process is available.
Thus I have demonstrated the defective homing of cytokine stimulated 
human adult CD34+ cells using a functional assay for CFC to assess human 
progenitor cells in the BM. In support of the functional assay to quantify the 
homing of human HSPC, Cashman and Eaves (Cashman & Eaves, 2000) in 
a systematic study of the homing behaviour of functionally defined subsets of 
human CD34+ cells have recently reported that the homing of repopulating 
units, CAFC and CFC are very comparable, ranging from 3-6%.
Nevertheless, the functional assay for CFC may be influenced by factors 
produced by the murine BM following irradiation (Cohen et al, 2000;Ferrara, 
1993). This may adversely affect the growth of cytokine activated CD34+ 
cells. I have shown however, that there was no difference in the number of 
assayable human progenitors in the presence of irradiated and non-irradiated 
murine BM cells, thus excluding a role for inhibitory factors on colony 
formation. These results indicate once again that irradiated murine BM cells 
do not preferentially affect cultured cells and that the impaired homing 
observed with cultured cells is not due to any inhibitory factor released by the 
irradiated BM.
The defective homing of cytokine stimulated human adult CD34+ cells was 
also confirmed using a cell tracking assay. Short term (24hr) homing of 
PKH26 labelled CD34+ cells was consistently reduced after 48 hr of culture in 
cytokines, with a mean 5 fold reduction in homing of the cytokine treated cells 
when compared to non-cultured fresh CD34+ cells. This reduction in homing 
has also been documented for murine stem cells using a similar assay. 
Cerny et al., (2002) used purified Lin' Sca-1+ murine BM cells stained with 
the dye CFSE and reported defective homing of these cells following culture
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for 48 hr (cytokines IL-3, IL-6, IL-11 and Steel factor) when compared to non­
cultured cells (Cerny et al, 2002;Dooner et al, 2004). An additional finding in 
my studies was that homing of both fresh and cultured cells to non-irradiated 
BM was 2-4 times higher than to irradiated BM, a finding reported earlier by 
(Hendrikx et al, 1996) for murine stem cells labelled with the dye PKH26. 
This effect of the irradiated murine BM appears to affect both fresh and 
cultured cells equally.
Immuno-histochemical staining of BM and spleen section for CD45RB 
confirmed that CD34+ cells identified in murine tissues at 24 hour post 
transplantation had transmigrated into extravasacular tissues. The staining of 
BM and spleen sections confirmed the presence of CD45 positive cells in the 
extravascular tissues. BM sections from animals that had received cytokine 
activated cells contained far fewer CD45+ cells at 24 hr post transplantation, 
when compared to animals that had received fresh cells. BM from engrafted 
animals showed the presence of numerous CD45+ cells, confirming 
haemopoietic engraftment.
Recently, there has been speculation that cytokine stimulation induces 
changes in adhesion molecule expression of HSCs resulting in decreased 
localisation of these cells to the BM, and increased accumulation in non- 
haemopoietic organs where clearance and destruction of these cells occurs 
(Dooner et al, 2004;Moore, 2002). The data I present here are in agreement 
with the hypothesis that the reduced engraftment documented previously with 
cultured cells may be due to the reduced homing of cells to the BM as a 
result of cells lodging in the lungs. The question still remains whether the 
cells are trapped in the lungs and therefore are unable to get into the BM, or 
if they unable to get into the BM because they have increased ability to 
migrate into non-haemopoietic tissue like the lungs.
In summary, I have demonstrated in adult MPB CD34+ cells that cytokine 
exposure ex vivo leads to a loss of engraftment ability in vivo which occurs 
rapidly and which is associated with a striking alteration in the tissue
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distribution of homed cells. Loss of homing to the BM and to a lesser extent, 
the spleen, coincides with increased accumulation of cells in the lungs.
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Chapter 4: Influence of cell cycle 
status on homing of MPB CD34+
cells
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4.1 INTRODUCTION
Influence of cell cycle phase on engraftment
Exposure of stem cells to growth factors in vitro reduces the in vivo 
repopulating ability of these cells, an effect which has been found to precede 
execution of a first cell division. Previous studies suggest that when human 
HSPC are stimulated to proliferate in vitro, there is a loss of engraftment 
ability as cells progress into active phases of the cell cycle (Glimm et al, 
2000;Orschell-Traycoff et al, 2000;Szilvassy et al, 2000;Gothot et al, 1997). 
Gothot e ta i, (1998) showed in freshly harvested populations of human MPB 
CD34+ cells, that NOD/SCID repopulating cells reside in G0 rather than Gi 
(Gothot et al, 1998). Following culture for 36 hr with IL-3, KL, and FL, CD34+ 
cells moved from Go to Gi and their repopulating capacity markedly 
diminished with the transit into Gi. Thus, both G0-G1 progression and entry 
into S/G2/M in vitro are associated with a decrease in HSC engraftment 
capacity. A study using highly purified murine stem cells found this 
engraftment defect to be reversible, and to oscillate as cells undergo 
synchronous cell cycle passage with engraftment nadirs in late S-and early 
G2-phases of the cell cycle (Habibian et al, 1998). In murine lin" BM cells 
cultured in FL, SCF, IL-11, repopulating capability fell dramatically just prior 
to cell division, but recovered 24 hours later at which time the repopulating 
cells were recovered in the divided fraction (Oostendorp et al, 2000). Ex vivo 
culture of murine bone marrow cells results in an engraftment defect 
concomitantly with progression of HSC through S phase, suggesting that cell 
cycle transit impairs their ability to engraft (Kittler et al, 1997). Based on 
these data, it has been hypothesised that position in the cell cycle may 
determine whether long term engraftment will occur and that certain phases 
of the cell cycle may be incompatible with the multistep pathway of homing 
and proliferation of self-renewing HSC (Moore, 2002). The hypothesis is that 
actively cycling stem/progenitor cells are unable to “home” to haemopoietic 
tissue, this homing defect being especially pronounced for cells in S/G2/M. 
Support for this hypothesis derives from murine studies where seeding of 
HPC/CFC to the BM/spleen was found to decrease following ex vivo cytokine 
exposure (Szilvassy etal, 1999;van der Loo & Ploemacher, 1995).
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In vitro migration of G0/G 1 and S+G2/M  fractions
In vitro studies in homing have focussed on the early critical step of 
transendothelial migration, whereby HSPC egress from the circulation into 
haemopoietic tissue. Yong et al., (1998) have shown that while CD34+ cells 
adhere readily to the endothelial surface, they do not undergo transmigration 
unless activated by cytokines that induce cell division (Yong et al, 1998). 
The former group also showed that the migratory capacity is selectively 
greater for cells which are in G0G1 phase of the cell cycle (Yong et al, 
2002b), a finding recently confirmed by other workers (Giet et al, 2002). 
Although these observations provide a possible basis for the cell cycle 
dependency of engraftment, workers have yet to obtain direct confirmation 
that the defective engraftment of cytokine cultured cells occurs as a result of 
reduced homing ability of actively cycling cells.
Modulating cell cycle progression and effects on engraftment 
If actively cycling HSPC have an engraftment defect, then modulating cell 
cycle progression to induce quiescence at time of infusion might restore the 
repopulating potential. Exposure to TGF-P increased the proportion of HSPC 
in G0G1 phase of the cell cycle, but did not aid engraftment in either a murine 
model or xenogeneic model (Wiesmann et al, 2000;Glimm et al, 2000). In a 
recent study, preactivated primate CD34+ cells were “rested” for 2 days in 
SCF and retronectin, resulting in an increase in the proportion of cells in 
G0G1 and in superior engraftment compared with control ‘non-rested’ cells 
(Takatoku et al, 2001). SDF-1 has recently been reported to enhance 
survival, while inhibiting cycling of HSPC (Cashman et al, 2002;Glimm et al,
2002). Incubation of proliferating cord blood CD34+ cells with SDF and TPO 
produced an increase in CRU frequency, although without any changes in 
the cell cycle profile of the cells (Glimm et al, 2002). Intriguingly, there is now 
evidence that the cell cycle constraints on engraftment may not apply to HSC 
from early ontogeny. Foetal liver CD34+ cells, whether in Go, G1 or S/G2/M 
are able to engraft immunodeficient animals (Wilpshaar et al, 2002). 
Although there may be ontogeny-related differences in the homing and 
engraftment behaviour of HSC from different sources, this finding raises the
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possibility that the engraftment defect of cultured cells is the result of ex vivo 
cytokine activation and is not directly related to cell cycling per se.
Chapter Aims
The observed engraftment defect of proliferating human HSC during passage 
through S/G2/M phases of the cell cycle and the failure to re-enter Go may 
have a considerable negative impact on the clinical utility of current ex vivo 
expansion or retroviral marking protocols dependent on maximal induction of 
stem cell cycling (Moore, 2002). The present study was designed to 
determine if alterations in the homing and engraftment of cytokine stimulated 
MPB CD34+ cells are cell cycle dependent. I investigated the cell cycle 
dependence of the homing and engraftment process by using sorted cells in 
G0G1 and S/G2/M phases of the cell cycle, and also by inducing cell cycle 
arrest at the G1/S border, followed by synchronised S phase progression.
4.2 Special Methods
4.2.1 Ceil synchronisation using aphidicolin
CD34+ cells were stimulated with SCF, Flt3L and TPO at 100ng/ml in X-VIVO 
10 /1%HSA at a cell density of 0.5x106/ml in tissue culture flasks (Nalge 
Nunc) at 37°C and 5% CO2. After 16 hours, aphidicolin (2|ug/ml, Sigma) was 
added and incubation continued for a further 24 hours. At the end of this 
incubation (40 hours altogether), cells were centrifuged at 1800 rpm for 10 
minutes and washed with 10ml X-VIVO 10/1% HSA. After aliquots were 
removed for cell cycle analysis, cells were re-cultured in X-VIVO 10/1% HSA 
with cytokines (SCF, Flt3L and TPO at 100ng/ml) at 0.5x106/ml in order to 
allow S phase progression. Cells were harvested at 3 and 6 hours thereafter 
to assess their position in the cell cycle (see section 2.2.8) and their homing 
ability.
4.2.2 Cell cycle fractionation with Hoechst 33342.
CD34+cells were cultured in X-VIVO 10/1% HSA supplemented with SCF, 
Flt3L (100ng/ml) IL-3, IL-6 (20ng/ml) at 37°C and 5% C 02 for 48 hr. Cultured 
cells were washed once in 10ml of Hst buffer (HBSS, 20mM HEPES, 1 g/l 
glucose, 10% FCS) and resuspended at 5x106/ml in 10pM solution of
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Hoechst (Hst) 33342 (Molecular probes) in Hst buffer. After incubation at 
37°C in a water bath for 45 minutes cells were incubated for another 45 
minutes at 37°C with Pyronin Y (2.5pg/ml, Sigma). Cells were washed once 
in 10ml of chilled Hst buffer, resupended in a maximum of 1ml Hst buffer, 
transferred to a sterile capped test tube and sorted on a FACS vantage 
equipped with a multiline ultraviolet laser (351-364nm) providing excitation for 
Hst. Hst signal was detected with a 424 ± 22nm band pass filter. Sorting 
windows were constructed to sort G0/Gi from S/G2/M populations. Cells were 
kept on ice during sorting to minimise dye leaking and were protected from 
light. No effect of Hst and Py staining on colony formation was detected 
(Table 4.2). Post sort analysis was performed on sorted cells with the use of 
initial instrument settings employed during sorting. Purity of sorted G0/G1 
cells exceeded 98% and of S/G2/M cells exceeded 83%.
4.3 RESULTS
4.3.1 Short term BM homing of sorted G 0 /G 1  and S+G2/M cells
4.3.1.1 Human MPB CD34+ cells placed in liquid culture rapidly enter cell 
cycle
CD34+ cells were cultured in X-VIVO 10/1% HSA supplemented with the 4 
cytokine mixture. Culture under these conditions increased the proportion of 
actively cycling cells from 3±1% to 28±3% in S/G2/M after 48 hours (Figure
4.1). As shown in Figure 4.1, 96±1% of freshly selected CD34+ cells were in 
G0/G1 whereas by 24 and 48 hr of culture this proportion had decreased to 
81 ±9% and 72±2%, respectively, n=3. Representative cell cycle profiles of 
freshly selected CD34+ cells (Figure 4.2Ai) and cells after 48hr post 
stimulation (Figure 4.2Aii) are shown in Figure 4.2A. The time course of the 
observed changes in BM homing (Chapter 3, Figure 3.10) closely follows the 
kinetics of cells entering into the active phase of the cell cycle (Figure 4.1), 
suggesting that cytokine induced changes in BM homing may relate to 
position in cell cycle. To directly address this question, I proceeded to sort 
cytokine stimulated CD34+ cells on basis of cell cycle status.
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Figure 4.1 - Cell cycle analysis of freshly isolated MPB CD34+ cells and 
cytokine stimulated cells. Freshly isolated CD34+ cells were cultured with 
SCF, Flt3L at 100ng/ml and IL-3, IL-6 at 20ng/ml as detailed in Chapter 2 
General Methods and aliquots removed for cell cycle analysis at time points 
indicated. Cells were fixed and stained with PI and analysed on an Epics- 
Elite flow cytometer (Coulter Electronics). The percentages of cells within 
G0/G1 phase of the cell cycle are shown. The data are the mean ± SEM of 3 
experiments, except time point 4hr n=1.
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Figure 4.2 - Cell cycle fractionation of cytokine stimulated CD34+ 
cells. Cell cycle analysis of MPB CD34+ cells by PI (A) and 
fractionation using Hst and Py Y staining (B). (A) DNA histograms of 
MPB CD34+ cells immediately after isolation (i) and 48hr post culture 
(ii) by PI staining. (B) Cultured CD34+ cells were simultaneously 
stained with Hst and Py Y, the flow histogram shows gates indicating 
G0/G1 (R1) and S/G2/M (R2) populations of MPB CD34+ cells (i). Sort 
windows to collect G0/G1 and S/G2/M cells are indicated as regions 
R1 and R2, respectively. The purity of sorted G0/G1 cells (ii) 
exceeded 98% and S/G2/M cells (iii) exceeded 83%. A representative 
experiment is shown.
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4.3.1.2 Cell cycle fractionation of cytokine stimulated CD34+ cells 
CD34+ cells were cultured in X-VIVO 10/1% HSA supplemented with the 4 
cytokine mixture for 48 hr, stained with Hst/Pyronin Y and sorted into G0/G1 
and S/G2/M fractions (Figure 4.2). The purity of sorted populations was 
determined by running the sorted cells with the use of initial instrument 
settings employed during sorting. As shown in Table 4.1, the purity of G0/G1 
sorted cells was 98±0.3% and of S/G2/M cells 83±4.7%, n=4. Representative 
cell cycle profiles of sorted G0/G1 (Figure 4.2Bii) and S/G2/M (Figure 4.2Biii) 
fractions are shown in Figure 4.2B. The morphological features of 
proliferating CD34+ cells sorted into G0/G 1 and S/G2/M fractions were 
observed by staining cytospin preparations with MGG, as shown in Figure 
4.3. G0/G1 sorted cells were more primitive in appearance with a scanty 
cytoplasm and a high nuclear to cytoplasmic ratio compared to S/G2/M sorted 
cells which were larger in size.
Table 4.1 - Cell cycle analysis and fractionation of MPB CD34+ cells by 
Hst & Py staining.
Population
% of cells 
(mean ± SEM)
Presort G0/G1 67.6 ± 3
S+G2/M 31.3 ±3.9
Post sort G0/G1 98.4 ±0.3
S+G2/M 83.6 ±4.7
CD34+ cells were stimulated with SCF (100ng/ml), Flt3L (100ng/ml), IL-3 
(20ng/ml), IL-6 (20ng/ml) in X-VIVO 10/1% HSA for 48hr (presort). Cultured 
cells were stained with Hst and Py Y as described in Chapter 4 Special 
Methods and sorted for G0/G1 and S+G2/M cell fractions on a flow cytometer. 
Percentage of cells in G0/G1 and S+G2/M presort and post sort is shown for 4 
independent experiments.
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Figure 4.3 - Morphology of sorted G0/G1 and S+G2/M MPB CD34+ cells after short term 
suspension culture. CD34+ selected PBSCs were cultured in X-VIVO 10/1% HSA with SCF 
(100ng/ml), Flt3L (100ng/ml), IL-3 (20ng/ml), IL-6 (20ng/ml) for 48 hr and stained with Hst and Py Y. 
Cells were sorted on a flow cytometer for G0/G1 and S+G2/M cells. Sorted fractions were spun onto 
glass slides and stained with MGG. Representative cytospins of G0/G1 and S+G2/M cells are shown. 
Cells were viewed with the magnification indicated in each plate.
4.3.1.3 Effect of Hst/Pyronin Ystaining and cell sorting on CFC numbers 
In order to determine the effect of Hst/Pyronin Y staining and cell sorting on 
colony forming activity, I assessed the functional activity of freshly isolated 
haemopoietic progenitors and cytokine expanded cells (48hr cytokine 
stimulation) stained with Hst/Pyronin Y and sorted into G0/Gi and S/G2/M 
fractions in the methylcellulose culture. As shown in Table 4.2, G0/Gi and 
S/G2/M sorted cells generated comparable numbers of total colonies (Table
4.2).
Table 4.2 - Effect of Hst & Py staining and cell sorting on colony 
forming cells (CFCs)
No. of GM-CFC per 1000 cells
Expt 1 Expt 2 Expt 3 Expt 4 Expt 5
Fresh 159 N/D N/D 33 33
Pre-sort 160 N/D N/D 70 68
Presort 106 N/D N/D N/D 45
stained
G0/G1 54 40 46 34 N/D
S+G2M 74 40 104 25 N/D
CD34+ cells (fresh) were stimulated with SCF (100ng/ml), Flt3L (100ng/ml), 
IL-3 (20ng/ml), IL-6 (20ng/ml) in X-VIVO 10/1% HSA for 48hr (presort). 
Cultured cells were stained with Hst and Py Y (presort stained) as described 
in Chapter 4 Special Methods and sorted for G0/Gi and S+G2/M cell fractions 
on a flow cytometer. Colony forming activity of cells was assessed in 
methylcellulose culture. Data are expressed per 1000 cells plated and given 
for 5 independent experiments.
4.3.1.4 Influence of cell cycle phase on short term BM homing of cytokine 
activated cells
In order to assess the influence of cell cycle phase on short term BM homing, 
sorted G0G1 and S/G2/M fractions (Figure 4.2B) of cultured CD34+ cells were 
tested for CFC homing to the BM. The BM of animals transplanted with 
CD34+ cells stimulated for 48 hr and sorted into G0Gi and S/G2/M fractions 
were recovered and single cell suspensions plated into semisolid culture. As 
shown in Figure 4.4, CFC from the G0G1 fraction transplanted animals 
showed a small increase (mean 0.5%, range 0.09-1.07%) in BM homing 
compared with their counterparts, CFC from the S/G2/M fraction (mean 0.3%, 
range 0.15-0.47%) however, this remained significantly lower than the
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homing of un-stimulated cells (Chapter 3, Figure 3.10). The homing levels of 
CFC to the BM of unsorted (48hr cytokine stimulated) cells whether stained 
or unstained were 0.3% (mean, range 0.05-0.89%) for unstained and 0.2%, 
(mean, range 0.06-0.34%) for stained.
Parallel studies on the engraftment of these cell fractions confirmed that 
sorted G0Gi cells had no engraftment advantage compared with either 
unsorted cells or cells in the S/G2/M fraction (G0G1 cells [0.1% CD45+], 
unsorted cells [0.2% CD45+], and S/G2/M cells [0.1% CD45+]).
4.3.2 Short term homing of cell cycle synchronised G o /G 1} S and G 2/ M  
cells
4.3.2.1 Aphidicolin induces cell cycle arrest of MPB CD34+ cells 
I cannot exclude the possibility that cell sorting might have an effect on 
homing capabilities of CD34+ cells, or that sorted G0G1 cells did not display 
higher levels of homing because the critical cells important for homing and 
engraftment lay in the S/G2/M fraction. In order to address these issues, I 
used aphidicolin to induce cell cycle arrest at the G1/S border prior to the first 
cell division (Huygen et al, 2002). CD34+ cells were stimulated with SCF, 
Flt3L and TPO and aphidicolin was used to arrest cells at G1/S border as 
detailed in the methods. As shown in Figure 4.5, freshly isolated CD34+ cells 
only contain a small percentage of cells that are in cycle (4.6±1.4% in 
S/G2/M), the majority of the cells reside in G0G1 phase of the cell cycle 
(Figure 4.1). After 40 hr of culture (ctl) the percentage of cells in cycle 
increases to 24.4±3.1%. However, treatment with aphidicolin (0) for 24hr 
induces cell cycle arrest and only 2.1± 0.9% of the cells are found in S/G2/M 
phase of the cell cycle (Figure 4.5). The aphidicolin treated cells were 
washed extensively and replated in fresh medium and cytokines. Cell cycle 
profiles of freshly isolated CD34+ cells and after 40 hr of culture and 
treatment with aphidicolin from one representative experiment are shown in 
Figure 4.6. In this experiment, at the end of the 40 hour culture period, 95% 
of live cells treated with aphidicolin (Figure 4.6ii) were in G0Gi compared to 
65% of control cells incubated in cytokines alone (Figure 4.6iii).
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Figure 4.4 - Cell cycle fractionation of cytokine stimulated CD34+ cells 
and the effect on homing. Short term BM homing of CD34+ cells in G0/G1 or 
S/G2/M. Sorted G0/G1 and S/G2/M fractions of cultured CD34+ cells were 
infused (0.5-2.0x106/animal) into sub-lethally irradiated NOD/SCID animal 
and BM homing of progenitor cells was assessed as described in Chapter 2 
General Methods. Cultured cells that were unstained (presort) or stained 
(presort stained) served as controls. The data are from 4 independent 
experiments, each data point represents 1 animal and numbers and bars 
indicate the means.
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Figure 4.5 - Cell cycle synchronisation of cultured CD34+ cells with 
aphidicolin. Freshly isolated CD34+ cells reside in G0/G 1 phase of the cell 
cycle (fresh). Cells were stimulated with SCF, Flt3L, TPO for 16hrs, after 
which they were reversibly blocked at the G1/S transition by 24hr treatment 
with 2jng/ml aphidicolin (0) or kept in initial conditions (Ctl). Aphidicolin- 
treated cells were washed extensively and replated in fresh medium and 
cytokines to allow cell cycle progression. Cells entered S phase after 3hr (3) 
and reached G2/M at 6 hr (6). Cell cycle status was determined by DNA 
staining with PI and percent cells in S/G2/M (mean ± SEM) of four 
independent experiments is shown.
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Figure 4.6 - Cell cycle synchronisation of cultured CD34+ cells with 
aphidicolin. Freshly isolated CD34+ cells reside in G0/G p h a se  of the cell 
cycle (i). Cells were stimulated with SCF, Flt3L, TPO for 16hrs, after which 
they were reversibly blocked at the G^S transition by 24hr treatment with 
2pg/ml aphidicolin (ii) or kept in initial conditions (iii). Aphidicolin-treated 
cells were washed extensively and replated in fresh medium and cytokines 
to allow cell cycle progression. Cells entered S phase after 3hr (iv) and 
reached G2/M at 6 hr (v). Cell cycle status was determined by DNA staining 
with PI and percent cells in G0/Gr or S/G2/M of one representative 
experiment is shown.
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After release from cell cycle block, cells moved into S (at 3 hours, Figure 
4.6iv) and then G2M (6 hours, Figure 4.6v) phases of the cell cycle in a 
synchronised manner. Gate E in Figure 4.6 indicates the proportion of 
apoptotic cells at each of these time points. Treatment with aphidicolin did 
not significantly alter the percentage of apoptotic cells (Figure 4.6 and Table
4.3). Cells were harvested at these time points of culture and infused into 
conditioned animals.
Table 4.3 - Cell cycle synchronisation of MPB CD34+ cells with 
aphidicolin and effect on cell viability.
% of cells in SubGo Mean 
Expt 1 Expt 2__________
Fresh 1 1 1
Ctl 6 7 7
0 10 9 9
3 8 10 9
6 11 14 12
Freshly isolated CD34+ cells (fresh) or cultured cells (ctl) were treated with 
aphidicolin (0) and then washed off and cell cycle progression continued for 3 
and 6 hrs as described in Chapter 4 Special Methods. Cultured cells were 
stimulated with SCF, Flt3L and TPO at 100ng/ml in X-VIVO 10/ 1% HSA for 
16hr, after which they were reversibly blocked at the G1/S transition by 24hr 
treatment with 2pg/ml aphidicolin. Cell cycle status was determined by DNA 
staining with PI and percentage of cells in sub Go (apoptosis) in 2 
independent experiments are shown.
4.3.2.2 Effect of aphidicolin cell cycle arrest on CFC numbers 
I assessed the functional activity of freshly isolated haemopoietic progenitors 
and cells treated with laphidicolim in the methylcellulose colony assay in vitro. 
As shown in Table 4.4, aphidicolin cell cycle arrested cells generated 
comparable numbers of total colonies compared to control non-treated cells 
(ctl), n=2.
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Table 4.4 - Effect of Aphidicolin cell cycle arrest on colony forming cells
(CFCs)
No. of GM-CFC per 1000 cells 
Expt 1_______________ Expt 2
Fresh 53 23
Ctl 88 43
0 74 32
3 90 24
6 85 30
Freshly isolated CD34+ cells (fresh) or cultured cells (ctl) were treated with 
aphidicolin (0) and then washed and cell cycle progression continued for 3 
and 6 hrs as described in Chapter 4 Special Methods. Cultured cells were 
stimulated with SCF, Flt3L and TPO at 100ng/ml in X-VIVO 10/ 1% HSA for 
16hr, after which they were reversibly blocked at the Gi/S transition by 24hr 
treatment with 2pg/ml aphidicolin. Colony forming activity of cells was 
assessed in methylcellulose culture. Data are expressed per 1000 cells 
plated and given for 2 independent experiments.
4.3.2.3 Effect of cell cycle synchronisation on BM homing of cultured CD34+ 
cells
Aliquots of cytokine activated CD34+ cells, untreated and following treatment 
with aphidicolin as described above, were infused into conditioned 
NOD/SCID mice. As far as possible, equivalent cell numbers were infused for 
each of the conditions/time points tested. As seen in Figure 4.7, these 
different cell populations displayed very similar levels of BM homing (mean 
0.5% of infused GM-CFC in BM), with the exception of cells at 3hr post 
aphidicolin block (45% in S+G2/M phase) which achieved lower levels of 
homing (mean 0.2%, range 0.06-0.3%; p value 0.0094 compared with ctl, 
Mann-Whitney U test). Importantly, cells arrested at the G1/S border 
displayed homing levels very similar to control cultured cells (mean 0.5%, 
range 0.43-0.54%) which had progressed unchecked through the cell cycle. 
Thus arresting cells at the G1/S border did not restore the homing ability of 
cultured cells.
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Figure 4.7 - Effect of cell cycle synchronisation on BM homing of 
cultured CD34+ cells. Cell populations ii-v as indicated in Figure 4.6 were 
infused into NOD/SCID (1-2x106cells/animal). Homing of CFC to the BM was 
analysed at 24 hours. Data are given for individual animals in 2 independent 
experiments, mean number of colonies for each condition is indicated.
** P<0.01 compared with ctl; Mann-Whitney U test.
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4.4 DISCUSSION
CD34+ cells cultured with the 4 cytokine mixture entered cell cycle rapidly as 
shown by cell cycle analysis. With this cytokine combination, at 4hr of culture 
the majority (98%) of the cells were in G0/G1 phase of the cell cycle, but at 48 
hr of culture this had fallen to only 72±2%. Cell cycle entry kinetics have been 
shown by (Giet et al, 2001) using MPB CD34+ cells but cultured with the 
cytokine combination of SCF 100ng/ml, TPO 50ng/ml, and FltL 100ng/ml. 
Kinetics of MPB CD34+ cell cycle entry have also been reported previously 
by (Yong et al, 1998) but using the cytokine combination of IL-3 12ng/ml, IL-6 
10ng/ml and SCF 10ng/ml and in the presence of serum. I used the 4 
cytokine mixture (SCF 100ng/ml, Flt3L 100ng/ml, IL-3 20ng/ml and IL-6 
20ng/ml) and much higher concentration of SCF which resulted in a more 
rapid entry in to cell cycle, very similar in kinetics to the behaviour of UCB 
CD34+ cells (20.2±1.2% of cells in S+G2/M phase of the cell cycle within 
24hr) reported by (Yong et al, 1999). This difference in the kinetics of cell 
cycle entry of MPB CD34+ cells may be due to the cytokine combination and 
the concentrations used.
MPB CD34+ cells cultured with the 4 cytokine mixture for 48hr and stained 
with Hst and Py Y (DNA and RNA staining dyes) contained 31 ±4% cells in 
S+G2/M. Similar results are obtained when cell cycle analysis is performed 
using PI (Figure 4.1). FACS sorting of proliferating CD34+ cells stained with 
Hst and Py into G0/G1 and S+G2/M fractions yielded a purity of 98±0.3% and 
83±4.7%, respectively. This level of purity is comparable to other reports in 
the literature for MPB CD34+ cells (Giet et al, 2001) and UCB CD34+ cells 
(Glimm et al, 2000). G0/G1 and S+G2/M sorted cells generated comparable 
numbers of GM-CFC, confirming previous reports (Glimm et al, 2000) using 
CB CD34+ cells. Therefore cell staining and sorting does not adversely affect 
CFC formation and CD34+ cells at different phases of the cell cycle contain 
equivalent numbers of CFCs.
Many workers have observed that the reduction in engraftment potential 
coincides with entry of cells into the active phases of the cell cycle (Habibian
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et al, 1998;Gothot et al, 1997;Oostendorp et al, 2000) in both human and 
murine HSC. It has been suggested that homing ability and thus engraftment 
potential of cytokine activated CD34+ cells alters during cell cycle transit, and 
is especially impaired during S/G2/M phase. The results I report here, 
however, do not support such an hypothesis. Although sorted G0/G1 cells 
showed slightly higher homing to the BM compared with sorted cells in 
S/G2/M, this did not reach significance, and remained significantly lower than 
the levels seen with fresh cells. Importantly, sorted cells in different phases of 
the cell cycle (G0/G1 vs S/G2/M) did not show differences in engraftment. My 
findings differ from those of Glimm and co-workers who used 5-day cultured 
cord blood CD34+ cells and found that cells in S and G2+M were ineffective in 
repopulation assays (Glimm et al, 2000) but engraftment after 6-8 weeks with 
both myeloid and lymphoid human cells was seen in mice transplanted with 
cells in G0/G1. The reasons for this difference are not clear but may relate to 
different culture conditions and to intrinsic differences between cord and adult 
CD34+ cells. The effect of cytokine culture may be different for ontogenically 
earlier cells such as cord and foetal HSC (Wilpshaar et al, 2000;Wilpshaar et 
al, 2002). Moreover, in this as in other studies, engraftment of cytokine 
activated cells was not compared with the levels achieved for fresh cells. My 
findings on in vivo homing of cytokine stimulated CD34+ cells also contrast 
with observations that the in vitro adhesive function of these cells alters with 
cell cycle. Yong et al., (2002b) and Huygen et al., (2002) have found that 
cultured CD34+ cells exhibit increased migration and reduced adhesion whilst 
in G0/G1 phase of the cell cycle compared to cells in S/G2/M (Yong et al, 
2002b;Huygen et al, 2002). It is clear however that extrapolation of these in 
vitro observations to the in vivo mechanisms whereby circulating CD34+ cells 
home to the BM must be made with caution.
In the second approach I used aphidicolin (a tetracyclic diterpene with anti­
mitotic properties) to synchronise the cells at the G1/S transition. Huygen et 
al., (2002) have previously demonstrated synchronisation of UCB CD34+ 
cells using aphidicolin and monitored changes in adhesion and motility at 
various stages during a single cell cycle transit (Huygen et al, 2002). Using 
similar culture conditions, I have demonstrated that MPB CD34+ cells
114
stimulated with SCF, Flt3L and TPO for 16 hr can also be arrested by 
treatment with aphidicolin for 24hr. This block at the Gi/S border and 
subsequent release by washing away the aphidicolin allowed synchronisation 
of cells as they progress into the S+G2/M phases of the cell cycle. In my 
experiments aphidicolin had no significant influence on CFC formation as 
previously reported by (Huygen et al, 2002) on UCB CD34+ cells. I also 
demonstrated that aphidicolin treatment has no significant influence on cell 
viability because there is not a significant difference in sub-Go (apoptotic) 
population of cells treated with or without aphidicolin. However, cells induced 
to accumulate at the G1/S border by treatment with aphidicolin did not show 
increased homing to the BM, compared with control cultured cells. The lower 
homing levels of cells in S-phase is interesting but does not explain the 
impaired BM homing of cultured cells.
Therefore both the above strategies have shown no significant difference in 
homing levels to the BM of G0/G1 vs S/G2/M cytokine stimulated MPB CD34+ 
cells in the NOD/SCID mice. These results for adult MPB CD34+ cells 
contrasts with previous reports on UCB cells albeit using different culture 
conditions. My observations suggest that other factors apart from cell cycle 
status are likely to influence the homing and engraftment capabilities of adult 
HSPC.
In summary, I have demonstrated that in adult CD34+ cells cytokine induced 
loss of BM homing to the BM is a phenomenon that occurs rapidly and does 
not appear to relate to cell cycle progression.
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Chapter 5: Strategies for improving 
homing of cytokine stimulated MPB
CD34+ cells
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5.1 INTRODUCTION
Cytokines and ex vivo expansion
Stimulatory cytokines have been utilised for ex vivo expansion of HSPC to 
aid stem cell transplantation or to optimise retroviral gene transfer. 
Additionally, many investigators have explored the possibility of accelerating 
engraftment by transplanting haemopoietic cells that have been expanded 
and partially differentiated in vitro by culturing in the presence of potent 
combinations of haemopoietic growth factors (Srour et al, 1999). Efforts to 
attain the maximal benefit of ex vivo expanded haemopoietic cells are 
however, currently hampered by deleterious changes, acquired in culture, in 
the engraftment ability of these cells, as described in previous sections.
It is thought that the loss of long term engraftment potential during culture is 
due to deleterious changes in the ability of these cells to home to the BM. 
The data presented in Chapter 3 confirm that adult CD34+ cells undergo a 
change in their in vivo homing behaviour following a period of culture in vitro. 
This change resulted in a significant decrease in the homing of cells to the 
BM. In Chapter 4, I tested the hypothesis that these changes in homing 
behaviour are cell cycle dependent, but found no difference between cells in 
different phases of the cell cycle. Furthermore, blocking Gi/S transition in 
cytokine-stimulated cells did not restore the loss of BM homing ability.
impaired BM homing
Therefore, perhaps nothing to do with cell cycle but the result of cytokine- 
stimulation. Indeed, HSPC from foetal and cord blood are able to engraft 
despite the fact they contain a significant proportion of cells in active phases 
of the cell cycle (Wilpshaar et al, 2000;Wilpshaar et al, 2002). Therefore the 
altered homing ability may be the result of cytokine activation, and 
manipulating the particular cytokine combination, or conditions of culture, 
may prevent the loss of BM homing.
Several combinations of cytokines known to act on primitive HSCs have been 
employed in vitro in an attempt to produce culture conditions suitable for HSC 
expansion (reviewed in (Moore, 2002)). The ligand for c-kit (SCF) and Flt3
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Ligand known to transduce signals crucial for HSC proliferation, and the c- 
mpl ligand, TPO shown to stimulate primitive HSC expansion, have all been 
regarded as key factors for triggering self-renewal (Williams et a l, 
1992;Rosnet et al, 1993;Matthews et al, 1991;Small et al, 1994;Young et al, 
1996;Yoshida et al, 1997;Sui et al, 1995;Knobel et al, 1994;Conneally et al, 
1998;Conneally etal, 1997;Bhatia et al, 1997;Piacibello et al, 1997;Ballen et 
al, 2000;Gammaitoni et al, 2003;Verfaillie, 2002b). Studies by (Conneally et 
al, 1997) and by others (Dao et al, 1997;Demaison et al, 2000), have shown 
that inclusion of Flt3L with the combination of IL-3, IL-6 and SCF augments 
the survival of the stem cells while they are in culture. On BM stem cells, only 
the so-called early acting growth factors such as TPO, SCF, Flt3L and IL-3 
are able to promote a net expansion of LTCICs, whereas the amplification of 
CFCs requires the presence of IL-6 and /or G-CSF (Petzer et al, 1996). 
Identification of these differential effects of cytokines on PBSC is therefore 
important in order to develop improved clinical expansion protocols aimed at 
both amplification of committed progenitors to shorten the neutropenic period 
and maintenance of the primitive stem cells with long term engraftment ability 
(Herrera et al, 2001). As indicated in the above studies the specific cytokine 
combination used in ex vivo expansion may play a major role in maintaining 
the repopulating ability of these cells, perhaps by influencing their homing 
ability.
Recently, much interest has focussed on modifying culture conditions so as 
to restore the engraftment capability of pre-activated cells. Interleukin-3 (IL-3) 
has been implicated in the loss of long term reconstituting activity of cultured 
HSC (Yonemura et al, 1996), while cytokines which selectively stimulate 
primitive HSC, such as TPO, SCF and FL, have been reported to preserve 
long term repopulating cells (Dao et al, 1997;Luens et al, 1998;Verfaillie, 
2002b). It is difficult to make direct comparison between such studies, which 
vary in terms of cell source, the use of serum free media, and the in vivo 
model (murine, or NOD/SCID, or SCID-hu bone) and not all take into account 
the degree of cell expansion after culture. Nevertheless, in HSC stimulated to 
divide following exposure to TPO/SCF/FL in vitro, NOD/SCID repopulating 
activity is maintained and is demonstrated by cells in the post-mitotic
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compartment (Danet et al, 2001;Herrera et al, 2001). If actively cycling 
HSPC have an engraftment defect, then modulating culture conditions to 
induce quiescence at time of infusion might restore the repopulating 
potential. Exposure to TGF-P increased the proportion of HSPC in G0G1 
phase of the cell cycle, but did not aid engraftment in either a murine model 
or xenogeneic model (Wiesmann et al, 2000;Glimm et al, 2000). In a recent 
study, preactivated primate CD34+ cells were “rested” for 2 days in SCF and 
retronectin resulting in an increase in the proportion of cells in G0G1 and in 
superior engraftment compared with control ‘non-rested’ cells (Takatoku et al, 
2001).
SDF-1 has recently been reported to enhance survival, while inhibiting 
cycling of HSPC (Cashman et al, 2002;Glimm et al, 2002). Cashman et a l,
(2002) provided evidence that SDF-1 can function as an inhibitor of human 
LT-CIC cycling and inhibited the cycling activity of HPP-CFC, but not the 
more mature LPP-CFC (Cashman et al, 2002). Incubation of proliferating 
cord blood CD34+ cells with SDF and TPO produced an increase in CRU 
frequency, although without any changes in the cell cycle profile of the cells 
(Glimm et al, 2002). In combination with other cytokines, SDF-1 was actually 
found to promote the proliferation of human CD34+ cells purified from normal 
adult PB although when SDF-1 was added alone, only survival was 
supported, not mitogenesis (Lataillade etal, 2000).
Fas expression and CD34+ cell homing
My finding in Chapter 4 and studies by Young et a l, (2001) and Liu et a l,
(2003) have shown that Fas receptor expression is upregulated on both MPB 
and UCB CD34+ cells during culture (Young et al, 2001 ;Liu et al, 2003). This 
may make these cells more susceptible to apoptosis in vivo when 
encountering Fas Ligand e.g. on surface of endothelium (Josefsen et al,
1999). For example, Fas Ligand within the mouse vasculature could induce 
aggregation of Fas receptor on cells post injection and trigger apoptosis, this 
could then contribute to the observed homing and engraftment defect of 
cultured cells. Young et a l, (2001) observed that caspase inhibitors of Fas- 
induced apoptosis significantly improved engraftment (2-3 fold) in a murine
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xenogeneic transplantation model (SCID-hu mouse) (Young et al, 2001). 
These authors suggested that cells with up-regulated Fas R expression were 
being protected by caspase inhibitor from apoptosis triggered by in vivo Fas 
L during homing and engraftment (Young et al, 2001).
A recent study using cord blood CD34+ cells found that the reduced homing 
levels of cultured CFC could be restored by incubating cells prior to 
transplantation with Fas/CD95 blocking mAb ZB4 (Liu et al, 2003). This is 
another approach used to protect cells from undergoing apoptosis by in vivo 
Fas L during homing and engraftment. This approach was used in this 
Chapter to determine whether increased Fas/CD95 levels caused the homing 
defect of cultured CD34+ cells from adult MPB.
Chapter Aims
I tested several ex vivo manoeuvres including several different culture 
conditions which have been reported to restore the engraftment of 
preactivated cells, to investigate if such strategies were able to modulate the 
homing behaviour of adult CD34+ cells.
5.2 Special Methods
5.2.1 Fas/CD95 blockade
CD34+ cells were stimulated in tissue culture flasks (Nalge Nunc) at a density 
of 0.5x106/ml with SCF, Flt3L (100ng/ml) and IL-3, IL-6 (20ng/ml) in X-VIVO 
10/1%HSA at 37°C and 5% CO2. In experiments using a blocking mAb, 48hr- 
cultured cells were pre-incubated for 30 minutes on ice with anti-Fas mAb 
(clone ZB4; mouse lgGi;MBL International, Watertown, MA) at 2pg/ml or 
5|ng/ml. Cells were not washed but injected in the presence of antibody in 
maximum volume of 500pl in HBSS.
In a second set of experiments, human recombinant soluble Fas Ligand at 
10, 50 and 100ng/ml (sFasL, Alexis Corporation Ltd) was included in the 
culture medium (48-72 hours). Before transplantation, cells were washed with
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10ml HBSS and resuspended in HBSS supplemented with sFasL for injection 
into NOD/SCID mice.
In order to confirm that anti-Fas mAb (ZB4) was functional, Jurkat T cells 
were preincubated with ZB4 and apoptosis triggered with FasL Plus 
recombinant protein (Oncogene). Jurkat T cells (purchased from ATCC) were 
grown in RPMI supplemented with 10% FCS and maintained at a cell density 
of 2x105/ml at 37°C and 5% CO2. Jurkat T cells were seeded into a 24 well 
plate at 2x105/ml in RPMI/10% FCS alone or with FasL plus (0.1, 1, and 
5ng/ml) with or without preincubation with ZB4 at 5pg/ml for 30 minutes at 
37°C. The proportion of apoptotic cells was determined after 6 and 24 hr.
5.2.2 Apoptosis assay
For apoptosis evaluation, cells were pelleted at 1600rpm for 10 minutes and 
then washed once in Annexin V binding buffer (140mM NaCI, 10mM HEPES, 
pH 7.4 and 5mM CaCL) before incubation for 5 minutes at room temperature 
with 1pl Annexin V-FLUOS (Roche) in 10Opil annexin V binding buffer per 
sample. Specific fluorescence was then determined using an EPICS Elite 
flow cytometer (Beckman-Coulter).
5.2.3 Retronectin coated plates
Retronectin treated plates were prepared by adding RetroNectin at 10pg/ml 
(TaKaRa Biomedicals T100A) to each well of a 6 well tissue culture plate for 
2 hours at room temperature, followed by blocking with 2% BSA in PBS w/o 
Ca++ Mg++ for 30 minutes at room temperature and finally three washes in 
PBS.
121
5.3 RESULTS
5.3.1 Role of culture conditions
5.3.1.1 Effect of IL-3 on the homing of cytokine activated CD34+ cells 
Omitting IL-3 from my cultures had no significant effect on the homing 
behaviour of cytokine activated cells (Figure 5.1). Cells cultured in the 
presence or absence of IL-3 produced similar levels of GM-CFC homing to 
the BM (0.4% for both, Figure 5.1). Cells cultured with or without IL-3 
generated comparable numbers of total colonies as fresh cells, n=2 (Table 
5.1).
Table 5.1 - Effect of IL- 3 on colony forming cells (CFCs)
No. of GM-CFC per 1000 cells
Expt 1 Expt 2
Fresh 106 108
-IL-3 94 106
+IL-3 N/D 102
Freshly isolated CD34+ cells (fresh) were stimulated in SCF, Flt3L, IL-3, IL-6  
(+IL-3) or SCF, Flt3L, TPO (-IL-3) in X-VIVO 10/1% HSA for 48hr as 
described in Chapter 2 General Methods. Colony forming activity of cells was 
assessed in methylcellulose culture. Data are expressed per 1000 cells 
plated and given for 2 independent experiments.
5.3.1.2 Effect of SDF-1 and of retronectin on the homing of cytokine activated 
CD34+ cells
Alterations in homing and engraftment may be dependent upon the particular 
culture conditions employed. Recent reports suggest that, in addition to its 
chemotactic properties, SDF-1 may also be important in the survival and cell 
cycle behaviour of CD34+ cells (Cashman et al, 2002;Glimm et al, 2002). 
Exposure of 4-day activated CD34+ cells to SDF-1 for a further 2 days 
increased the proportion of cells in G0G1 (from 72% to 85%). These cells 
generated comparable CFC numbers as compared with control cells cultured 
with and without SDF-1, and fresh non-cultured cells (Table 5.2). Despite the 
increase in G0/G 1 fraction, SDF-1 exposed cells displayed similar homing 
levels to the BM to that seen with control CD34+ cells cultured in the absence 
of SDF-1 (Figure 5.2).
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Figure 5.1 - Effect of varying culture conditions on homing of CD34+ 
cells in NOD/SCID mice. Freshly isolated CD34+ cells (fresh) were 
compared to cells stimulated in the presence or absence of IL-3 as indicated 
and 24hr BM homing of CFC determined. The data are from 2 independent 
experiments, each data point represents 1 animal, and the mean values are 
indicated.
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Table 5.2 - Effect of SDF-1 and retronectin on colony forming cells
(CFCs)
No. of GM-CFC per 1000 cells 
Expt 1____________Expt 2
Fresh 117 60
Ctl 134 71
+2d 94 29
+2d SCF, TPO 92 N/D
+2d SCF, TPO, SDF1 87 44
Ctl Rn N/D 77
+2d Rn N/D 56
CD34+ cells were cultured for 4 days in SCF (100ng/ml), Flt3L (100ng/ml), IL- 
3 (20ng/ml), IL-6 (20ng/ml) on retronectin (ctl Rn) or without (ctl). Some cells 
were washed and replated for a further 2 days in the same cytokines (+2 d), 
or on retronectin (+2d Rn) or with SDF1 (+2d SCF, TPO, SDF1) as indicated. 
Colony forming activity of cells was assessed in methylcellulose culture. Data 
are expressed per 1000  cells plated and given for 2 independent 
experiments.
Finally, culture on retronectin has been reported to result in superior 
engraftment potential (Takatoku et a/, 2001). We included retronectin in our 
standard cytokine culture, or took 4-day cultured CD34+ cells, washed and 
re-plated them on retronectin in the presence of SCF and tested for BM 
homing ability in conditioned animals. Cells cultured under these different 
conditions generated comparable numbers of CFCs (Table 5.2). We did not 
find that either of these culture methods using retronectin was able to restore 
the homing levels of cytokine activated CD34+ cells (Figure 5.2). As shown in 
Figure 5.2, cells cultured with or without retronectin showed very similar 
mean levels of homing to the BM (0.17, 0.22, and 0.25%).
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Figure 5.2 - Effect of varying culture conditions on homing of CD34+ 
cells in NOD/SCID mice. CD34+ cells were cultured for 4 days in SCF, Flt3L, 
IL-3 and IL-6 on retronectin (ctl Rn) or without (ctl). Some cells were washed 
and re-plated for a further 2 days in the same cytokines (+2 d), or on 
retronectin (+2d Rn) or with SDF (+2d SCF, TPO, SDF-1) as indicated. At the 
end of the culture period, cells were washed and injected into conditioned 
animals (2x106 cells/animal) and 24hr BM homing of CFC determined. The 
data are from 2 independent experiments, each data point represents 1 
animal, and the mean values are indicated.
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5.3.2 Role of Fas-ligand:
The findings in Chapter 4 suggest that cell cycle progression could not 
explain the reduced BM homing behaviour of cytokine activated CD34+ cells. 
Among the surface receptors which are altered by cytokine exposure of 
CD34+ cells is Fas. As seen in Chapter 3, Figure 3.2, Fas expression on 
CD34+ cells increased from 6±1% to 65±9% after 2 days of culture, P<0.01. 
Ligation of surface Fas molecules with endogenous Fas-ligand in vivo may 
lead to premature destruction of infused cells. I used 2 different approaches 
to attempt to block Fas engagement in vivo.
5.3.2.1 CD95/Fas blocking mAb (ZB4) inhibits the apoptosis of Jurkat T cells 
In the initial experiment, I confirmed that ZB4 was able to inhibit the 
apoptosis of Jurkat T cells triggered by FasL Plus. Jurkat T cells were 
cultured in RPMI/10% FCS with either FasL Plus or pre-incubated with ZB4 
(5pg/ml) for 30 minutes and then incubated with FasL Plus, as described in 
Chapter 5 Special Methods. The percentage of annexin V positive cells was 
determined at both 6 and 24hr of culture by flow cytometry. Control Jurkat T 
cells cultured in RMPI/10% FCS contained 19% annexin v positive cells after 
6 hrs. Culture of cells with FasL Plus at 0.1 and 1ng/ml resulted in 17 and 
14% Annexin v positive cells, respectively. In contrast culture with FasL Plus 
at a concentration of 5ng/ml reduced cell viability and 43% of Jurkat T cells 
were annexin v positive. Pre-incubation with ZB4 prior to culture with FasL 
Plus (5ng/ml) blocked this increase in apoptosis (Table 5.3). This confirmed 
that ZB4 mAb was capable of blocking apoptosis of Jurkat T cells. Annexin V 
staining of Jurkat T cells at 24hr of culture showed a similar trend (Table 5.3), 
with a decrease in cell viability following exposure to FasL Plus at 5ng/ml, 
(37% of cells annexin v positive). Pre-treatment with ZB4 resulted in 
blockade of apoptosis (reduced to 13%, Table 5.3).
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Table 5.3 - Blocking apoptosis in Jurkat T cells using ZB4.
% annexin v positive cells 
6hr 24hr
Control 19 5
FasL 0.1ng/ml 17 11
FasL 1ng/ml 14 20
FasL 5ng/ml 43 37
ZB4 + FasL 0.1ng/ml 20 13
ZB4 + FasL 1ng/ml 20 12
ZB4 + FasL 5ng/ml 17 13
Jurkat T cells were cultured in RPMI/10% FCS (control) with either FasL 
Plus® at 0.1, 1, 5ng/ml or pre-incubated with ZB4 (5ug/ml) for 30 minutes and 
then incubated with FasL Plus® (0.1, 1, 5ng/ml) as detailed in Chapter 5 
Special Methods. Percentage annexin v positive cells was determined at 6 
and 24hr of culture by flow cytometry. Data are shown from a representative 
experiment.
5.3.2.2 Effect of Fas/CD95 blocking mAb (ZB4) on CFC numbers 
In order to exclude any negative impact of ZB4 incubation on CFC activity. I 
assessed the functional activity of freshly isolated haemopoietic progenitors 
and CD34+ cells cultured for 48hr in the 4 cytokine mix in the presence or 
absence of ZB4 in the methylcellulose culture. As shown in Table 5.4, cells 
treated with ZB4 at 2 and 5pg/ml generated comparable numbers of total 
colonies compared with control cells cultured for 48 hr in the absence of ZB4, 
n=2 .
Table 5.4 - Effect of ZB4 on colony forming cells (CFCs)
No. of GM-CFC per 1000 cells 
Expt 1 Expt 2
Fresh 82 76
Cultured 89 181
ZB4 2ng/ml 94 101
ZB4 5ng/ml 103 101
Freshly isolated CD34+ cells (fresh) were stimulated with SCF (100ng/ml), 
Flt3L (100ng/ml), IL-3 (20ng/ml), IL-6 (20ng/ml) in X-VIVO 10/1% HSA for 
48hr (0) and then incubated with ZB4 at 2 or 5pg/ml for 30 minutes on ice. 
Colony forming activity of cells was assessed in methylcellulose culture. Data 
are expressed per 1000  cells plated and given for 2 independent 
experiments.
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5.3.2.3 Blocking Fas ligation with the blocking anti-Fas mAb (ZB4)
In the first approach to attempt to block Fas engagement in vivo, I pre­
incubated cytokine stimulated CD34+ cells with the blocking anti-Fas mAb, 
ZB4 prior to infusion. Freshly isolated haemopoietic progenitors and CD34+ 
cells cultured for 48hr in the 4 cytokine mixture in the presence or absence of 
ZB4 were infused by the tail vein route into NOD/SCID mice. Mononuclear 
cells recovered from murine BM 24 hr post transplantation were plated into 
semisolid culture for enumeration of human CFC, as described in Chapter 2 
General Methods. Aliquots of pre infusion CD34+ cells were set up in parallel 
methylcellulose culture and used as reference in order to quantify homing 
efficiency of CFC. As shown in Figure 5.3, this manoeuvre was not 
successful in rescuing the impaired homing of 48-hour cultured CD34+ cells. 
Cytokine stimulation resulted in a marked reduction in the homing of CFC to 
the BM when compared to fresh cells (fresh GM-CFC mean 3.6% vs 0.4% for 
cultured cells), Figure 5.3, (Chapter 3, Figure 3.8a). Cytokine stimulated 
cells pre-incubated with blocking mAb ZB4 showed lower levels of CFC 
homing to the BM (0.02% of infused GM-CFC in BM). Homing of fresh and 
post cultured cells treated with or without ZB4 to the spleen was also 
analysed, as the spleen is a haemopoietic site in the mice. Cytokine activated 
CD34+ cells showed a reduction in homing to the spleen (Table 5.5), as seen 
previously in Chapter 3, Figure 3.8B. As shown in Table 5.5, fresh CD34+ 
transplanted mice formed 67, 52 and 98, 86  GM-CFC colonies per 106 
murine spleen cells for experiment 1 and experiment 2 , whereas cultured 
CD34+ transplanted mice formed less colonies 15, 96 and 38, 24 for 
experiment 1 and experiment 2, respectively. In contrast ZB4 treated CD34+ 
transplanted mice formed lower colonies 5, 9, 2 and 0, 5, 4 GM-CFC colonies 
per 106 murine spleen cells for experiment 1 and experiment 2 , respectively.
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Figure 5.3 - Blocking Fas ligation and effect on homing. Cultured CD34+ 
cells were pre-treated with ZB4 (2 and 5pg/ml) for 30 minutes before 
transplantation into animals (2x106 cells/animal). Short term BM homing was 
assayed 24 hours post infusion. The homing of fresh cells is shown for 
comparison. The data are from 2 independent experiments, each data point 
represents 1 animal, and the mean values are indicated.
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Table 5.5 - Homing of MPB CD34* cells to the spleen: effect of ZB4
No. of GM-CFC per 1x10“ cells 
Expt 1 Expt 2
Fresh 67, 52 98, 86
Cultured 15, 96 38, 24,
ZB4 2jng/ml 0 , 0 , 21 0 , 0 , 0
ZB4 5pig/ml 5, 9 ,2 0, 5 ,4
Freshly isolated CD34+ cells (fresh) were stimulated with SCF (100ng/ml), 
Flt3L (100ng/ml), IL-3 (20ng/ml), IL-6 (20ng/ml) in X-VIVO 10/1% HSA for 
48hr (Cultured) and then incubated with ZB4 at 2 or 5|ng/ml for 30 minutes on 
ice before transplantation into animals (2x106 cells/animal). Homing of cells 
to the spleen at 24hr post transplantation is shown. Each data point 
represents one animal. Data are presented as GM-CFC per million spleen 
cells from 2 independent experiments.
5.3.2.4 Blocking Fas ligation with sFasL
In the second approach to attempt to block Fas engagement in vivo, I treated 
cytokine stimulated CD34+ cells with sFasL, which has been suggested to 
have a protective role by competing against membrane-bound Fas-ligand 
(Josefsen et al, 1999). Freshly isolated CD34+ cells were cultured for 4 days 
in the 4 cytokine mixture and treated with sFasL before transplantation into 
mice. Cells cultured under these conditions generated comparable numbers 
of total colonies as control cells (Table 5.6). As above mononuclear cells 
recovered from murine BM 24 hr post transplantation were plated into 
semisolid culture for enumeration of human CFC, as described in Chapter 2 
General Methods. Aliquots of pre infusion CD34+ cells were set up in parallel 
methylcellulose culture and used as reference in order to quantify homing 
efficiency of CFC. Figure 5.4 shows that this manoeuvre was not successful 
in rescuing the impaired homing of 48-hour cultured CD34+ cells. CD34+ cells 
cultured for 4 days resulted in 0.38% of GM-CFC homing to the BM, in 
comparison the same cells treated with sFasL at 10, 50 and 100ng/ml 
displayed similar levels of homing to the BM (0.13, 0.16 and 0.11%, 
respectively).
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Table 5.6 - Effect of sFasL on colony forming cells (CFCs)
No. of GM-CFC per 1000 cells 
Expt 1____________Expt 2
Fresh 53 59
Cultured 75 130
sFasL 10ng/ml 70 128
sFasL 50ng/ml 78 88
sFasL 100ng/ml 59 134
Freshly isolated CD34+ cells (fresh) or cultured cells (0) were treated with 
sFasL at 10, 50, 100ng/ml as described in Chapter 5 Special Methods. 
Colony forming activity of cells was assessed in methylcelluose culture. Data 
are expressed per 1000  cells plated and given for 2 independent 
experiments.
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Figure 5.4 - Blocking Fas ligation and effect on homing. Cultured CD34+ 
cells were treated with sFasL at 10, 50, and 100ng/ml before transplantation 
into animals (2x106 cells/animal). Short term BM homing was assayed 24 
hours post infusion. The data are from 2 independent experiments, each data 
point represents 1 animal, and the mean values are indicated.
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5.4 DISCUSSION
In this chapter, I evaluated several different strategies to augment the BM 
homing of cultured adult CD34+ cells. Alterations in homing and engraftment 
may be dependent upon the particular culture conditions employed. Studies 
by (Conneally et al, 1997) and by others (Dao et al, 1997;Demaison et al,
2000), have shown that inclusion of Flt3L with the combination of IL-3, IL-6 
and SCF augments the survival of the stem cells while they are in culture. In 
contrast other studies have shown that inclusion of IL-3 in stimulation 
cultures may be detrimental to engraftment potential of expanded cells 
(Herrera et al, 2001). Interleukin-3 (IL-3) has been implicated in the loss of 
long term reconstituting activity of cultured HSC (Yonemura et al, 1996), 
while cytokines which selectively stimulate primitive HSC, such as TPO, SCF 
and FL, have been reported to preserve long term repopulating cells (Dao et 
al, 1997;Luens et al, 1998). Such effects may be mediated at the level of 
homing to haemopoietic tissue. Thus, I addressed the effect of manipulating 
the ex vivo culture conditions on the homing of cytokine activated CD34+ 
cells.
In order to determine if IL-3 in the cytokine cocktail was able to modulate the 
homing behaviour of adult CD34+ cells, cells were stimulated with Flt3L, SCF, 
IL-6 with or without IL-3, and tested for homing in the NOD/SCID. Ommiting 
IL-3 from my cultures had no significant effect on the homing behaviour of 
cytokine activated cells. This is in contrast to the finding of (Herrera et al,
2001 ) who observed that groups of mice transplanted with cells cultured with 
TPO+SCF+FL showed higher levels of human engraftment when compared 
with mice injected with the similar cell doses of CD34+ cells cultured with 
TPO+SCF+FL+IL-3+IL-6. In the latter group, no evidence of human 
engraftment was found at any of the doses tested (Herrera et al, 2001). They 
conclude that when IL-3 and IL-6 were added to the culture there is a loss of 
ability to engraft NOD/SCID mice. On the other hand, other groups have 
found that IL-3 and IL-6 do not compromise the engraftment potential of 
primitive stem cells (Conneally etal, 1997;Piacibello et al, 1999).
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As reviewed in Chapter 4, many studies suggest that actively cycling HSPCs 
have an engraftment defect when compared with quiescent cells in Go phase 
of the cell cycle (Gothot et al, 1998). In the murine model, there is some 
evidence that this defect may be reversible, if cells are allowed to come back 
out of active cycle before transplantation (Habibian et al, 1998). In a recent 
study, preactivated primate CD34+ cells were “rested” for 2 days in SCF and 
retronectin resulting in an increase in the proportion of cells in G0G1 and in 
superior engraftment compared with control ‘non-rested’ cells (Takatoku et al,
2001). Similarly SDF-1 has recently been reported to enhance survival, while 
inhibiting cycling of HSPC (Cashman et al, 2002;Glimm et al, 2002). 
Incubation of proliferating cord blood CD34+ cells with SDF and TPO 
produced an increase in CRU frequency, although without any changes in 
the cell cycle profile of the cells (Glimm et al, 2002).
In order to determine if the above mentioned approaches were able to 
improve homing of MPB CD34+ cells, I treated freshly isolated CD34+ cells 
with SDF-1 and retronectin as described in Chapter 2 General Methods. I 
firstly demonstrate that cells cultured with SDF-1 and on retronectin 
generated comparable numbers of GM-CFCs and therefore these culture 
conditions had no significant effect on the colony formation of the CD34+ 
cells. This has been shown by (Glimm et al, 2002) using UCB cells and found 
no significant difference in fold increase in CFC between cells cultured in 
SF+TPO vs SF+TPO+SDF-1. The role of SDF-1 in inhibiting the cycling of 
primitive HSPC (UCB and adult BM) in vitro has been shown previously by 
(Cashman et al, 2002;Glimm et al, 2002). I demonstrated that exposure of 4- 
day activated MPB CD34+ cells to SDF-1 for a further 2 days increased the 
proportion of cells in G0/G1 from 72% to 85% but without any effect on BM 
homing ability. My findings differ from those of (Plett et al, 2002) who used 2- 
3 day cultured MPB CD34+ cells and found that in 3 of 4 experimental 
groups, recovery of SDF-1 a pretreated (100ng/ml) MPB CD34+ cells in 
NOD/SCID BM 26-40 hours post injection was increased compared to cells 
not exposed to SDF-1 a i.e. cultured in IMDM/10% FCS only (fold increase 
8 .6 , 14.7, 0.7, 1.3; n=1-2 mice/group). They also demonstrated that SDF-1 a
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pretreatment of MPB CD34+ cells resulted in 40-50% higher chimerism in 
NOD/SCID mice while pretreatment of BM CD34+ cells with SDF-1 a did not 
affect the engraftment potential. The reason for this difference is not clear but 
may relate to the use of IMDM and FBS in their culture systems, the different 
technique of analysing homing (CFSE+ labelled cells) and the use of 1x107 
nonadherent CD34' adult BM cells as accessory cells in the study by Plett et 
al., (Plett et al, 2002).
Finally I did not find that culture of cells on retronectin was able to restore the 
homing levels of cytokine activated cells. This contrasts with an earlier 
observation by (Takatoku et al, 2001) who showed that rhesus CD34+ cells 
transferred to culture in SCF on the CH-296 fibronectin fragment 
(Retronectin) after 4 days of culture in stimulatory cytokines demonstrated 
superior engraftment ability compared with cells cultured for 4 days in 
stimulatory cytokines only. My findings differ from two recent studies, one 
carried out by (Takatoku et al, 2001) who used rhesus CD34+ cells and found 
an enhanced engraftment of cells cultured in SCF+Rn. The second study by 
(Glimm et al, 2002) used Lin' UCB cells and used cells cultured for 96 hr in 
Flt3L, Steel factor, IL-3, IL-6 and G-CSF. These were then transferred to 
medium containing Steel factor and TPO with or without SDF-1 for 48hr, after 
which cells cultured in the presence of SDF-1 demonstrated enhanced ability 
to engraft NOD/SCID animals. These differences may relate to intrinsic 
differences between cord and rhesus vs adult CD34+ cells and also studies 
by (Cashman et al, 2002) and (Takatoku et al, 2001) used engraftment in 
NOD/SCID mice or rhesus animals as a readout, whereas my readout was 
short term BM homing.
Jurkat T cells cultured in RPMI/10% FCS supplemented with FasL Plus at 
5ng/ml demonstrated a significant level of apoptosis. However, pre­
incubating the cells with anti human Fas mAb ZB4 of IgGi subclass 
(antagonistic) resulted in inhibition of apoptosis to levels seen with control 
Jurkat cells cultured in RPMI/10% FCS, demonstrating that the ZB4 mAb was 
functional and inhibiting apoptosis. This confirms a finding by Fadeel et al., 
(1997), who demonstrated that the ZB4 antibody, efficiently blocked
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apoptosis of Jurkat cells induced by CH-11, an agonistic Fas/CD95 mAb 
(Fadeel et al, 1997).
Freshly isolated CD34+ cells and cells stimulated for 48hr with the 4 cytokine 
mix in the presence or absence of ZB4 generated comparable numbers of 
total GM-CFCs, indicating that ZB4 had no adverse effect on colony forming 
ability of CD34+ in the methylcellulose culture. This has also been reported 
by Liu et al., (2003) and showed that there was no difference found in the 
number of CFC among cells not incubated with mAb or after incubation with 
IgGi or ZB4 (Liu et al, 2003).
My finding in Chapter 4 and studies by Young et al., (2001) and Liu et al.,
(2003) have shown that Fas receptor expression is upregulated on both MPB 
and UCB CD34+ cells during culture (Young et al, 2001 ;Liu et al, 2003). In 
order to determine whether increased Fas/CD95 levels caused the homing 
defect of cultured CD34+ cells, I preincubated cytokine stimulated MPB 
CD34+ cells with the blocking anti-Fas mAb for 30 minutes, prior to infusion 
into NOD/SCID mice. As control, freshly isolated CD34+ cells and cells 
stimulated in the absence of ZB4 were also injected. I demonstrate, as in 
Chapter 3, that human MPB CD34+ cells acquire a homing impairment in 
irradiated NOD/SCID mice after short term culture. In addition, I demonstrate 
that the homing defect was not restored by incubating cytokine stimulated 
MPB CD34+ cells prior to transplantation with Fas/CD95 blocking mAb ZB4. 
My findings differ from those of Liu et al., (2003) who used cord blood CD34+ 
cells and found that the reduced homing levels of cultured CFC could be 
restored by incubating cells prior to transplantation with Fas/CD95 blocking 
mAb ZB4 (Liu et al, 2003). The reason for this difference is not clear but may 
relate to intrinsic differences between cord and adult CD34+ cells and also 
may be related to a technical difference because CD34+ cells after culture 
were re-purified on the Miltenyi Biotec MACS by Liu et al., (Liu et al, 2003).
In the second approach I used sFasL to inhibit the interaction between 
endogenous FasL and Fas receptor, which has been suggested to have a 
protective role by competing against membrane-bound Fas-Ligand (Josefsen
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et al, 1999). This group demonstrated that sFasL stimulation of the more 
mature adult human BM CD34+ CD38+ cells slightly increased cells death 
(50%) after 48hr of culture compared to cells cultured in medium alone 
(40%). However in striking contrast, spontaneous cell death of CD34+ CD38' 
cells was reduced from 46% to 29% in the presence of sFasL 48hr of culture 
as compared to cells cultured in medium alone. This was thought to be due 
to the sFasL inhibiting the interaction of FasL with Fas receptor. Barcena et 
al., (1999) showed that foetal liver CD34+ CD38' cells, incubated with soluble 
Fas Ligand (sFasL) displayed a 2-4 fold increase in CFU and HPP-CFC 
formation when cultured for up to 1 week (Barcena et al, 1999). I 
demonstrate that adult MPB CD34+ cells cytokine stimulated (4 days) and 
treated with or without sFasL generated comparable numbers of total GM- 
CFCs, demonstrating no adverse effect on colony formation. This difference 
seen by (Barcena et al, 1999) may be due to the longer period of culture (4 
days vs 1 weeks) and also the intrinsic differences between foetal liver and 
adult MPB CD34+ cells, as reviewed in Chapter 4.
In order to determine if blockage of Fas receptor In vivo with sFasL could 
restore homing ability of cytokine stimulated cells, I treated cytokine 
stimulated cells with sFasL but this did not rescue the impaired homing of 
cultured CD34+ cells. The levels of homing of sFasL treated cells was 
comparable to cells cultured in the absence of sFasL, therefore both 
approaches I used to block Fas engagement in vivo were unsuccessful in 
reversing the homing impairment of cytokine stimulated cells, suggesting an 
alternative explanation for the homing defect of cytokine cultured cells.
My observations suggest that other factors apart from particular culture 
conditions or cell cycle status or apoptosis are likely to influence the homing 
and engraftment capabilities of adult HSPC. In summary, I have 
demonstrated in adult MPB CD34+ cells that the loss of BM homing was not 
restored by blocking Fas ligation in vivo. Also altering the culture conditions 
for example by excluding IL-3, culturing the cells in the presence of SDF-1 
and retronectin did not restore the homing defect.
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Chapter 6: Effect of co-infusing 
non-haemopoietic stem cells and T- 
cells on the homing of CD34+ ceils 
in the NOD/SCID mouse model
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6.1 INTRODUCTION
MSC homing and role in supporting human CD34+ cell engraftment 
Recent results have shown that co-transplantation of human ex vivo 
expanded MSCs together with HSCs may enhance haemopoietic recovery 
following a bone marrow transplantation in animal models (Nolta et al, 
1994;Nolta et al, 2002;Brouard et al, 1998;Noort et al, 2002;Bensidhoum et 
al, 2004) and in humans (Koc & Lazarus, 2001 ;Koc et al, 2000;Koc et al, 
1999). Noort et al., (2002) identified a population of MSCs derived from 
human foetal lung, which upon co-transplantation promote engraftment of 
UCB CD34+ cells in bone marrow, spleen, and blood of irradiated (3.5 Gy) 
NOD/SCID animals by mechanisms that may not require homing of MSCs to 
bone marrow (Noort et al, 2002). Angelopoulou et al., (2003) showed that co­
transplantation of human mesenchymal stem cells with CD34+ selected MPB 
cells enhanced myelopoiesis and megakarypoiesis in the NOD/SCID mice 
(Angelopoulou et al, 2003). Devine et al., (2001) confirmed that cultured 
baboon mesenchymal stem cells could home to the BM in non-human 
primates (Devine et al, 2001). Rombouts & Ploemacher, 2003 showed that 
primary murine MSC show highly efficient homing to the bone marrow but 
lose homing ability following culture (Rombouts & Ploemacher, 2003). They 
suggest that in vitro propagation of BM-derived MSC dramatically decreases 
their homing to BM and spleen. A study by Almeida-Porada et al., (2000) 
showed that co-transplantation of human bone marrow stromal cells 
increased the level of human peripheral blood donor cell expression 
(Almeida-Porada et al, 2000). These results suggest the possibility of using 
MSCs to promote engraftment of UCB in an attempt to accelerate the 
engraftment delay associated with UCB transplantation and with small grafts 
using adult HSC.
T cells and CD34+ cell homing
Previously published reports have suggested that presence of CD8+ cells led 
to an increase in the engraftment of CD34+ cells. Martin et al., (1999) showed 
clinical trials in humans demonstrating that the presence of CD8+ cells but 
not CD4+ cells results in an increased level of engraftment in the allogeneic 
transplant setting (Martin et al, 1999). Studies of allogeneic transplants in
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mice have also shown that CD8+ cells facilitate engraftment (Kaufman et al, 
1994;Gandy et al, 1999;Schuchert et al, 2000).
A recent study showed that cord blood CD8+ T cells cooperate to augment 
stem cell migration, homing, and engraftment (Adams et al, 2003). The 
authors demonstrate that neighbouring cells modify CD34+ cell migration 
suggesting that combinatorial effects between cells of different types can 
influence cell localisation. Their results suggest that CD8+ T cells contribute 
to stem/progenitor cell localisation through augmentation of the entry to the 
bone marrow microenvironment, an essential part of establishing bone 
marrow haemopoiesis. This model is one in which events between co­
transplanted cells influence the efficiency of localisation and engraftment in 
haemopoietic tissues. The strategy of co-infusing CD8+ T cells could be to 
used to enhance homing and engraftment of HSPCs. The effect seen with 
CD8+ T cells may be similar to finding of others that have shown human bone 
marrow engraftment in mice can be enhanced by different accessory cell 
populations including irradiated mononuclear cells (Bonnet et al, 1999). In 
contrast a study by Watts et al., (1995) indicated that accessory cells 
(lymphocytes and monocytes) reinfused with PBSC collections was not 
responsible for the subsequent cytokine profile or rapid haematological 
recovery in humans (Watts et al, 1995).
Chapter Aims
The aim of the present study was firstly, to isolate, expand and characterise 
MAPCs from postnatal BM and secondly to determine if co-transplantation of 
non-haemopoietic stem cells and heterologous T cells enhanced CD34+ cell 
homing to the BM in the NOD/SCID mice. I investigated the influence of 
MSCs and MAPCs on short term BM homing of freshly isolated CD34+ cells 
by co-infusion of cells at 1:1 ratio. I also determined if CD4+ and CD8+ cells 
co-infused at a 1:1 ratio enhanced the homing potential of CD34+ cells to the 
BM in the NOD/SCID mouse model.
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6.2 Special Methods
6.2.1 CD4+ and CD8+ cell selection
In order to obtain a homogeneous starting population of CD4+ and CD8+ 
cells, the CD34' negative fraction of a 1ml of PBSC harvest product was 
immunomagnetically selected using the VarioMACS LS columns (Miltenyi 
Biotec) in a similar manner as described for CD34+ selection (Chapter 2, 
General Methods), except that cells were selected using anti-CD4 or anti- 
CD8 iron/dextran conjugated antibodies (20pl per 107 total cells; Miltenyi 
Biotec). The purity of the T cell subsets are shown in Table 6.3.
6.2.2 T cell co-culture with MPB CD34+ cells
Selected CD34+ cells (2x106) were placed in culture in 6 well plates at a 
density of 0.5x106/ml in IMDM supplemented with 10% FCS and co-cultured 
with purified CD4+ or CD8+ cells at a 1:1 ratio at 37°C and 5% CO2 for 3 
hours. Cells were harvested by gentle pipetting into a 20ml universal and 
centrifuged at 1800 rpm for 10minutes. The cell pellet was resuspended in 
400pl of HBSS, transferred to a sterile 1.5ml microfuge eppendorf tube and 
injected into the tail vein of sub-lethally irradiated (325 rads) NOD/SCID mice.
6.2.3 Fibronectin coated plates
Fibronectin treated plates were prepared by adding Fibronection at 100pg/ml 
(Sigma) to appropriate tissue culture flasks or plates for 30 minutes at room 
temperature.
6.2.4 MSC Isolation and characterisation
Human MSCs were obtained from the BM of healthy donors undergoing bone 
marrow harvests after informed consent according to the institutional 
guidelines under a protocol approved by the local ethics committee. 
Mononuclear cells were separated by centrifugation over Ficoll-Paque 
gradient and plated at the density of 2x105 cells/cm2 in Mesencult Culture 
Medium (Stem Cell Technologies). Nonadherent cells were removed after 48 
hours and adherent cells cultured until they reached confluence. Cells were
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trypsinised, subcultured at densities of 1x 104/cm2 and immunophenotyped 
(see section 2.2.9) and used for experiments.
6.2.5 Isolation and culture of Human Umbilical Vein Endothelial Cells 
Human umbilical vein endothelial cells were isolated from umbilical cords by 
a modification of the method originally described by Jaffe et al., (Jaffe et al, 
1973). Briefly, umbilical cords were obtained within 24 hours of delivery and 
stored at room temperature in HBSS. The cords were checked for needle or 
clamp marks and any areas of damage or bruising removed. The ends of the 
cord were trimmed with a surgical blade and the vein of the cord at both ends 
were cannulated with 14 gauge intravenous cannulae and secured in place 
using sterile ties. The vein was flushed out using HBSS and this was 
continued until the cord was free from blood and the effluent ran clear. After 
ensuring the complete removal of the HBSS, warm collagenase (670^ig/ml or 
0.067% in HBSS) was inserted into the cord and the cannulae ends closed 
with plugs. The cord was incubated for 20 minutes at 37°C. After incubation 
the cord vein was flushed out with warm HBSS/1% FCS, the contents 
collected and centrifuged at 1000rpm for 5 minutes. The pellet was 
resuspend in complete culture medium (Iscove’s Modified Dulbecco’s 
Medium with 20% FCS, 50ng/ml ECGS and 20U/ml heparin). The cells were 
grown to confluence in 25cm2 Falcon tissue culture flasks pre coated with 
fibronectin (lOO^g/ml) for 30 minutes at room temperature. Once the 
endothelial cells had reached confluence the growth media was removed and 
the cells washed gently in HBSS. Warm trypsin/EDTA was added to the cells, 
and following incubation at 37°C for 2-5 minutes, 5-10ml of HBSS/2% FCS 
were added and the detached cells collected, centrifuged for 5 minutes at 
lOOOrpm and the cell pellet resuspended in complete culture medium. The 
cells were then further grown to confluence in 75cm2 tissue culture flasks 
(passages 3-6) and stored in liquid nitrogen with 20% DMSO as a 
cryopreservant for later use.
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6.2.6 Isolation, expansion and characterisation o f Multipotent Adult 
Progenitor Cells
Human MAPCs were isolated from BM by a modification of the method 
originally described by Reyes et al., (Reyes et al, 2001). BM was obtained 
from healthy donors at UCLH in accordance with local Ethical guidelines and 
processed within 4 hours of harvest collection. BMMNCs were obtained by 
Ficoll-Paque density gradient centrifugation. Briefly, 10ml of BM was diluted 
in equal volume with PBS and layered onto 20ml of Ficoll-Paque and 
centrifuged at 1800rpm for 30 minutes at room temperature. The 
mononuclear cell interface was harvested using a fine tip pasttete and the 
cells washed once with 10ml PBS. The cell pellet was resuspended in 1ml 
PBS and cell viability and counts performed. The cells were centrifuged once 
more at 1800rpm for 10 minutes and following aspiration of the supernatant, 
resuspended in anti-CD45 and anti-Gly-A iron/dextran (microbeads) 
conjugated antibodies (20pl per 107 cells) and incubated for 20 minutes at 
4°C. The VarioMACs LD column, placed in its magnetic retainer, was washed 
once with 3ml of PBS/EDTA (CliniMACS buffer, Miltenyi Biotec) to remove 
residual azide. The immunolabelled cells were then washed once with 10 ml 
PBS w/o Ca++ Mg++ and resuspended in 1ml of PBS/EDTA and loaded onto 
the column. The cell suspension was allowed to run through the column and 
effluent collected was the depleted fraction (CD45' Gly-A' cells). The column 
was washed with 2 ml of PBS/EDTA and total effluent collected as depleted 
fraction (CD45' Gly-A' cells). Cells were then passed down a fresh column in 
a similar manner to maximize purity if necessary. The depleted fraction was 
centrifuged at 1800rpm for 15 minutes and resuspended in 200jla I of MAPC 
expansion medium (60% low glucose DMEM, 40% MCDB-201, 1x ITS 
[insulin, transferrin, and selenium], 1x LA-BSA [0.5mg/ml linoleic acid, +BSA], 
0.05jaM dexamethasone, 1x ascorbic acid-2-phosphate [0.1 mM], 2% FBS, 
PDGF-BB [plate-derived growth factor-BB] 10ng/ml, and EGF [epidermal 
growth factor] 10ng/ml) and a neat cell count performed using a 
haemocytometer. We plated 10x103 CD45' Gly-A' cells in 200jlx I expansion 
medium into flat bottomed wells of 96 well plates pre coated with fibronectin 
(100pg/ml) for 30 minutes at room temperature. Cells were incubated at 37°C
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and 5% CO2 and refed every 4-6 days with MAPC expansion medium. After 
7-21 days, small clusters of adherent cells developed (Figure 6.1). Once 
adherent cells were more than 50% confluent (usually between 2-3 weeks; 
clusters of about 103 cells, Figure 6.1), the growth medium was removed and 
the cells washed gently in HBSS. Warm trypsin/EDTA was added to the cells, 
and following incubation at 37°C for 2 minutes, DMEM low glucose/2% FBS 
was added and the detached cells centrifuged for 15 minutes at 1800rpm and 
the cell pellet resuspended in 200pl of MAPC expansion medium. A neat cell 
count was performed and cells replated under the same conditions at a cell 
density between 2-8000 cells/cm2. Cells were further grown maintaining the 
cell density between 2-8000 cells/cm2 (Table 6.1) in tissue culture treated 
plates (48, 24, 12 and 6 wells) and at selected intervals (passage 17, 13, 10 
and 7) cells were assessed for surface phenotype and functional ability.
Table 6.1 - MAPC density maintained between 2000-8000 cells/cm2
Plate brand No. of wells Growth area cm2 Total cells per well
Nunc 96 0.33 660-2640
Costar 48 0.8 1600-6400
Costar 24 1.9 3800-15200
Costar 12 3.8 7600-30400
Costar 6 9.5 19000-76000
Nunc T25 flask 25 50000-200000
Nunc T80 flask 80 160000-640000
6.2.7 MAPC endothelial cell differentiation
To induce MAPC differentiation into endothelial cells, 60,000 MAPCs 
(passage 17, Donor 1) were replated into a fibronectin coated well (surface 
area =9.5 cm2) of a Lab-Tek chamber slide (1 well permanox slide; Nalge 
Nunc Inc 177410) or a 6 well plate (Costar) and cultured in 2ml of MAPC 
basal medium (60% low glucose DMEM, 40% MCDB-201, 1x ITS [insulin, 
transferrin, and selenium], 1x LA-BSA [0.5mg/ml linoleic acid, +BSA], 0.05pM 
dexamethasone, 1x ascorbic acid-2-phosphate [0.1 mM]) supplemented with 
VEGF at 10ng/ml. Cultures were maintained by media exchange every 4-5 
days for up to 14 days at 37°C and 5% CO2.
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6.2.8 Immunocytochemistry for vWF
MAPC derived endothelial cells, HUVECs and MSCs were grown in Lab-Tek 
chamber slides (Nalge Nunc Inc 177410). Slide preparations were fixed in 
70% methanol at -20°C for 2 minutes and washed with 2ml PBS w/o Ca++ 
Mg++ (PBS). Slides were blocked with 5% BSA in PBS for 2 hours at 37°C 
and washed three times with PBS, before overlaying with anti-vWF mAb 
(1:50 in PBS). After an overnight incubation in a humidified chamber at 37°C, 
the slides were washed again with PBS, overlayed with FITC RAM (1:200 in 
PBS), and incubated for a further 2 hours at room temperature. After a final 
3 washes slides were mounted in Vectashield (Vector Laboratories) and 
viewed under a fluorescent microscope.
6.2.9 In vitro vascular tube formation
A 10ml vial of Matrigel basement membrane matrix (BD) was thawed on ice 
and using a cooled 1ml glass pippette (Volac) mixed to homogeneity. A 24 
well tissue culture plate (Costar) was placed on ice for 5 minutes and then 
500pl of Matrigel was added to each well. The plate was then incubated at 
37°C for 3 hours. After 3 hours each well was washed once with 0.5ml HBSS 
and 60,000 cells (MAPC-derived endothelial cells, HUVECs, and 
Mesenchymal Stem Cells) seeded into each well in a total volume of 0.5ml 
medium (MAPC-derived endothelial cells cultured in basal medium plus 
VEGF 10ng/ml; HUVECs cultured in HUVEC culture medium; MSCs cultured 
in MSC growth medium). The plate was incubated overnight at 37°C and 5% 
CO2 and vascular tube formation examined the following morning on an 
inverted microscope.
6.2.10 Ac-LDL uptake
Cells were grown in a 6 well tissue culture plate (as detailed above) and 
incubated with Dil-Ac-LDL at 10pg/ml (Human low density lipoprotein 
acetylated and labelled with the fluorescent probe, 1,T-dioctadecyl-3,3,3’3’- 
tetramethylindocarbocyanine perchlorate (Dil) Tebu-Bio) in the cell growth 
medium overnight at 37°C and 5% CO2. The following morning the Dil-Ac- 
LDL medium was removed and cells washed once with 2ml of HBSS. Cells
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were visualised with an Olympus 1X70 inverted fluorescence microscope 
(Olympus) using a standard rhodamine excitation/emission filter. The 
fluorescent label, Dil is internalised and the cell remains viable, therefore 
labelled cells can be trypsinised and be reseeded.
6.2.11 MSC and MAPC co-injection with MPB CD34+ celis 
Selected CD34+ cells (2x106) were transplanted in the presence or absence 
of MSCs (1 million) and MAPCs (1, 0.5 and 0.2 million). Cells were 
resuspended in 400pl of HBSS, transferred to a sterile 1.5ml microfuge 
eppendorf tube and injected into the tail vein of sub-lethally irradiated (325 
rads) NOD/SCID mice.
6.3 RESULTS 
6.3.1 Isolation, expansion and characterisation of MAPCs from  
postnatal BM
6.3.1.1 Culture of undifferentiated MAPCs and morphology
Normal BMMNCs were depleted of CD45+ and GlyA+ cells using the MACs 
immunomagnetic beads. CD45' GlyA' cells were plated on fibronectin coated 
96 well plate in expansion medium with 2% FBS, 10ng/ml EGF, and 10ng/ml 
PDGF-BB. As shown in Figure 6.1, panel 1-3, small clusters of adherent cells 
developed between 7-21 days after culture. When clusters appeared of 
approximately 1000 cells, cells were passaged and replated under the same 
culture conditions. Cell densities were maintained between 2-8000 cells/cm2 
(Figure 6.1, panel 5). MAPCs cultured at a low density and with 2% FBS 
were small and have scant cytoplasm with few vacuoles and granules. The 
cell growth rate was monitored for 4 BM donors and the cell doubling time 
varied from donor to donor and was between 40-60 hr (Figure 6.2). The 
population doublings was 5, 3, 6 and 7 for donors 1, 2, 3 and 4, respectively.
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Figure 6.1 - Morphology of undifferentiated MAPCs. CD45' GlyA' cells were plated in 96 well plates (1-4) on Fn in 
expansion medium with 2% FBS (Hyclone ES screened), 10ng/ml EGF, and 10ng/ml PDGF-BB and passaged as 
detailed in Chapter 6 Special Methods. After 7-21 days, small clusters of adherent cells developed (panel 1-3) and when 
clusters appeared of approximately 1000 cells, cells were detached and replated (panel 5) into a 48 well plate and 
maintained at a cell density of 2-8x103/cm2. A representative example is shown (Donor 1). Cells were analysed by bright- 
field microscopy. Shown are bright-field microscopy pictures at magnification as indicated in each plate.
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Figure 6.2 - MAPC cell growth curve. CD45' Gly A‘ cells were plated on Fn 
in expansion medium with 2% FBS, 10ng/ml EGF, and 10ng/ml PDGF-BB as 
detailed in Chapter 6 Special Methods and passaged at time points indicated. 
Cells were maintained between 2-8000 cells/cm2. Cells were counted at each 
passage with a haemocytometer. The data is from a single normal BM donor.
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6.3.1.2 Immunophenotypic analysis o f undifferentiated MAPCs 
Undifferentiated MAPCs were generated as outlined above and 
immunophenotyped by flow cytometry. Cell phenotype was performed on 4 
normal BM donors at passages 17, 13, 10 and 7. Undifferentiated MAPCs did 
not express CD34, CD45 and HLA-DR (Table 6.2). Cells expressed high 
levels of CD13, SH2, SH4, HLA-ABC, CD44 and intermediate levels of 
CD49b (Table 6.2).
Table 6.2 -  MAPC cell surface antigen profile
Antigen Donor 1
% positive cells 
Donor 2 Donor 3 Donor 4
CD45 0 4 0 6
CD34 0 0 0 0
CD13 98 94 82 99
SH2 99 - - 69
SH4 97 - - 96
HLA-DR 0 - - -
HLA-ABC 99 - - -
CD49b - 39 - 37
CD49d - - - 18
CD44 - 82 - 79
BM MNC CD45' GlyA' cells were plated on Fibronectin coated plates in 
expansion medium with 2% FBS, 10ng/ml EGF, and 10ng/ml PDGF-BB as 
described in Chapter 6 Special Methods. Cells were harvested and labelled 
with antibodies directly conjugated to the flurochromes FITC or PE and 
analysed by flow cytometry. Cell phenotype was performed at passages 17, 
13, 10 and 7 for Donors 1, 2, 3 and 4 respectively. Data are given for 4 
normal BM donors and isotype control staining has been subtracted. (- not 
determined)
6.3.2 Functional characterisation of MAPC derived endothelial cells
6.3.2.1 Human MAPCs differentiate into cells with phenotypic characteristics 
of endothelium
Undifferentiated MAPCs generated as described above from normal BM 
(Donor 1), were induced to differentiate into endothelial cells. MAPC derived 
endothelial cells were plated at a high confluence (60000 cells/well) in 6 well 
plate Fibronectin coated and grown in expansion medium without serum and 
EGF, PDGF-BB, but with VEGF at 10ng/ml for 14 days. MAPC-derived
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endothelial cells were replated on Fibronectin coated chamber slides. Cells 
were then stained with antibodies against vWF (FITC) by 
immunocytochemistry. vWF staining is found throughout the cytoplasm of 
MAPC-derived endothelial cells (Figure 6.3, panel a). Primary human 
endothelial cells (HUVECs) served as a positive control and stained strongly 
for vWF throughout the cytoplasm (Figure 6.3, panel b). In contrast MSCs 
were negative for vWF staining (Figure 6.3, panel c).
6.3.2.2 Functional characteristics of MAPC derived endothelial cells 
A functional characteristic of endothelial cells is that they take up LDL 
(Steinberg et al, 1985). This was tested by incubating MAPCs induced to 
differentiate with VEGF for 14 days with Dil-Ac-LDL overnight. Dil uptake was 
very strong in primary human endothelial cells and staining was seen 
throughout the cytoplasm in majority of the cells (Figure 6.4, panel b). The 
uptake of Dil was not as strong in MAPC derived endothelial cells but cells 
could be seen with Dil staining throughout the cytoplasm (Figure 6.4, panel 
a). In contrast MSCs did not take up Dil and were negative for Dil staining 
(Figure 6.4, panel c).
Another characteristic of endothelial cells is the ability to form vascular tubes 
when plated on Matrigel. As shown in Figure 6.5, culture of primary human 
endothelial cells (HUVECs) on matrigel resulted in vascular tube formation 
with a complex lattice pattern (Figure 6.5, panel b). MAPC-derived 
endothelial cells formed vascular tubes but not the complex lattice pattern 
seen with primary endothelial cells (Figure 6.5, panel a). In contrast MSCs 
did not form any vascular tubes (Figure 6.5, panel c).
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Figure 6.3 - von Willebrand factor expression by MAPC-derived endothelial cells. Undifferentiated MAPCs 
were plated on Fibronectin coated 6 well plate (60000 cells/well) in expansion medium without serum, EGF or 
PDGF-BB, but with VEGF 10ng/ml for 14 days. MAPC-derived endothelial cells were replated on fibronectin coated 
chamber slides. Cells were then stained with antibodies against vWF (FITC) and analysed by confocal microscopy. 
vWF staining is found throughout the cytoplasm of MAPC-derived endothelial cells (a) and HUVECs (b), but absent 
in MSCs (c). Representative example is shown (Donor 1). HUVECs served as a positive control.
Figure 6.4 - Ac-LDL uptake by MAPC-derived endothelial cells. Undifferentiated MAPCs were plated on 
Fibronectin coated 6 well plate (60000 cells/well) in expansion medium without serum, EGF or PDGF-BB, but with 
VEGF 10ng/ml for 14 days. Cells were incubated overnight with Dil-Ac-LDL and analysed by confocal microscopy. 
Dil uptake was found in both MAPC-derived endothelial cells (a) and HUVECs (b), but absent in MSCs (c). 
Representative example is shown (Donor 1). HUVECs served as a positive control.
a b c
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Figure 6.5 - Vascular tube formation by MAPC-derived endothelial cells. Undifferentiated MAPCs were plated 
on Fibronectin coated 6 well plate (60000 cells/well) in expansion medium without serum, EGF or PDGF-BB, but 
with VEGF 10ng/ml for 14 days. Cells were then replated in Matrigel with VEGF 10ng/ml. After overnight incubation 
at 37°C, typical vascular tubes could be seen in both MAPC-derived endothelial cells (a) and HUVECs (b), but 
absent in MSCs (c). Representative example is shown (Donor 1). HUVECs served as a positive control. Cord 
formation was analysed on a confocal microscope
6.3.2.3 Immunophenotypic analysis o f MSCs
Bone marrow stromal cells were isolated from normal BM donors and 
expanded in specially designed Mesencult culture medium for 2 days prior to 
removal of nonadherent cells. Initially a heterogeneous adherent cell layer 
including fibroblast-like cells were observed which changed after few 
passages to a uniform spindle shaped population. These cells were 
immunophenotyped by flow cytometry. MSCs did not express the 
haemopoietic markers CD34 (2.9%) and CD45 (2.5%) but expressed high 
levels (>99%) of SH2, SH4 and CD13.
6.3.3 Influence of MSCs and MAPCs on short term BM homing of freshly 
isolated CD34* cells
6.3.3.1 Effect of MSC and MAPCs on CFC numbers
In order to exclude possible roles of MSCs and MAPCs on colony formation, 
fresh CD34+ cells were cultured in the presence or absence of MSCs and 
MAPCs. The number of assayable progenitors was determined by 
methylcellulose colony assay. As shown in Table 6.3, CD34+ cells cultured in 
the presence of MSCs and MAPCs generated slightly higher numbers of total 
colonies with comparison to CD34+ cells alone.
Table 6.3 - Effect of MSCs and MAPCs on colony forming cells (CFCs)
Donor 1
No. of GM-CFC per 1000 cells 
Donor 2 Donor 3 Donor 4
CD34+ 102 25 48 63
CD347MSC 160 69 70 72
CD347MAPC 137 15 N/A 68
Freshly isolated CD34+ cells in the presence or absence of MSCs and 
MAPCs was assessed in methylcellulose culture for colony forming cells. 
Data are expressed per 1000 cells plated and given for 4 normal BM donors.
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6.3.3.2 Effect o f MSC or MAPCs co-infused with CD34+ cells on short term 
BM homing
In order to assess the influence of MSCs and MAPCs on short term BM 
homing, MSCs and MAPCs were co-infused with CD34+ cells and CFC 
homing to the BM quantified. The BM of animals transplanted with CD34+ 
cells in the presence or absence of MSCs and MAPCs was recovered at 24hr 
post-infusion and single cell suspensions plated into semisolid culture. As 
shown in Figure 6.6, CFC from CD347MSC transplanted animals showed a 
small increase (median 0.84, range 0.5-1.63%) in BM homing compared with 
control animals transplanted with CD34+ cells alone (median 0.56, range 
0.38-1.21%) however, this was not statistically significant (P value 0.2416, 
Mann-Whitney U test). The homing levels of CFC to the BM of CD347MAPC 
transplanted mice (median 0.22, range 0.16-1.2%) was comparable to control 
mice infused with CD34+ cells only.
155
2-1
CD
c
O
U_o
o
c
0.6
o 0 .5 -
0.2
CD34+ CD34+/MSC CD34+/MAPC
Figure 6.6 - Effect of MSCs and MAPCs on homing of MPB CD34+ cells 
in the NOD/SCID mice. Freshly isolated MPB CD34+ cells (2 million) were 
transplanted alone or in the presence of MSCs (1 million) and MAPCs (1, 0.5 
and 0.2 million). Short term BM homing was assayed 24hr post 
transplantation. The data are from 4 independent experiments, each data 
point represents 1 animal and numbers and bars indicate the medians.
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6.3.4 Role of T cell subsets
6.3.4.11solation of CD4+ and CD8+ cells
The CD34-negative cell fraction was selected for CD4+ and CD8+ cells using 
the immunomagnetic VarioMACS system as described in Chapter 6 Special 
Methods. I analysed by flow cytometry the purity of the isolated cells by 
staining the cells with a fluorochrome conjugated anti- human CD4 and CD8. 
As shown in Table 6.4, the purity of CD4+ cells and CD8+ cells was 88 ± 6% 
(n=3) and 96 ± 2% (n=4), respectively. Both cell fractions were strongly 
positive for CD3 (>90%), as expected.
Table 6.4 - Purity of CD4+ and CD8+ cells from adult mobilised peripheral 
blood (MPB). CD4+ and CD8+ cells were positively selected from CD34' cell 
fraction using the immunomagnetic VarioMACS system as described in 
Chapter 6 Special Methods. Purified cell fractions were stained with RD1 and 
FITC-conjugated anti-human CD4 and CD8 respectively, and analysed by 
flow cytometry. Data are presented of % positive cells for 4 independent 
experiments.
Purity (%)
Experiment No. CD4+ cells CD8+ cells
1 83 95
2 95 99
3 N/D 95
4 85 97
Mean ± SD 88±6 96±2
6.3.4.2 Effect o f CD4+ and CD8+ cells on CFC numbers 
In order to determine the effects of CD4+ and CD8+ cells on colony forming 
activity. I assessed the functional activity of freshly isolated haemopoietic 
progenitors cultured for 3hr in IMDM/10% FCS alone or with purified CD4+ 
and CD8+ cells at 37°C and 5% CO2 in the methylcellulose culture. As shown 
in Table 6.5, CD34+ cells cultured in the presence of CD4+ and CD8+ cells 
generated comparable numbers of total colonies compared with control 
CD34+ cells alone, n=3.
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Table 6.5 - Effect of T cell subsets on colony forming cells (CFCs)
No. of GM-CFC per 1000 cells
Expt 1 Expt 2 Expt 3
Fresh 50 98 102
CD34+/CD4+ 52 88 98
CD34+/CD8+ 58 119 80
Freshly isolated CD34+ cells were cultured in IMDM/10% FCS alone (fresh) 
or with purified CD4+ and CD8+ cells at a 1:1 ratio at 37°C and 5% C 02for 3 
hr. Colony forming activity of cells was assessed in methylcellulose culture. 
Data are expressed per 1000 cells plated and given for 3 independent 
experiments.
6.3.4.3 Effect of CD4+ and CD8+ cells on in vivo homing of CD34+ cells to the 
BM
Freshly isolated haemopoietic progenitors and purified CD4+ and CD8+ cells 
were co-cultured for 3 hr in lscoves/10% FCS and were infused by the tail 
vein injection into NOD/SCID mice. Mononuclear cells recovered from murine 
BM 24 hr post transplantation were plated into semisolid culture for 
enumeration of human CFC, as described in Chapter 2 General Methods. 
Aliquots of pre infusion CD34+ cells were set up in parallel methylcellulose 
culture and used as reference in order to quantify homing efficiency of CFC. 
As shown in Figure 6.7, CD34+ cells co-infused with CD4+ cells resulted in 
similar levels of CFC homing to the BM compared with control CD34+ cells 
alone (GM-CFC mean of 0.98, range 0.75-1.19% and 1.17, range 0.62- 
1.57% for CD34+ only and CD34+ co-infused with CD4+ cells, respectively), 
n=3. Co-infusion of CD8+ cells slightly enhanced the homing to the BM 
(mean 1.3, range 0.74-1.59%), but this was not statistically significant (P 
value 0.1229, Mann-Whitney U Test). To determine if this modest 
enhancement of CD34+ cells homing was distinct to the BM environment, 
homing to the spleen was evaluated (Table 6.6). Consistent with that seen in 
the marrow, very similar levels of CD34+ cell homing was noted when CD8+ 
cells or CD4+ cells were co-infused (Table 6.6), n=3. As shown in Table 6.6, 
in experiment 3, fresh CD34+ transplanted mice formed 42 and 38 GM-CFC 
colonies per 106 murine spleen cells, whereas CD4+ and CD8+ admixed 
transplanted mice formed 44, 40 and 41, 36 GM-CFC colonies per 106
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murine spleen cells, respectively. Saline control and irradiation control mice 
grew no colonies.
Thus, no consistent effect of co-infusing MSCs, MAPCs or CD8+ T cells on 
short term BM homing of freshly isolated CD34+ cells was observed in the 
NOD/SCID mouse model.
Table 6.6 - Homing of MPB CD34* cells cultured with T cell subsets to 
the spleen.
No. of GM-CFC per 1x106 cells
Expt 1 Expt 2 Expt 3
Fresh 82, 14 122, 140 42, 38
CD34+/CD4+ 42,4 156, 225, 58 44, 40
CD34+/CD8+ 56, 71 112, 71, 58 41, 36
Saline N/D 0 N/D
Irradiation ctl 0 N/D N/D
Freshly isolated CD34+ cells were cultured in IMDM/10% FCS alone (fresh) 
or with purified CD4+ and CD8+ cells at a 1:1 ratio at 37°C and 5% CO2 for 3 
hr. Homing of cells to the spleen at 24hr post transplantation is shown. Each 
data point represents a animal which were sub-lethally irradiated and infused 
with 2x106 cells of each population by tail vein injection. Data are presented 
per million spleen cells and from three independent experiments.
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Figure 6.7 - Effect of T cell sub-population on homing of CD34+ cells in 
the NOD/SCID mice. Freshly isolated MPB CD34+ cells were cultured in 
IMDM/10% FCS alone and with purified CD4+ (purity >83%) or CD8+ (purity 
95%) cells at a 1:1 ratio at 37°C for 3hr, before transplantation into 
NOD/SCID animals (2 million cells of each population per animal). Short term 
BM homing was assayed 24hr post transplantation. The data are from 3 
independent experiments, each data point represents 1 animal and numbers 
and bars indicate the means.
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6.4 DISCUSSION
MSC characterisation
MSCs can be readily obtained from adult BM samples and rapidly expanded 
ex vivo. MSCs did not express the haemopoietic markers CD34 and CD45 
but expressed high levels of SH2 (CD105) and SH4 (CD73) and this concurs 
with surface antigenic properties of MSC described by others (Deans & 
Moseley, 2000).
MAPC characterisation
MAPCs isolated and expanded from normal adult BM donors in 2% FBS 
were small cells with scant cytoplasm with few vacuoles and granules. This 
morphology remained unchanged as long as cells were maintained at cell 
density of 2-8000 cells/cm2. Similar morphology of MAPCs has been 
documented by (Reyes et al, 2001). The cell doubling time was ranged from 
40-60 hr, similar to reports by Reyes et al., (Reyes et al, 2001).
Immunophenotypic analysis by flow cytometry of undifferentiated MAPCs 
showed that cells did not express CD34, CD45 and HLA-DR. Cells 
expressed high levels of CD13, SH2, SH4, HLA-ABC, CD44 and 
intermediate levels of CD49b. My findings differ from those of Reyes et al., 
(2001) who immunophenotyped cells obtained after 10-15 cell doublings and 
showed that the cells did not express CD10, CD31, CD34, CD36, CD38, 
CD50, CD62E, CD106, CD117, H1P12, fibroblast surface antigen (1B10), 
HLA-DR, HLA-ABC, CD45, Tie, Tek. Cells expressed low levels of 
P2microglobulin, CD44 (Hyaluronic acid receptor), CDw90, KDR, Flt1 and 
high levels of CD13 and CD49b (Reyes et al, 2001). The reason for these 
differences in HLA-ABC, CD44 and CD49b (VLA-2) expression are not clear 
but may relate to unintentional differences in culture conditions. Reyes et al.,
(2001) showed that MPCs cultured at low density and with 2% or lower FCS 
are class l-HLA' and HLA-DR' and express only low levels of CD44. Culture 
with greater than 2% FCS or culture at high density (greater than 8000 
cells/cm2) yielded cells that were significantly larger and more vacuolated, 
and caused acquisition of high levels of of CD44, HLA-DR and Class I HLA
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and decreased levels of CD13 and CD49b (Reyes et al, 2001). The 
phenotype I report here for MAPCs, was similar to the phenotype seen when 
cells were cultured with greater than 2% FCS or culture at high density 
(greater than 8000 cells/cm2), although I expanded the cells with 2% FCS 
and maintained the cells between 2-8000 cells/cm2. The phenotype of 
undifferentiated MAPCs I generated, however, were similar to the phenotype 
reported for MSCs (Colter et al, 2000;Gronthos et al, 1994;Pittenger et al, 
1999). MSCs have only been shown to be capable of making a handful of 
tissues such as bone, cartilage, fat and muscle (Pittenger et al, 1999;Mackay 
et al, 1998). Recently, (Lodie et al, 2002) have shown that a systematic 
analysis of reportedly distinct populations of multipotent bone marrow derived 
stem cells (MAPCs vs MSCs) reveals a lack of distinction between them. 
Each cell, for example, expressed the same or similar cell surface markers, 
or antigens. They also showed common ability to undergo differentiation into 
nerve, cartilage, muscle, and endothelial cells based on culture conditions. 
There is also debate over a seemingly small, but potentially important change 
in the method that (Lodie et al, 2002) used to obtain MAPCs. A key step in 
obtaining MAPCs, according to (Reyes et al, 2001) is to grow bone marrow 
cells at a very low density. Yet (Lodie et al, 2002) obtained nothing this way 
and instead grew cells at a high concentration.
In order to investigate this further, the undifferentiated MAPCs generated 
were tested for their ability to differentiate into cells of viceral mesodermal 
origin, such as endothelial cells. When this was tested, there was no 
evidence that MSCs cultured under conditions initially developed by 
(Pittenger et al, 1999) differentiate into cells with endothelial characteristics 
(Reyes et al, 2001). However, very recently Oswald et al., (2004) have 
shown that by culturing confluent MSCs in low-serum (2% FCS) 
supplemented with VEGF (50ng/ml), the MSCs acquire several features of 
mature endothelium, including the expression of VEGF receptors (KDR and 
FLT1), VE-cadherin, VCAM-1, and vWF. They showed also an enhanced 
ability to form capillary-like structures in semi-solid medium (Oswald et al, 
2004).
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Reyes et al., (2002) demonstrated that MPCs from BM have the ability to 
differentiate into endothelial cells that have in vitro functional characteristics 
that are indistinguishable from those of mature endothelial cells (Reyes et al, 
2002). I demonstrated not only that MAPCs differentiate into cells that 
express markers of endothelial cells, such as vWF, but show that VEGF 
induced MAPCs to function like endothelial cells. MAPC derived endothelial 
cells, like primary endothelial cells such as HUVECs, have the ability to 
takeup LDL and form vascular tubes in an in vitro matrigel assay, although 
there were subtle differences between MAPC derived endothelial cells and 
primary endothelial cells (HUVECs). In comparison MSCs do not express 
vWF and do not takeup LDL and form cords on an extracellular matrix. The 
above data demonstrate that the undifferentiated MAPCs I generated are 
different to MSCs, in that undifferentiated MAPCs could be induced to 
differentiate into endothelial cells. However, very recently it has been shown 
that MSCs can be differentiated into endothelial cells in vitro (Oswald et al, 
2004).
Effect of co-transplantation of MSCs and MAPCs on CD34+ cell homing 
Recent results have shown that co-transplantation of human ex vivo 
expanded MSCs together with HSCs enhances haemopoietic recovery 
following a bone marrow transplantation in animal models (Nolta et al, 
1994;Nolta et al, 2002;Brouard et al, 1998;Noort et al, 2002;Bensidhoum et 
al, 2004) and in humans (Koc & Lazarus, 2001 ;Koc et al, 2000;Koc et al, 
1999). Noort et al., (2002) identified a population of MSCs derived from 
human foetal lung, which upon co-transplantation promote engraftment of 
UCB CD34+ cells in bone marrow, spleen, and blood however, these MSC do 
not appear to home to bone marrow (Noort et al, 2002). Angelopoulou et al., 
(2003) showed that co-transplantation of human mesenchymal stem cells 
with CD34 selected MPB cells enhances myelopoiesis and megakarypoiesis 
in the NOD/SCID mice (Angelopoulou et al, 2003). These results suggest the 
possibility of using MSCs to promote engraftment of UCB cells in an attempt 
to accelerate the engraftment delay associated with UCB transplantation.
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Because co-transplantation of marrow derived stromal cells has been shown 
to enhance engraftment of human UCB HSCs, we hypothesised this may be 
mediated at the level of initial homing of CD34+ cells to the BM of NOD/SCID 
mice. We tested this hypothesis by transplanting MPB CD34+ selected cells 
into sublethally irradiated NOD/SCID mice with or without culture expanded 
MSCs or MAPCs and evaluated the homing ability to the BM by enumeration 
of human CFCs.
CD34+ cells cultured in the presence of MSCs or MAPCs generated slightly 
higher numbers of total colonies with comparison to CD34+ cells alone. 
Therefore the presence of MSCs or MAPCs in the CFC assay had no 
significant effect on CD34+ cell colony forming activity. I demonstrate that 
CD34+ cells co-transplanted with MSCs in the NOD/SCID mice showed a 
small increase in BM homing compared with control animals transplanted 
with CD34+ cells alone, however, this was not statistically significant (P value 
0.1229, Mann-Whitney U test). In contrast the homing levels of CFC to the 
BM of CD34+/MAPC transplanted mice was comparable to control mice 
infused with CD34+ cells only. A similar finding was reported by Noort et al.,
(2002) who examined the possibility that homing of UCB CD34+ cells was 
affected by co-transplantation of MSC (Noort et al, 2002). These authors 
determined the percentage of CD45+ cells in the BM, PB, lungs, spleen, and 
liver by flow cytometry 24hr after transplantation of CD34+ cells (0.5-1 million) 
in the presence or absence of MSCs (5 million). They found no difference in 
the percentage of the injected UCB CD34+ cells in the BM, PB, lungs, liver 
and spleen of mice transplanted in the presence or absence of MSCs (Noort 
et al, 2002). They concluded that homing of CD34+ cells seems not to be 
affected by co-transplantation of MSC (Noort et al, 2002).
My finding reported here, together with previous reports that co­
transplantation of human ex vivo expanded MSCs hastens haemopoietic 
recovery following a bone marrow transplantation in animal models (Nolta et 
al, 1994;Nolta et al, 2002;Brouard et al, 1998;Noort et al, 2002;Bensidhoum 
et al, 2004) and in humans (Koc & Lazarus, 2001 ;Koc et al, 2000;Koc et al,
1999). Suggests that the engraftment benefit seen with co-transplanted
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MSCs may be independent of an effect on CD34+ cell homing to the BM. 
Noort et al., (2002) concluded that upon co-transplantation, MSC, but not 
irradiated CD34' or B cells, promote engraftment of UCB CD34+ cells in bone 
marrow, spleen, and blood by a mechanism that may not require homing of 
MSC to the BM (Noort et al, 2002). The ability of MAPCs to enhance homing 
has not been studied to date, but I demonstrate that these cells do not 
significantly increase the homing ability of adult MPB CD34+ cells in the 
NOD/SCID mice model.
The CD34 negative cell fraction positively selected for CD4+ and CD8+ cells 
yielded a purity of 88% and 96%, respectively. This level of purity is 
comparable to the report by (Adams et al, 2003). CD34+ cells cultured in the 
presence of CD4+ and CD8+ cells generated comparable numbers of total 
colonies compared with control CD34+ cells alone. Therefore the presence of 
CD4+ or CD8+ cells does not adversely affect CFC formation.
Adams et al., (2003) have reported that UCB CD34+ cells admixed with CD4+ 
cells consistently engrafted less well than those admixed with CD8+ cells 
(Adams et al, 2003). CD34+ cells admixed with CD8+ cells engrafted with a 
mean 10 fold increase over control CD34+ cells. This enhanced engraftment 
correlated with the finding that CD8+ cells significantly enhanced the homing 
to the BM of CFDA-SE labelled CD34+ cells. I was unable to demonstrate 
that either CD4+ or CD8+ cells co-infused with adult MPB CD34+ cells 
enhanced the homing to the BM. CD34+ cells admixed with CD8+ cells 
showed slightly higher homing to the BM compared with CD34+ cells injected 
alone or CD34+ cells admixed with CD4+ cells, this did not reach statistical 
significance (P value 0.1229, Mann-Whitney U test). My findings differ from 
those of Adams et al., (2003) who used UCB CD34+ cells labelled with the 
CFDA-SE dye and found that CD8+ cells enhanced homing to the BM 
(Adams et al, 2003). The reasons for this difference are not clear but may 
relate to intrinsic differences between cord and adult CD34+ cells (UCB vs 
MPB) and also differences in the assay used to study homing. Adams et al.,
(2003) studied homing to the BM using direct examination of fluorescently 
labelled (CFDA-SE) cells in vivo (Adams et al, 2003). In contrast I used the
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CFC assay to determine homing to the BM. It is also now well established 
that CB lymphocytes are more naive than adult lymphocytes. The evidence 
for this, comes from the observation that the majority of CB lymphocytes 
express CD45RA, whereas the majority of adult lymphocytes are CD45RO 
(Bradstock et al, 1993;Keever, 1993;Bofill et al, 1994). Adult and CB cells 
also exhibit differences in cytokine production and in general it has been 
noted that the frequency of T cells with the ability to produce TNFa, IFNy, IL- 
2, IL-4 or IL-10 is reduced in CB compared to adult blood (reviewed in 
(Cohen et al, 1999). Thus, CB CD8+ cells may function differently in the 
homing assay when compared with adult CD8+ T cells. Another difference is 
the strains of mice used, I used the NOD/SCID strain while Adams and co­
workers used the more sensitive and recently developed P2m NOD/SCID 
strain. The P2m knockout NOD/SCID mice in addition to the B and T cell 
defect and defects in the complement pathway and macrophage function in 
NOD/SCID mice, also lack natural killer (NK) cells and thus facilitate 
multilineage differentiation of 10-fold fewer human CB cells than required to 
achieve comparable levels of engraftment in NOD/SCID hosts (Kollet et al,
2000). To determine if this enhancement of CD34+ cell localisation was 
distinct for the bone marrow environment, homing to the spleen was 
evaluated. Consistent with that seen in marrow, I demonstrate that there was 
no difference in CD34+ cell homing to the spleen when CD8+ or CD4+ cells 
were admixed with CD34+ cells. My finding on homing to the spleen also 
contrast with the observations of Adams and co-workers who demonstrated 
increased CD34+ homing to the spleen when CD8+ cells were added (Adams 
et al, 2003).
In summary, I have demonstrated that undifferentiated MAPCs generated 
from normal BM donors showed the ability to differentiate into endothelial-like 
cells that have in vitro functional characteristics that are indistinguishable 
from those of mature endothelial cells. I have also demonstrated that adult 
MPB CD34+ cells co-transplanted with MSCs or MAPCs and CD4+ or CD8+ T 
cells showed no significant difference in homing levels to the BM in the 
NOD/SCID mice.
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Chapter 7: Conclusions
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7.1 CONCLUSIONS
The main question that this thesis has attempted to address is whether the 
reduced engraftment of cytokine activated adult human CD34+ cells is due to 
alterations in homing behaviour and the basis for such alterations. The data 
presented go some way towards answering these questions.
In Chapter 3, I showed, that MPB CD34+ cells cultured in serum free medium 
with cytokines have reduced engraftment in vivo, which is evident by 48 
hours of culture. Ex-vivo culture had a striking effect on the homing behaviour 
of CD34+ cells, resulting in a marked fall in homing to the BM, with a 
concomitant increase in cells localising to the lungs. I tested the hypothesis 
that such alterations in homing behaviour are due to cell cycle progression, 
using two different approaches in Chapter 4. In the first approach, sorted 
G0/Gi cells showed slightly higher homing to the BM compared with sorted 
cells in S/G2/M, this did not reach significance, and remained significantly 
lower than the levels seen with fresh cells. Importantly, sorted cells in 
different phases of the cell cycle did not show differences in engraftment. In 
the second approach, cells induced to accumulate at the G1/S border by 
treatment with aphidicolin did not show increased homing to the BM, 
compared with control cultured cells.
Cytokine activated CD34+ cells expressing high levels of Fas may undergo 
apoptosis in vivo upon binding membrane FasL on vascular endothelium. In 
Chapter 5 I demonstrated that Fas levels on CD34+ cells rise rapidly (by 48- 
72 hours) following cytokine exposure. My attempts to block Fas engagement 
on CD34+ cells using either soluble FasL, or blocking anti-Fas mAb did not 
however lead to restoration of homing ability in cultured CD34+ cells. Other 
strategies to restore the engraftment potential of cytokine-activated HSPC 
included altering culture conditions. Omitting IL-3 or addition of SDF-1 and 
retronectin from my cultures had no effect on the reduced BM homing of 
cultured cells. Finally, the data in Chapter 6, showed that adult MPB CD34+ 
cells co-transplanted with accessory cells (such as MSCs, MAPCs or 
heterologous T cells) have no significant difference in homing levels to the 
BM compared with CD34+ cells injected alone.
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Thus, in adult CD34+ cells cytokine induced loss of homing to the BM is a 
phenomenon that occurs rapidly and does not appear to relate to cell cycle 
progression. It is also not easily explained by surface CXCR4 or Fas receptor 
levels, or adhesion and migration behaviour in vitro. I suggest, based on data 
presented in this thesis, an alternative explanation which takes into account 
the tissue distribution of infused CD34+ cells. Although migration within the 
BM and subsequent adhesion to endosteal niches are important steps in 
homing, it is the initial encounter with vascular endothelium that dictates the 
tissue destination of circulating CD34+ cells. Previous work by Yong et ai., 
(1998) has shown that freshly isolated cord and adult CD34+ cells do not 
migrate across endothelium unless activated by cytokines (Yong et al, 1998), 
a finding subsequently confirmed by other investigators (Voermans et al, 
1999). This effect of cytokine stimulation on transendothelial migration 
applies to both random and SDF-1 directed migration (Yong et al, 1998). 
Thus, when infused in vivo, cytokine stimulated cells have a greater 
propensity to migrate out of the vasculature. This could lead to the 
inappropriate egress of transplanted cells into non-haemopoietic tissue. 
Unstimulated cells, on the other hand, have low migratory potential, only 
undergoing transendothelial migration when stimulated by appropriate 
cytokines within the BM micro-vasculature. This would be a mechanism for 
the selective egress of CD34+ cells into the BM. Impaired BM homing and 
hence engraftment that occurs as a result of ex-vivo cytokine exposure thus 
relates to changes in the tissue pattern of homing. The work from this thesis 
suggest that cytokine stimulation increases CD34+ cell localisation to the 
lungs while reducing homing to the BM and would support such a hypothesis. 
The increased apoptotic tendency of cytokine activated cells may lead to the 
loss of any cells that had migrated into non-haemopoietic tissue, thus 
contributing to the loss of engraftment potential in cultured cells.
Future directions
One issue raised by these studies is the adequacy, or appropriateness of the 
intravenous transplantation model for addressing the in vivo mechanisms of 
homing and engraftment. Conventionally HSPC repopulation assays are
169
based on intravenous injection, a complex process that requires circulation 
through blood, recognition of endothelium and extravasation through bone 
marrow vasculature, and migration to a supportive microenvironment. Cells 
travel into the right atrium, ventricle, and lungs in which most of the cells are 
trapped, then into the systemic circulation and lodge in organs according to 
organ blood flow, therefore, only a small fraction of injected cells initially 
arrive in the BM. Hence this system may detect a low homing efficiency with 
only 3-6% of the infused cells homing to the BM (van Hennik et al, 
1999;Cashman & Eaves, 2000) and some classes of HSPCs may remain 
undetected.
A new sensitive assay of assessing stem cell potential is the intra-BM 
transplantation technique (Kushida et al, 2001;Yahata et al, 2003;Mazurier et 
al, 2003). The assay involves directly injecting cells into the bone marrow 
cavity, thus excluding the stem cell homing interference (e.g. stem cell 
trapping in lung and/or liver, transendothelial migration step). Therefore it 
may be possible to avoid the cells distributing to organs with rich vascular 
beds (e.g. liver and lungs) after intravenous administration. This approach 
might yield a more immediate and successful outcome than manipulations to 
enhance homing to bone marrow, especially when cultured cells are used for 
transplantation. It will also enable us to address the question: is it migration 
into the BM or the subsequent anchorage step that is altered in cytokine 
activated CD34+ cells.
Recently another approach has been shown in a syngeneic mouse model to 
improve the localisation of primitive haemopoietic cells to the BM but not 
engraftment (Chabner et al, 2004). This approach involves the injection of 
donor primitive haemopoietic cells into the femoral artery through an intra- 
arterial catheter. Intra-arterial delivery of BM cells resulted in a 10-fold excess 
of cells homing (one hour following injection) in the ipsilateral BM compared 
with the contralateral BM and a 47-fold excess compared with intravenously 
injected cells (Chabner et al, 2004). This suggests that local arterial injection 
markedly enhanced the delivery of primitive cells to the local haemopoietic 
site. In contrast to the results from the homing assays, Chabner and co-
no
workers saw similar levels of engraftment of CD45.1 cells (in both the 
Ipsilateral and contralateral BM) irrespective of their route of injection 
(intravenous vs intra-arterial). Therefore, unlike direct injections into the 
marrow cavity, concentrated stem cell delivery by vascular route does not 
improve engraftment in the BM, suggesting that in this murine model, the 
homing of intravenously injected stem cells is efficient to the BM.
As mentioned earlier cytokine activated CD34+ cells may have a problem in 
securing anchorage to appropriate HSPC niches. Two alternative ways to 
look at the fate of transplanted cells at the single cell level are in situ fixation 
by perfusion (Nilsson et at, 2001) and through an optical window surgically 
implanted on the mouse femur (Askenasy & Farkas, 2002;Askenasy et al, 
2002). Both these approaches may also enable us to address the question: is 
it migration into the BM or the subsequent anchorage step that is altered in 
cytokine activated CD34+ cells? Nilsson and co-workers investigated the 
spatial distribution of CFSE labelled HPCs within the femoral BM of 
nonablated recipients in situ fixation by perfusion. Candidate stem cells 
demonstrated selective redistribution and were significantly enriched within 
the endosteal region, whereas mature terminally differentiated and lineage- 
committed cells selectively redistributed away from the endosteal region and 
were predominantly in the central marrow region (Nilsson et al, 2001). Thus, 
the failure of the ‘homing’ process may be a failure to migrate into 
appropriate niches and/or secure anchorage within these niches.
This work also raises the question: Why have studies on stem cell homing 
produced conflicting observations? These differences may be due to 
methodological differences for example surrogate vs direct homing assays. 
Generally two techniques have been used to quantify homing. The first is one 
in which whole unseparated marrow is infused and a surrogate assay (e.g. 
functional CFC assay) is used as marker for stem cells (Frenette et al, 
1998;Szilvassy et al, 1999;Oostendorp et al, 1999). However, this approach 
raises concerns for the validity of the surrogate assay and the possibility that 
the biological phenotype of the cell may change after engraftment. In the 
second, purified stem cells are labelled (for e.g. with fluorescent dye PKH26)
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to enable them to be tracked after infusion (Hendrikx et al, 1996;Lanzkron et 
al, 1999;Cui et al, 1999;Szilvassy et al, 2001b). This second approach is 
difficult because of the relatively large number of purified stem cells needed. 
Other reasons for conflicting observations include in vitro vs in vivo 
experiments and differences in cell source such as UCB vs MPB CD34+ 
cells. When foetal liver cells were used for homing studies, their homing to 
adult recipients was at least 10-fold lower than homing to adult BM cells 
(Szilvassy et al, 2001a). These findings were confirmed by Srour et al., 
(2001), for foetal liver cells irrespective of their gestation period and for cord 
blood (Srour et al, 2001). In contrast to these data, however, van Hennik et 
al., (1999) did not find that foetal liver cells or human CB cells had inferior 
homing in NOD/SCID mice (van Hennik et al, 1999). Several of the in vitro 
data do not appear to predict the in vivo situation of homing. My findings on 
in vivo homing of cytokine stimulated CD34+ cells also contrast with 
observations that the in vitro adhesive function of these cells alters with cell 
cycle. Yong et al., (2002), and others, have found in vitro that cultured CD34+ 
cells exhibit increased migration and reduced adhesion whilst in G0/G1 phase 
of the cell cycle compared to cells in S/G2/M (Yong et al, 2002b;Huygen et al, 
2002). These observations highlight the fact that the regulation of HSC 
homing to the BM is a complex process and involves interplay between 
adhesion molecules, chemokines, and differential shear stress in the 
vascular compartment. Finally, to what extent results with NOD/SCID or 
NOD/SCID (32m mice can be directly extrapolated to firm conclusions about 
human cell homing is currently being explored.
Bone marrow homing, apart from its biological significance, is of practical 
importance because it can influence the outcome of engraftment in clinical 
transplantation. However, the development of strategies to improve the 
efficiency of ex vivo expanded stem cell grafts will depend heavily on a full 
understanding of the molecular mechanisms that govern the homing of 
haemopoietic stem cells.
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Appendix I
List of materials, plastics, antibodies, reagents (including compositions), 
equipment and suppliers
ITEM SIZE SUPPLIER CAT NO
Plastics and tissue culture
materials
96 well flat bottomed tissue 96 well Nunc 167008
culture plate
Bijou polypropylene vials 7ml Sterilin 129B
Filter 0.22pm Sartorius 16532 GU
Fine tip pastettes 2ml Alpha Labs LW4070
Kwi ll/straw 5” Avon Medicals E910
Lab-Tek chamber slides 1 well Nalge Nunc Inc 177410
w/cover
Microscope slides BDH 406/0181/04
Pipette tips 200pl Sarstedt 70.760.002
1000pl 70.762
Sterile glass pipette 1 ml Volac D804/PS
Sterile plastic pipettes 5ml Sterilin 40305
10mls 47310
25mls 40125
Sterile polypropylene 50ml Greiner 210261
universal
Sterile polypropylene 15ml Falcon 352097
universal
Sterile polystyrene universal 30ml Sterilin 128A
Tissue culture flasks T252 Nunc 153732
T752 163371
Tissue culture flasks T252 Falcon 353014
(HUVECs) T752 3530324
Tissue culture plates 6 well Costar 3516
12 well 3513
24 well 3524
48 well 3548
Equipment for cell isolation
Cannulae plugs Vygon 9888
Capped plastic test tubes for Becton Dickinson Falcon 352054
flow cytometry Division
Cell strainer 40pM BD 352340
Click lock injection site plug Vygon 5811.01
Cryogenic vials 1.8ml Nalge 5000-0020
Disposable cytofunnels Shandon 5991040
Disposable syringes 50ml Becton Dickinson 300866
Disposable syringes 1ml Terumo BS-01T
2ml SS-02S
5ml BS-05S04
10ml SS-10ES
20ml BS-20ES
Intravenous cannulae (14 Abbotts 4535-14
gauge) sterile
Microfuge eppendorf tubes 0.5ml Sarstedt 72.692.005
1ml
Parafilm 2” x 250 ft BDH PM-992
Sterile needles 26g Microlance BD 303800
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ITEM SIZE
Sterile needles 0.8 x 40mm
Sterile surgical swabs and
towels (10x10)
Surgical blade
General cell culture reagents
20% Human Albumin Grifols 50ml
Bovine serum albumin 100g
CaCI2
Collagenase A from
Closridium histolyticum
D(+)-Glucose 500g
Dexamethasone
Dimethyl Sulphoxide 10 ml ampoule
(Tissue culture
(DMSO) grade)
DMEM low glucose 500ml
EDTA 500g
Endothelial cell growth 15mg
supplement (ECGS)
Fibronectin- from human 5mg
plasma
Ficoll-Paque 500ml
Foetal bovine serum (FBS) for 500ml
MAPCs; ES screened US
origin-heat inactivated at 56°C
for 30 min
Foetal calf serum- heat 500ml
inactivated at 56°C for 30 min
Hank’s Balanced Salt Solution 500ml
(HBSS)
Heparin (monoparin) 1,000U/ml
HEPES 50g
Iscove's (IMDM) with 500ml
Glutamax-1
ITS 100x
LA-BSA 100mg/ml
L-Ascorbic acid 2 phosphate
Matrigel 10ml
MCDB-201
Methocult 80ml
Mouse serum 1ml
NaCI 500g
N aH C 03 500g
NH4CI 500g
Paraformaldehyde
Penicillin / Streptomycin 5000U/ 5mg
Phosphate Buffered Saline with Ca++ or
Mg++Phosphate Buffered Saline without Ca++ or
Mg++
Retro Nectin 0.5mg
RPMI 1640 with L-glutamine 500ml
Sodium azide 100g
Trypsin/EDTA 100ml
SUPPLIER CAT NO
Neolus NN-2138R
Smith and Nephew 90623255
Swann-Mortan 0507
ALPHA PL12930/0001
Sigma A-4503
Boerhinger Mannheim
BDH 101174Y
Sigma D2915
Sigma D2650
Gibco BRL 31885-023
BDH 104284C
Sigma E-2759
Sigma F-2006
Pharmacia Biotech 
Hyclone
17-0840-03
PAA Labs A15-773
Gibco BRL 14170
CP Pharmaceuticals Ltd., BN95013559
Wrexham, UK
Sigma H7523
Gibco BRL 31980
Sigma 13146
Sigma L9530
Sigma A8960
Becton Dickinson 354234
Sigma M6770
Stem cell Technologies H4230
Inc (Dist by Metachem.
Diagnostics Ltd in UK)
Dako X0910
BDH 102414J
BDH 102474V
BDH 100173D
Sigma P6148
Sigma P4458
Gibco BRL 14040-091
Gibco BRL 14190-094
Takara Biomedicals T100A
Gibco BRL 21875-034
Sigma S-2002
Sigma T4299
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ITEM SIZE SUPPLIER CAT NO
Water for irrigation BP 10ml Braun 3627608
X-VIVO 10 1000ml
Hospital pharmacy 
Biowhittaker 04-380Q
Recombinant human 
arowth factors and 
chemokines:
EGF 200pg Sigma E9644
Erythropoietin 1000U/ml Boehringer Mannheim PL15722
Fas Ligand Plus recombinant 5pg Oncogene Research PF092
protein
Fms-like tyrosine kinase 3 10pg/ml
products
Peprotechec 300-19
ligand (Flt3L) 
G-CSF 250pg/ml Chugai Pharma
GF-409-61granulocyte/monocyte - 250pg/ml Hoechst
colony stimulating factor (GM- 
CSF)
IL-3 300pg/ml Sandoz (clinical trial vial)
lnterleukin-6 (IL-6) 20pg/ml Peprotechec 200-06
PDGF-BB 10pg R&D sysytems 220-BB
Soluble Fas Ligand (sFasL) 10pg Alexis Corporation Ltd 522-001-C010
Stem Cell Factor (SCF) 10pg/ml Peprotechec 300-07
Stromal cell derived factor-1 a 10pg Peprotechec 300-28A
(SDF-1 a)
Thrombopoietin (TPO) 10pg Peprotechec 300-18
Vascular endothelial cell 10pg Peprotechec 100-02
growth factor (VEGF)
Immunohistochemistrv 
100% alcohol 
DAB tablets 10mg
BDH
Bio-Stat Ltd 896102
Formalsaline 
Formic acid 500ml
Ken-En-Tec AS Denmark
Sigma
Fisons F/1900/PB08
Hydrogen peroxide (H20 2) Sigma 95294
Methanol 1L BDH 10158AF
Sodium chloride 
Sodium citrate 
Styrolite mounting medium 500ml
Sigma
Sigma
BDH 361704Y
Tris
Xylene 1L
Sigma
BDH 120932D
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ITEM
Antibodies for flow cvtometrv
SIZE SUPPLIER CAT NO
anti-CD34 PE BD Biosciences 345802
Anti-CD34 FITC BD Biosciences 345801
Anti-CD38 PE BD Biosciences 345806
Anti-CD45 FITC BD Biosciences 345808
Anti-CD45 PerCP BD Biosciences 345809
Anti-CD3 FITC BD Biosciences 345763
Anti-CD2 PE BD Biosciences 347597
Anti-CD19 PE BD Biosciences 345777
Anti-CXCR4 PE 2ml BD Pharmingen 555974
Anti-CD95 PE 2ml BD Pharmingen 555574
Anti-CD31 PE BD Biosciences 340297
Anti-CD44 FITC 2ml BD Pharmingen 555478
Anti-CD49b FITC 2ml BD Pharmingen 555498
Anti-VLA4 (CD49d) PE BD Biosciences 340296
Anti-VLA5 (CD49e) PE 2ml BD Pharmingen 33225X
Anti-CD11a FITC BD Biosciences 347983
Anti-lgG1 PE isotype control BD Biosciences 349043
Anti-IgM FITC isotype control BD Biosciences 345815
Anti-lgG1 PerCP isotype 
control
BD Biosciences 345817
Anti- lgG2a mouse PE isotype 
control
BD Pharmingen 5555574
SH2 FITC 
SH4 FITC 
HLA-DR APC 
HLA-ABC FITC
Anti-CD 13 FITC 
Anti-CD38 FITC 
Anti-lgG1 FITC isotype 
control
Anti-CD8 FITC/CD4 RD1/CD3 
PC5
Anti-mouse lgG1 
FITC/RD1/PC5 isotype 
control
1ml
1ml
1ml
0.5ml
0.5ml
Stem Cell Technologies 
Stem Cell Technologies 
BD Pharmingen 
BD Pharmingen
Dako
Dako
Dako
Beckman Coulter 
Beckman Coulter
F0831
F7101
X0927
PN6607053
PN660754
Antibodies for 
immunohistochemistrv
Anti-CD45RB 1ml Dako M0833
MOM Immunodetection kit Vector Labs PK2200
Antibodies for 
immunocvtochemistrv
Anti-Von Willebrand factor 1ml Dako M0616
Rabbit anti-mouse FITC 2ml Dako F0313
Blocking antibodies
Anti-Fas lOOjmg in 100pil MBL Ltd MD113
Inhibitors and enzymes
RNAase Sigma R5503
Aphidicolin from Nigrospora Sigma A0781
sphaerica
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ITEM SIZE SUPPLIER CAT NO
Dves and stains
0.4% Trypan Blue 100ml Sigma T8154
Annexin V FLUOS 500p,l Roche 1828681
Dil-Ac-LDL 200^ ig/ml tebu-bio 4003
Hoechst 33342 100mg Molecular Probes H-1399
PKH26 staining kit Sigma PKH26-GL
Propidium Iodide Sigma P4170
Pyronin Y ig Sigma P9172
Vectorshield mountant 10ml Vector Labs H-1000
Positive cell selection
CliniMACS buffer Miltenyi Biotec
Human CD34 Microbeads Miltenyi Biotec
Human CD4 Microbeads 2ml Miltenyi Biotec 130-045-101
Human CD8 Microbeads 2ml Miltenyi Biotec 130-045-201
Pre-separation filters 30pM Miltenyi Biotec 130-041-407
VarioMACS LS column Miltenyi Biotec 130-041-306
Neaative cell selection
Human CD45 Microbeads 2ml Miltenyi Biotec 130-045-801
Human Glycophorin A 2ml Miltenyi Biotec 130-050-501
Microbeads
LD column Miltenyi Biotec 130-042-901
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Equipment
Equipment Model and Company
C02 Incubator Galaxy R, Scientific Lab Supplies Ltd
Centrifuges Centaur 2, MSE 
MS3000, MSE
Class II Microbiological safety cabinet Walker safety cabinets Ltd, UK
Flow cytometers 
Epics Elite
FACS vantage (cell sort)
Beckman Coulter, UK
Inverted microscopes 211102 Olympus, Japan 
Zeiss Stemi 2000-C
Irradiator Gammacell CIS IBL 437
Light microscope BH-2 Olympus, Tokyo
Phase contrast microscope Phase contrast 2 18813 Nikon, Japan
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Buffers and solutions
Citrate buffer:
Sodium citrate 8.82g
Made up to 3 litre with dd H20  and pH adjusted to 6
Freeze mix solutions:
CD34+ cells:
PBS w/o Ca2+ Mg2+ 9ml
DMSO (v/v) 3ml
HSA 20% (v/v) 8ml
Human Umbilical Vein Endothelial Cells:
Iscoves MDM 6ml
FCS 2ml
DMSO 2ml
Made up fresh and chilled at 4°C for 30 minutes just before use.
Hoechst buffer:
D Glucose 200mg
HEPES 953mg
FCS 20ml
HBSS 180ml
pH adjusted to 7.3 and filtered through a 0.22pM filter and stored at 4°C
PI cell cycle staining solution:
Propidium iodide 2mg/ml in ddH20 200pl
RNase 10mg/ml in 10mM Tris (pH 7.5) 15mM NaCI 500pl
PBS w/o Ca2+M g2+ 10ml
Pass through a 0.2pM filter and store at 4°C
RBC lysis buffer:
NH4CI 8.3g
NaH C 03 1.68g
EDTA 0.4g
Made up to 1000ml with ddH20 , filtered solution through a 0.22pM filter and stored in 50ml 
aliquots at -20°C
RBC lysis rescue buffer:
BSA 5% (w/v) 10ml
Glucose 10% (w/v) 5ml
HBSS 35ml
Filtered through a 0.22pM filter and stored at 4°C
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Staining buffer:
PBS w/o Ca2+ Mg2+ 35ml
BSA 5% (w/v) 10ml
Sodium azide 1 % (w/v) 5ml
Filtered through a 0.22pM filter and stored at 4°C
Tris buffered saline (TBS):
Sodium chloride 80g
TRIS 6.05g
Made up to 10 litre with dd H20  and pH adjusted to 7.6
Wash buffer:
PBS w/o Ca2+ Mg2+ 40ml
BSA 5% (w/v) 10ml
Filtered through a 0.22pM filter and stored at 4°C 
Culture media
HUVEC complete culture medium:
Iscove’s MDM 16ml
FCS 4ml
Heparin 1000U/ml 400pl
ECGS 1 mg/ml 332pl
Filtered through a 0.22pM filter and stored at 4°C
MAPC expansion medium:
DMEM low glucose 12ml
MCDB-201 8ml
ITS x100 200pl
l-A-BSA 10Omg/ml 1OOpI
Ascorbic acid-2-phosphate 10mM 200pl
FBS (Hyclone) 400pl
Dexamethasone 1pM 1ml
PDGF-BB 1Opg/ml 20pl
EGF 100pg/ml 2pl
Filtered through a 0.22pM filter and stored at 4°C.
Stock solutions
Aphidicolin reconstitution:
Aphidicolin 1mg
Reconstituted in 1 ml DMSO and stored at -20°C (stable for 6 weeks).
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L-ascorbic acid 2 phosphate 1M solution:
Ascorbic acid-2-phosphate 2.561 g
Made up to 10 ml with dd H2O and filtered and stored at 4°C
BM, spleen, lungs and liver collection media:
RPMI 1640 45ml
FCS 5ml
Heparin 1000U/ml 1ml
5% BSA solution:
BSA 2.5g
Made up to 50ml with HBSS and filtered through a 0.22pM filter and stores at 4°C
Dexamethasone 1mM solution:
Dexamethasone 3.92g
Made up to 10ml with dd H20  and filtered and stored at 4°C
EGF human recombinant solution:
EGF 200pg
Reconstituted in 2ml of 10mM acetic acid+0.1% HAS and 10Opil aliquots stored at -20°C  
FasL Plus solution (recombinant protein)
FasL Plus 5pg
Dissolved in 50pl of sterile water and 10pil aliquots frozen at -20°C (stable for 1 year). 
Further dilutions were made with medium containing 5% FCS.
sFas Ligand (soluble, human recombinant):
Fas Ligand 10pg
Dissolved in 10Opil of ddH20  and aliquots stored at -20°C. Further dilutions were made with 
medium containing 5% FCS.
Fibronectin solution:
Fibronectin 5mg
Water for irrigation 2ml
HBSS 8ml
Aliqouts of 2 ml in autoclaved glass bottles were stored at -20°C. For use an aliquot was 
thawed and made up to 8ml with HBSS and plastic coated appropriately.
10% Glucose solution:
Glucose 5g
Made up to 50ml with HBSS and filtered through a 0.22p,M filter and stored at 4°C
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MCDB-201 solution:
MCDB 201 M6770 Powdered media (1 bottle)
Made up to 900 ml with dd H20  and pH adjusted to 7.3 (with the use of 1N HCI or 1N 
NaOH). Add additional dd H20  to bring the solution to final volume (1 Litre) and sterilised 
immediately by filtration using a membrane with a porosity of 0.22 microns. Medium was 
dispensed into sterile containers (T80 tissue culture flasks, Nalge Nunc) and stored at 4°C.
PDGF-BB human recombinant solution:
PDGF-BB 10pg
Reconstituted in 1ml of 4mM HCI +0.1% HSA and 50pl aliquots stored -20°C. 
Retronectin solution:
Retronectin 0.5mg
dd H20  0.5ml
PBS w/o Ca2+ Mg2+ 4.5ml
Filtered through a 0.5pm filter and 200pl aliquots stored at -20°C.
RNAase stock solution:
10mg/ml RNAase in 10mM Tris (pH 7.5)
15mM NaCI
Filter solution and heat to 100°C for 15 minutes (to destroy any contaminating DNAase). 
Aliquot and store at -20°C.
1% Sodium Azide solution:
Sodium azide 250mg
Made up to 25ml with dd H20  and filtered through a 0.22pM filter and stored at 4°C
Propidium iodide stock solution:
2mg/ml in distilled water
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